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FOR HARD TISSUE APPLICATIONS 
Nicole J. Ostrowski, PhD 
University of Pittsburgh, 2015 
Magnesium phosphate based ceramic implants and cements are currently under development and 
have received much attention to challenge the current standards for bone grafting materials. 
Compared to current calcium phosphate implants, magnesium phosphate implants display higher 
levels of resorption in vivo while maintaining high biocompatibility and osteoconductivity and 
low inflammatory response. The magnesium phosphate ceramics under development include 
dense pellets as well as cement putty, and fiber reinforced cement composite embodiments. In 
pellet form, amorphous tri-magnesium phosphate pellets displayed higher solubility than 
crystalline tri-magnesium phosphate while inducing rapid mineralization on the pellet surface 
which aided high osteoblast cytocompatibility of the amorphous pellet. These crystalline and 
amorphous tri-magnesium phosphates were therefore explored as precursor materials for a 
variety of cementing reactions. Amorphous, semi-crystalline and crystalline tri-magnesium 
phosphate precursors were correspondingly reacted with an ammonium phosphate solution 
to explore the effect of tri-magnesium phosphate crystallinity on the cementing reaction. 
The amorphous and semi-crystalline tri-magnesium phosphate powders were highly 
reactive, resulting in mechanically weak cements, while the crystalline tri-magnesium phosphate 
powder reacted efficiently with the reacting solution and were mechanically strong following 
reaction completion reaction while also displaying a neutral pH during incubation in saline 
v 
solution. This crystalline tri-magnesium phosphate was next evaluated with solutions of 
ammonium, potassium and sodium phosphate to explore the effect of each reacting salt solution 
on the cement reaction and product. The sodium and potassium phosphate solutions resulted in 
long setting times and poor mechanical resilience due to a lack of reaction completion 
while the ammonium phosphate solution resulted in mechanically resilient cement 
exhibiting clinically relevant setting times. This magnesium ammonium cement 
formulation was then further modified by the addition of soluble mannitol sugar crystals, or 
wet-spun degradable polycaprolactone fibers to evaluate the influence of added porosity or fiber 
reinforcement. Mannitol inclusion improved the porosity while reducing the mechanical 
strength. Polymeric fibers addition increased the toughness of the cement and, when removed, 
led to significant increase in macroporosity contributing to improved cellular 
infiltration. Based on the reults of the compositions studied, magnesium ammonium 
phosphate cements containing amounts of mannitol or more significant amounts of degradable 
fiber serving as initial reinforcement as well as eventual pore formers appear to be promising 
formulations to explore in the future.   
vi 
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1.0  INTRODUCTION 
1.1 CERAMIC BONE CEMENTS 
1.1.1 Clinical Need 
Currently, autografting remains the primary solution of many clinicians for the repair of dental, 
craniofacial and orthopedic boney critical-sized defects. However autografting requires a painful 
secondary surgery site which increases the risk of patient pain, infection and complications. The 
use of synthetic bone void filling materials eliminates the need to resect boney tissue from a 
secondary location in the body and also does not carry the same risk of disease transmission as 
allografting materials [1-3]. Synthetic materials also do not have same risk of low supply or high 
cost associated with autografts and allografts nor do these materials suffer from inconsistency 
which occurs due to variability in donor bone quality [4]. For these reasons, the market for 
synthetic bone filling materials is expected to continue to increase as surgeons and dentists move 
away from autograft and allograft materials favoring synthetic substitutes [5]. Bone grafting 
substitutes utilize synthetic materials, typically polymers or ceramics, to fill routine, chronic or 
traumatic voids along with non-degradable metal based fixation devices [6].  Applications of 
bone void fillers are widespread, ranging from filling holes left by routine tooth removal, to 
space filling during spinal fusions to maxillofacial reconstruction of wounded soldiers after 
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traumatic combat and battlefield injuries [7-9]. Degradable materials provide the additional 
benefit of resorbing over time to be replaced by native tissue, avoiding the long-term rejection 
issues seen in non-degradable materials systems [3]. Based on the US Food and Drug 
Administration (FDA), calcium and magnesium implants of this type are formally termed ‘bone 
void fillers’, separating them from the poly (methyl methacrylate) (PMMA)-type polymeric 
cements. It should be noted however ‘cement’ is colloquially used to refer to these materials in 
the literature, thus ‘cement’ will be used throughout this discussion and the subsequent chapters 
of this thesis.  
1.1.2 History of Bone Cements 
Calcium phosphate (CaP) scaffolds have been the preferred choice for bone repair scaffold 
because these materials mimic the chemical composition of hydroxyapatite (Ca10(PO4)6(OH)2, 
HA), the mineral found in human bone [10]. Due to this similarity in chemistry, CaPs show 
excellent biocompatibility. However, the commercial products now available, such as particulate 
fillers and bone cements, are less than ideal in other aspects. Ceramic bone cements are generally 
consisting of two component systems, a powder containing calcium phosphate salts and an 
aqueous solution. Upon mixing the powder and liquid results in the formation of freely moldable 
slurry with a paste-like consistency. This undergoes a chemical reaction, transitioning from a 
viscous, injectable liquid, requiring less invasive surgery, to a solid implant by entanglement of 
the crystals precipitating within the paste [11, 12]. While the use of a ceramic bone substitute was 
initially explored more than 100 years ago, research and development into CaP cements (CPC) 
as they are currently understood began in the early 1980s with LeGeros, 1982, and Brown and 
Chow, 1983 [13-15]. Not long after, CPCs were commercialized, and at present, myriad 
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commercial formulas are available for a wide variety of applications, including the repair of 
craniofacial, dental, and fracture defects [8, 16-18].   
1.1.3 Commercial Calcium Phosphate Cements and Limitations 
Commercially available CPCs exhibit two main formulations: brushite, or dicalcium phosphate 
dihydrate, (CaHPO4·2H2O, DCPD) forming and hydroxyapatite (HA) forming. Within these two 
classifications, there are numerous additives and reacting solutions, including reaction 
accelerants, cohesion promoters, fillers, plasticizers and radiological contrast agents [16, 18]. 
DCPD cements resorb well and set rather rapidly but exhibit low mechanical strengths and are 
acidic during the setting reaction [19]. HA forming cements on the other hand, achieve higher 
strengths however the reaction proceeds very slowly, risking early failure of the implant [20]. 
However, it should be noted that the formed HA by cement setting reactions is micro-structurally 
and chemically similar to natural inorganic component of bone (apatite) rendering CPCs 
biologically more active than the bulk ceramic related sintered blocks of HA [21, 22]. 
Additionally, the most popular HA grafts currently in use today may remain unchanged and only 
partially resorbed in the patient’s body for an extended period of time due to the sintered nature 
of HA, potentially resulting in tissue inflammation and poor integration with the patient’s bone 
[23-25]. Even brushite cements may display slower than expected degradation rates in vivo, as 
some researchers have found re-precipitation of apatite within the brushite cements, slowing the 
cement resorption [26, 27]. For these reasons, it is important to explore more bioactive, faster-
degrading grafts with suitable mechanical properties for orthopedic, craniofacial and dental 
implantation which is the focus of the current study.   
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1.1.4 Magnesium Phosphate Bone Cements 
The use of magnesium phosphate (MgP) based materials, particularly cements, have been 
proposed for clinically adoptable implants as an alternative to the options discussed earlier [28-
33]. The first published instances of research into MgP cement (MPC) for biomedical 
applications occurred in the mid-1990s, with Driessens et al exploring CPC/MPC cement 
mixtures (CMPC) [34, 35]. The majority of MPC research however has been completed in the 
past decade. Nevertheless, the body of published research regarding MPCs for biomedical 
applications is still limited in both, variety as well as depths of fundamental study. A PubMed 
search (http://www.ncbi.nlm.nih.gov/pubmed) for “magnesium phosphate cement” yielded 19 
results while a similar search for “calcium phosphate cement” yielded 856 results. Similarly, a 
search of the same terms in ISI Web of Science (http://www.webofknowledge.com/) yielded 65 
and 1826 results, respectively. While these searches are not completely exhaustive or mutually 
exclusive, the results do give an indication of the depth of MPC research conducted to date.  
Some researchers have also observed that MPCs can achieve a more ideal combination of 
strength, setting time and resorption rate than calcium phosphate cements while remaining 
biocompatible in vitro [28, 29, 34, 36-39].  
In addition to calcium, many other ions such as magnesium, silicon, zinc, potassium and 
copper play important roles in bone regeneration, from regulating metabolic processes and genes 
pertaining to osteoblastic differentiation to promoting angiogenesis and increasing bone cell 
adhesion [40, 41]. Magnesium has been shown to play a vital role in calcification and increasing 
bone density, mineral metabolism, HA crystal formation and increased bone cell adhesion and 
stability [19, 34, 42]. The specific role of magnesium in bone regeneration is still under 
investigation but has been shown to be dependent upon the local concentration as well as the 
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differentiation stage of the bone cells [41, 43]. While a high level of magnesium increases 
osteoblast proliferation, it has been shown to have the opposite effect on osteoclast formation 
and function, temporarily suspending the formation of polynucleated osteoclast cells in vitro [44-
46]. The utilization of magnesium-based implants is arguably acceptable from a biological 
standpoint. However, high concentrations of any of these ions, including calcium, can 
significantly impede the viability of cells [47]. The goal of the present study is to review the 
scientific development and achievements of magnesium cements to date. Furthermore, the 
objective is to assess how these cements compare with calcium phosphate competitors and to 
analyze the future directions and outlook for the research, development and clinical 
implementation of these cements. 
1.1.5 History of Magnesium Phosphate Cements 
While the research work in the field MPCs is relatively young, similar formulations have 
witnessed a longer history of study in the fields of structural engineering and waste remediation 
[48-52]. These cements, often called chemically bonded phosphate ceramics or cold-setting 
ceramics, undergo a defined series of reaction steps, including an exothermic acid-base reaction, 
to form a hard product [52, 53]. Typically, MPCs are formed by reacting the solid magnesium 
oxide with an acid phosphate solution, resulting in the dissolution of the oxide into the solution, 
forming a solution of cations with water termed aquosol. These aquosols then react with the 
phosphate salts, forming a gel. As more dissolution occurs, aquosol formation and gelation occur 
leading to thickening of the mixture and eventual solidification causing crystallization to occur 
around any unreacted core of the remaining oxide [54]. This process is depicted in Figure 
1-1 [54].  The rate at which this reaction proceeds depends primarily on the dissolution 
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step [12, 53]. If more than one solid precursor is involved in the cement setting reaction, the rate 
of the reaction will be controlled by the precursor with the least solubility and therefore, can 
significantly alter the cement handling, setting characteristics as has been similarly observed for 
CPCs [55]. While the traditional industrial applications are different, the base knowledge 
surrounding select cementing properties, including setting time, mechanical strength and 
workability of these industrial cements may be useful for the development of magnesium based 
bone cements. 
Figure 1-1 Schematic of reaction process of chemically bonded phosphate ceramic formation, from 
Wagh et al [54] 
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1.2 MAGNESIUM CEMENT SYSTEMS 
Magnesium cement systems are typically generated using a matrix of two ceramics, magnesium 
oxide (MgO) and trimagnesium phosphate anhydrous (Mg3(PO4)2, TMPA), with a variety of 
soluble phosphate salt solutions such as phosphoric acid (H3PO4, PA), monoammonium 
hydrogen phosphate (NH4H2PO4, MAHP), disodium hydrogen phosphate (Na2HPO4, DNaHP) 
and dipotassium hydrogen phosphate (K2HPO4, DKHP) [36-38, 56-59]. Table 1-1 shows the 
possible magnesium cement precursor and product phase chemical formulas, common names and 
acronyms as well as commonly utilized calcium phosphate phases for comparison.  
The bulk of research, both in the biomedical application as well as other applications 
mentioned above, involve use of magnesium oxide as the starting ceramic, typically reacted with 
ammonium or potassium phosphate salts, including the work of Mestres, Yang and Wu [29, 38, 
52, 58]. To a lesser extent, trimagnesium phosphate has been explored with similar reacting salts, 
such as the work done by Klammert and Moseke, [31, 32, 60-62].  In the patent landscape, 
filings for magnesium cements and fillers for biomedical applications are evenly split between 
MgO and TMPA based formulations, with an additional large body of patents based on MgO 
formulations optimized for non-biomedical purposes [63-72].  While in the academic landscape, 
research has spanned basic science to product development, the work covered under patent 
landscape primarily involves two formulation embodiments: magnesium oxide plus potassium 
phosphate and calcium-substituted trimagnesium phosphate plus ammonium phosphate [66, 67, 
71]. Of particular interest is the work by Mr. Thomas Lally focusing on the magnesium oxide 
and potassium phosphate formulation which has led to the OsteoCreteTM product from Bone 
Solutions, Inc. (BSI) [67]. This is the only magnesium based cement formulation that has been 
approved by the FDA, having proceeded through the Section 510(k) substantial equivalence 
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route. OsteoCreteTM has been approved as a bone void filler for long-bone and pelvic 
applications, which should be ready to be commercially launched in 2015. BSI President Drew 
Diaz plans to pursue additional applications with the product, including the use as an adhesive 
and in spinal surgeries (personal communication, January 30th, 2015).   The success, or lack 
thereof, of this BSI product could likely set the stage clinically for other researchers and 
companies to follow, as this class of products finds its place in the medical community.  
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Table 1-1 Magnesium cement related compounds. 
Chemical Formula Phase Name(s) (*Most Common) Acronym 
MgO Magnesium Oxide, Magnesia*, Periclase MgO 
Mg3(PO4)2 
Trimagnesium phosphate*, Farringonite*, Trimagnesium 
phosphate anhydrous, Magnesium phosphate tribasic  TMPA 
Mg3(PO4)2·8H2O Bobierrite*, trimagnesium phosphate octohydrate TMPO 
Mg3(PO4)2·22H2O Cattiite*, trimagnesium phosphate hydrate Ct 
MgHPO4 
Dimagnesium phosphate, Magnesium biphosphate, Magnesium 
hydrogen phosphate* MHP 
MgHPO4·3H2O Newberyite*, Magnesium phosphate dibasic trihydrate, Nb 
MgNH4PO4·6H2O Struvite*, Magnesium Ammonium Phosphate Heptahydrate Sv 
Mg(NH4HPO4)2· 
2H2O 
Schertelite* Sh 
MgKPO4·6H2O Magnesium potassium phosphate hexahydrate, k-struvite* KSv 
Mg3(NH4)2(HPO4)4·
8H2O
Hannayite* Hn 
Mg2PO4OH·4H2O Holtedahlite* Ho 
Mg(OH)2 Magnesium hydroxide*, Brucite MH 
5Mg(OH)2·MgCl2· 
8H2O 
Magnesium oxychloride* MOc 
MgCl2 Magnesium Chloride* MC 
Ca10(PO4)6(OH)2 Hydroxyapatite* HA 
Ca3Mg3(PO4)4 Stanfieldite* Sf 
Ca9Mg(PO4)6(HPO4) Whitlockite* W 
Ca9(PO4)5HPO4OH Calcium deficient hydroxyapatite* CDHA 
CaHPO4·2H2O Brushite*, Dicalcium phosphate dehydrate DCPD 
CaHPO4 Dicalcium phosphate anhydrous* DCPA 
Ca(H2PO4)2·H2O Monocalcium phosphate monohydrate* MCPM 
α, β-Ca3(PO4)2 Alpha, Beta-Tricalcium phosphate* 
αTCP/ 
βTCP 
Ca4(PO4)2O Tetracalcium phosphate* TTCP 
Ca8H2(PO4)6·5H2O Octocalcium phosphate* OCP 
NH4H2PO4 
Monoammonium hydrogen phosphate*, Ammonium dihydrogen 
phosphate MAHP 
(NH4)2HPO4 Diammonium hydrogen phosphate*, Diammonium phosphate DAHP 
KH2PO4 
Monopotassium hydrogen phosphate* Potassium dihydrogen 
phosphate MKHP 
K2HPO4 Dipotassium hydrogen phosphate*  DKHP 
NaH2PO4 
Monosodium hydrogen phosphate*, Sodium dihydrogen 
phosphate MNaHP 
Na2HPO4 Disodium hydrogen phosphate* DNaHP 
CaSO3·1/2H2O Calcium sulfate hemihydrate* CSH 
CaSO3·2H2O Calcium sulfate dehydrate CSD 
Na4P2O7 Sodium Pyrophosphate* SPP 
(NH4)2C6H6O7 Diammonium citrate*, Citric acid diammonium salt DAC 
C6H8O7 Citric Acid* CA 
H3PO4 Phosphoric Acid*, Orthophosphoric acid PA 
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1.3 MATERIALS PROPERTIES 
The variety and extent to which raw material characteristics and resulting cement product 
properties affect the biochemical and biomechanical properties of bone putties is the basis for the 
vast majority of research and development that is much needed to advance this field. Cement 
properties which should be controlled or well understood include the following listed in no 
particular order of importance or preference: phase composition; setting time and handling 
characteristics; injectability and cohesion; exothermicity; setting pH; strength and porosity; 
adhesion; biocompatibility and toxicity; osseointegration and osseoinduction; solubility and cell-
mediated degradation.  
1.3.1 Chemical Composition 
Precursor material properties which are important to consider include powder phase(s), particle 
size and shape, which affect the particle solubility and reactivity, liquid chemical composition 
and concentration,  as well as the material source and level of purity. The phases used in a 
cementing reaction affect the reaction products, as discussed in the previous section. The size 
and shape of the powder particles expectedly affect the kinetics of the ensuing reaction and thus 
have an effect on the majority of subsequent properties including setting time and mechanical 
strength, such as increasing surface defects to increase wetting and nucleation sites [73]. The 
cement may be composed of ceramic powder with the reacting salt in aqueous solution or it may 
contain both the ceramic and salt in powder form, with reaction occurring following the addition 
of water [29, 62]. In some instances, the reacting salt(s) may be delivered in both powder and 
solution [74].  The control of particle size and reactivity are typically achieved through ball 
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milling, which reduces the particle size and increases the surface area therefore increasing the 
reactivity, and thermal treatment, or dead-burning, which decreases the surface reactivity. Dead-
burning is very common for MgO powder. 
1.3.2 Particle Size 
The size of particles, and thus the surface area of the stating precursors, in MPCs affects not only 
the reaction rate of the cement but the handling characteristics such as injectability which 
ultimately may or may not affect the final strength of the cement [49]. The size or surface area of 
the starting powders is not frequently reported in the MPC literature. When reported, typical 
particle sizes for MgO and TMPA in MPCs range between 5-100 µm. For example, Mestres et al 
reported the use of MgO and MAHP or monosodium hydrogen phosphate (NaH2PO4, MNaHP) 
in powder form with mean (D50) particle sizes of 5 µm (MgO), 7 µm or 185 µm (MNaHP), and 
14 µm, 33 µm or 275 µm (MAHP) [29, 38]. Klammert et al tested a series of MgxCa3-x(PO4)2 
cements, where the magnesium-calcium phosphate powder was ground repeatedly several times, 
altering the D50 between 15 µm and 56 µm [60]. The grinding time was found to directly affect 
the setting time, with more grinding resulting in lower D50 and lower set times.  Yu et al and Wu 
et al used MgO that were sieved between 200-300 meshes, to yield particle sizes in the 0.05-
0.075 mm range particle diameters [36, 58].  Beyond this, many researchers report synthesis and 
post-processing protocols, which are easily followed, but do not report final raw powder size, 
shape or surface area. For example, Grossardt et al used TMPA that was sieved through -125 µm 
mesh then ball-milled for 1 hour and Moseke et al sieved TMPA through a -355 µm mesh then 
ball milled for 2 hours, Wang et al calcined MgO at various temperatures (1100 °C to 1500 °C) 
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for 3 hours [37, 62, 74].  A final particle size or surface area is however not reported in these 
publications, hence it is difficult to compare results with the information provided.   
1.3.3 Cement Composition 
As discussed above, the typical starting materials for MPCs is MgO or TMPA ceramic powder 
reacted with water soluble monoatomic or diatomic phosphate salts of ammonium, potassium or 
sodium.  These precursors typically result in newberyite (MgHPO4·3H2O, Nb), struvite 
(MgNH4PO4·6H2O, Sv), Sv analogs, or amorphous products with unreacted precursors. A 
variety of proposed chemical reactions between MgO or TMPA and phosphate salts can be seen 
in Table 1-2. A few less stable phases, such as schertelite (Mg(NH4HPO4)2·2H2O, Sh) and 
hannayite (Mg3(NH4)2(HPO4)4·8H2O, Hn) may be formed as well.  Table 1-3 contains a 
summary of cement compositions noted in the field of biomedical magnesium cements. Most 
researchers note varying levels of unreacted MgO or TMPA powder within the resulting cement 
structure. This tends to disappear, either through transformation or dissolution, following 
incubation in aqueous solutions. Some authors also note the formation of less stable phases, such 
as Sh and Hn which transition to more stable Sv and Nb phases after exposure to aqueous 
solutions [29, 38, 75]. As Moseke, Wang and many others note, the amount of unreacted ceramic 
powder increases with increasing powder to liquid ratio (P:L), attributed to the lack of phosphate 
salt available for continued reaction as well as physiochemical constraints due to water 
consumption and reaction progression [37, 57, 62]. Additionally, the ratio of ceramic powder to 
salt plays a role in the final composition and MPC properties. The molar ratio of ceramic to salt 
is typically kept at greater than 3:1, as excess ceramic contributes to moving the acid-base 
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reaction forwards towards completion [76, 77]. However, this ratio, if controlled by the P:L, may 
affect the materials strength and other properties, not just the degree of completion of the 
reaction [57]. When assessing trends in mechanical strength or cytocompatibility, it is not often 
possible to separate the effects of phase composition from the effects of microstructure and 
porosity. For this reason, it is best when authors provide a comprehensive documentation of the 
cement properties, such as reported in Kanter et al, which allows for a holistic review of the 
research results [78].   
Table 1-2 Proposed magnesium cement chemical reactions. 
Possible Chemical Reactions in the Magnesium Cement Systems Reference 
MgO + 2H3PO4  Mg(H2PO4)2·H2O Wagh 2004 [79] 
MgO + H3PO4 + 2H2O  MgHPO4·3H2O  Wagh 2004 [79] 
3MgO + 2H3PO4  Mg3(PO4)2 + 3H2O Wagh 2004 [79] 
MgO + NH4H2PO4 + 5H2O  MgNH4PO4·6H2O Yang 2014 [52] 
MgO + 2NH4H2PO4  Mg(NH4)2(HPO4)2·4H2O Sugama  1983 [80] 
MgO + (NH4)2HPO4 + 5H2O  MgNH4PO4·6H2O + NH3 ↑ Sugama 1983 [81] 
MgO + KH2PO4 + 5H2O  MgKPO4·6H2O Qiao 2012 [82] 
MgO + H3PO4  Mg(H2PO4)2·2H2O + Mg(H2PO4)2·4H2O * Finch 1989 [83] 
MgO + (NH4)2HPO4  Mg3(PO4)2·4H2O + Mg(OH)2 + 
MgNH4PO4·6H2O * 
Sugama 1983 [80, 
81] 
MgO + NH4H2PO4  MgNH4PO4·6H2O + Mg(NH4)2(HPO4)2 * Sugama 1983 [80, 81] 
6MgO + 3Ca(H2PO4)2·H2O  2Mg3(PO4)2 + Ca3(PO4)2 + 6H2O Jia 2010 [84] 
2Mg3(PO4)2 + 3(NH4)2HPO4 + 36H2O  6MgNH4PO4·6H2O + 
H3PO4
Klammert 2010 [32] 
Mg3(PO4)2 + (NH4)2HPO4  + 15H2O  2MgNH4PO4·6H2O + 
MgHPO4·3H2O 
Moseke 2011 [62] 
Mg3(PO4)2 + NH4H2PO4/(NH4)2HPO4  
Mg3(NH4)2H4(PO4)4·8H2O * 
Ostrowski 2015 [75] 
* Not Balanced
Less common formulations include the use of magnesium hydroxide (Mg(OH)2, MH) and PA to 
create cement of pure Nb, the use of MgO and monocalcium phosphate monohydrate 
(Ca(H2PO4)2·H2O, MCPM) to create TMP and TCP, and recently the creation of magnesium 
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oxychloride (5Mg(OH)2·MgCl2·8H2O, MOc) cement by combining MgO and magnesium 
chloride(MgCl2, MC) with PA  [39, 84, 85]. 
There are however, two dominant MPC precursor ceramic powders, MgO and TMPA, 
which both have shown appropriate working properties namely, high initial compressive strength 
and high levels of cytocompatibility. This has led to significant segmentation between research 
groups, with a group focusing solely on one of the two MPC styles. However, there has not been 
a direct comparison of analogous cements from each category in order to assess the two types of 
products directly. For example, a study comparing each powder reacted with the often studied 
3.5 M diammonium hydrogen phosphate ((NH4)2HPO4, DAHP) solution, while controlling the 
powder surface area and P:L, could yield insight into the degree of reaction completion, cement 
strength morphology, and cytocompatibility.  Additionally, while many researchers report 
cement morphology, and correlations can be drawn between morphology and cement properties, 
particularly strength, there is no systematic research reported in the MPC field into controlling 
the reaction parameters to achieve control of morphology or regulating morphology to control 
the cement properties.   
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Table 1-3 Cement systems in the biomedical MPC literature. 
Author/Reference 
Reactants: Powder/ Solution/ Additive 
(*Retardant, #Radiopacity, ^Other) Product Matrix P:L 
Set Times 
(min) 
1st/2nd 
Compressive Strength 
(C Compacted, H Humid/ 
Wet Setting, ^Other) 
Porosity 
(%) 
Density 
g/cm3 
Magnesium Cement Systems 
Ewald (2011) [86] TMPA+Sv / 3.5M DAHP Sv+TMPA 2:1 - 6.6 MPaH - - 
Grossardt (2010) [74] TMPA+Sv / 3.5M DAHP Sv + TMPA 2:1 - - - - 
Kanter (2014) [78] TMPA / 3M DAHP+0.5MAHP / - TMPA+Sv 2:1 and 3:1 - / 3.3-6 57.5 to 65.5 MPa
H  5-7 - 
Klammert (2010) 
[60] TMPA+MCPM / 0.5M CA / - Nb+DCPD 3:1 - / 21 10-45MPa
H - - 
Mestres (2013) [28] MgO+MAHP / Water / Borax* Sv+Sh+MgO+Borax 7.7:1 13/14 43.4 MPa^(7 days in vitro) 22 MPa^(dentin pushout) - - 
Mestres (2013) [28] MgO+MNaHP / Water / Borax* MgO+Amorphous+Borax 7.7:1 6.5/7 30.8 MPa^(7 days in vitro) 21 MPa^ (dentin pushout) - - 
Mestres (2013) [28] MgO+MAHP+MNaHP / Water / Borax* Sh+Sv+MgO+Borax 7.7:1 7.5/8.5 46.1 MPa^(7 days in vitro) 20 MPa^ (dentin pushout) - - 
Mestres (2014) [38] MgO+MAHP/ Water / Borax*, Bi2O3# Sv+Sh+Mgo+Borax+Bi2O3  7.7:1 7.2/8.8 
17MPaH, 41MPa^(7 days 
in vitro) 11 - 
Mestres (2014) [38] MgO+MNaHP/ Water / Borax*, Bi2O3# MgO+Amorphous+Borax+ Bi2O3 7.7:1 5.8/7.4 
12MPaH, 40MPa^(7 days 
in vitro) 5.0 - 
Mestres (2014) [38] MgO+MNaHP+MAHP/ Water / Borax*, Bi2O3# 
Sv+Sh+MgO+Borax+Bi2O3 7.7:1 9.0/11.4 
15MPaH, 32MPa^(7 days 
in vitro) 4.2 - 
Mestres (2011) [29] MgO+MAHP/Water/Borax* Sv+Sh+MgO+Borax 7.7:1 15/16 
30 MPaH, 47MPa^ (7 days 
in vitro) - - 
Mestres (2011) [29] MgO+MNaHP/ Water / Borax* MgO+Amorphous+Borax 7.7:1 8/9 28 MPa
H, 45 MPa^ (7 days 
in vitro) - - 
Mestres (2011) [29] MgO+MNaHP+MAHP/ Water / Borax* Sh+Sv+MgO+Borax 7.7:1 12/13 30 MPa
H, 18MPa^ (7 days 
in vitro) - - 
Moseke (2011) [62] TMPA / 3.5M (DAC+DAHP) Sv+TMPA 2.5:1 2-90+ / - 3.7-64.6 MPa H - 1.48-1.88 
Ostrowski (2015) 
[75] TMPA/ 3.0 M (MAHP+DAHP) / - Hn+TMPA 
2:1 to 
1:3 <1 - >60 
2-30 MPa, 0-15 MPa^ (2 
days in vitro) - - 
Tan (2015) [85] MgO/MC+PA/ - MOc 1.7:1 to 1:1 - 
19-27 MPa, 5-32 MPa^ (21 
days in vitro)  - - 
Vorndran (2011) [87] TMPA / 3.5M DAHP / - Sv+Nb+TMPA 3:1 - / 4 45-65 MPaH 14-19 - 
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Table 1-3 (Continued). 
Wang (2013) [37] MgO+MKHP / Water / - MgO+KSv 4:1 to 1.5:1 - / 2.5-17 11-23 MPa
H 7-22 - 
Wu (2008) [58] MgO+DAHP/Water/ - Sv+MgO 8:1 - / 11 58 MPa C,H  - - 
Yang (2014) [88] MgO+MAHP / Water / - Sv+MgO - -/ 3 18 MPa
H, 36 MPa^ (4 
weeks in vitro) - - 
Yu (2010) [89] MgO+MAHP/ Unknown / Unknown* - - - 85MPa
H, 28MPa^ (3 
months  in vivo) - - 
Zhou (2013) [39] MH/PA/ - Nb 1.25:2 3.5/11.8 13MPaH - - 
Zhou (2013) [39] Nb/water/- Nb 2.5:1 2.8/6.7 30 MPaH - - 
Combination Systems 
Driessens (1995) [15, 
34] DCPD +MgO+Nb / Water / - CaMg2(PO4)2 - - 
11 MPa,  3 MPa^ (8 weeks 
in vivo) - - 
Jai (2010) [84] MgO+MCPM / Water / - TMPA+TCP 5:1 to 1.9:1 - /  5-12 30-75 MPa 
C,H - - 
Klammert (2011) 
[31] Mg2.25Ca0.75(PO4)2 / 0.05M CA / - 
DCPD+Nb, transformed to  W after 
implantation  3:1 - 
10 MPa, 4 MPa^  (15 
months in vivo) - - 
Klammert (2011) 
[31] Mg2.25Ca0.75(PO4)2 / 3.5M DAHP / - 
TMPA+Sv, transformed to 
TMPA+W (implanted) 
3:1 - 12 MPa, 1 MPa^ (15 months in vivo) - - 
Wu (2008) [58] MgO+MAHP+TTCP+DCPA / Water / - HA+MgO+Sv+TTCP 8:1 to 4:1 - / 6-12 33-83 MPa
 C,H - - 
Klammert(2010) [60] MgxCax-3(PO4)2+MCPM / 0.5M CA / - DCPD+TCP+Nb (with Mg) 3:1 - / 8-60< 10-45MPaH - - 
Pijocha (2011) [90] MgO+MAHP+HA/ Water / SPP* or CSH* - 3.85:1 to 1.4:1 - - - - 
Vorndran (2011) [87] MgxCa3-x(PO4)2 / 3.5M DAHP / - Sv+(Nb or DCPD)+(Sf or TMPA) 
3:1 to 
1.5:1 - / 3.5-32 20-80 MPa
H 17-32 - 
Wu (2008) [58] MgO+DAHP+TTCP+DCPA/Water/ - Sv+MgO+HA+TTCP 8:1 - / 6-9 68-91 MPa C,H - - 
Yang (2014) [88] MgO+MAHP+CSH / Water / - Sv+MgO+CSH - - / 6-12 15-26MPa
H, 25-70MPa^ (4 
weeks in vitro) - - 
Other Notable Systems 
Klammert (2010) 
[32] TMPA+DAHP / 0.75M DAHP+0.75M MAHP TMPA+Sv+Nb 3:1 - / 2.5-26 
0.23-7.01 MPa^ (3D 
Printed Scaffolds)  - - 
Kumar (2009) [91] MgO+MKHP / Water / SiO2^ (filler) Note: Cast cement, thermally treated MgO + KSv + K2MgSi5O12 - - - - 
2.15-
2.50 
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1.3.4 Setting and Handling 
Setting times are a critical aspect of bone cement design. The cement must set slowly enough to 
allow the clinician to mix, handle and make adjustments to the material. However it must also set 
rapidly enough to ensure fast completion of surgery as well as provide the needed mechanical 
support or rigidity to handle the cement. First (or initial) and second (or final) set times, as 
defined by ASTM C266-13, are the times at which the cement can withstand 0.25 and 1.0 
pounds (113 and 454 grams) of weight without indentation [7]. Practically, the cement can no 
longer be manipulated after the first set time and is not truly functional until after the second set 
time.  In general, first and second set times of 8 and 15 minutes are regarded as ideal for most 
clinical applications [92]. However, too short a first setting time is not suitable for most clinical 
application as the handling of the cement can be progressively difficult as it approaches the first 
setting time and therefore, can be unworkable before completion of the proper implantation [21, 
93]. Another important aspect, which has often been neglected in the cement literature, is the 
setting of the cement in the presence of blood and serum [94]. It is inevitable that the cement 
paste will be in contact with the blood during implantation which can considerably delay the 
setting of the cement as well as affect the final mechanical strength of the implant [94]. Thus it is 
important to formulate the cement with a setting time that allows the surgeon to perform 
implantation fast enough to prevent delaying the operation or creating unpredictable problems 
due to interaction of the cement with the excess blood leading to incomplete reaction and slow 
setting leaving the cement as a slurry or paste with no perceivable rigidity. 
Setting times are affected by the material and environmental conditions including powder 
size, surface area and reactivity, setting solution or reacting salt concentration, P:L, temperature 
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and humidity. One of the great advantages of MPCs is the significant control over setting time 
which researchers are able to command, as revealed in Table 1-3. For example, Wang et al 
observed that both the calcining temperature as well as the P:L ratio affected the setting time of 
cement from MgO and monopotassium hydrogen phosphate (KH2PO4, MKHP) powders, ranging 
from 2 minutes (1100 °C, 4:1) to 17 minutes (1500 °C, 1.5:1), as shown in Figure 1-2 [37]. They 
demonstrated robust control over the setting time by controlling these two parameters, which 
would allow for set time optimization. Similarly, Moseke et al reported that cements of TMPA 
and 3.5 M DAHM resulted in set times of 1.5 to 16 minutes, with set time increasing with 
decreasing P:L [62]. On more extreme ends, Klammert et al found that grinding of the reacting 
precursors significantly reduced the setting times for cements of MCPM + MgxCa3-x(PO4)2, 
reducing the setting time from greater than 1 hour to only 9 minutes with 2 hours of grinding 
[60]. Similar ranges of setting times, from 1 minute to 1 hour, have been observed by the vast 
majority of researchers through the control of P:L and particle surface area [29, 78, 84]. 
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Figure 1-2 Setting time of MgO MPCs varying with P:L (here liquid-to-solid ratio, L:S) and calcining 
temperature, from Wang et al  [37]. 
From the CPC literature it is well known that most CPCs disintegrate upon early contact 
with aqueous solution or body fluids such as blood [92]. Cohesion time, defined as the time from 
which the cement paste no longer disintegrates when immersed in a specific solution or fluid, 
becomes a critical property for these cements [92, 93]. While not frequently discussed in the 
MPC literature, it is important clinically to ensure the cement putty remains intact during 
application. For clinical use the cement paste must have a shorter cohesion time than the first 
setting time. Along with the cohesion time, “anti-washout-ability” is another parameter which is 
also frequently used in the field of CPCs [93]. Although definition of anti-washout-ability is very 
similar to the cohesion time, the former is the time required for disintegration of the paste under 
dynamic aqueous conditions whereas a static environment is used to measure the latter. The 
“anti-washout-ability” time is generally much longer than the cohesion time, although cohesion 
time is typically reported [12]. Although there are no specific procedures to measure the 
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cohesion time for bone cements, a modified version of the test method for determining the 
resistance of freshly mixed concrete to washing out in water or test method used by Bohner et al 
can be employed [95]. Despite the importance of cohesion time, only one author, Mestres, has 
reported the cohesion of MPC, determining time of cohesion visually to be less than 6 minutes 
for both MAHP and MNaHP  cement formulations [28]. In the CPC literature, there is not 
always agreement upon the definition or metrics for cohesion determination. Bohner has 
reviewed the CPC literature, determining that cohesion may be improved through enhancing van 
der Waals forces, decreasing electrostatic forces or through increasing the cement viscosity [16, 
18]. This may be achieved through decreasing the mean particle size and increasing the ionic 
strength of the solution or adding hydrogels to the liquid [16, 18].   
Though not frequently reported in the MPC literature, injectability is clinically important 
to allow for minimally invasive surgeries or the filling of complicated defect sites. It is typically 
measured by the volume which can be extruded by a predetermined level of force, and can be 
affected by the time between mixing and testing as well as the maximum force, injection speed 
and aperture size of the injection needle. Filter pressing is a concern related to injectability, 
where the force of injection ejects proportionally more liquid than the solids in the mixture [76]. 
This results in an ‘in-use’ product which may vary quite significantly from the anticipated 
properties. 
Cohesion is intricately related to injectability, and many of the additives which improve 
injectability may also improve cohesion.  Typical methods to promote cohesion and injectability 
include additives, such as glycerol, chitosan, carboyxmethyl cellulose (CMC) or nanoparticles, 
and increasing the viscosity or altering the wetabillity of the particle surfaces [13, 14, 17, 18, 26, 
62, 96]. Mestres et al observed injectability of 89 % for MgO+MNaHP cements but only 36 % 
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for MgO+MAHP cements [38]. Moseke et al determined for a cement of TMPA with 3.5 M 
DAHP solution an injectability of 78 % at a P:L 2.0 but only 20% at a P:L of 2.5 [62]. The 
supplementation of the reacting solution with diammonium citrate ((NH4)2C6H6O7, DAC) greatly 
improved the injectability at the same P:L, with 2.0 achieving 88 % at 3.0 M/0.5 M 
phosphate/citrate ratio and 99 % at 2.0 M/1.5 M phosphate/citrate ratio. The effect is more 
dramatic at P:L 2.5, increasing to 47 % at 3.0 M/0.5 M and 98 % at 2.0 M/1.5 M 
phosphate/citrate ratios. The improved injectability was not due to increased zeta potential as had 
been anticipated, but instead was attributed to the fact that the citrate ions are not consumed 
during the setting reaction [62]. Although the majority of additives to improve injectability 
negatively affect other cement properties, the addition of certain chemicals, such as the 
polymerized aminosalicylic acid explored by Ginebra et al, which would contribute additional 
positive cement properties, are likely the best to explore moving forward [26].  
1.3.5 Mechanical Strength and Porosity 
Due to the hierarchical structure of HA mineral and collagen, natural bone displays high 
strengths, on average 130-190 MPa for cortical bone and 3.6-9.3 MPa for cancellous bone [97]. 
When clinicians utilize bone implants, the mechanical properties of those implants must 
therefore be taken into serious consideration, depending upon the application and necessary 
properties for the application. For example, highly load baring applications will require a 
material which is capable of bearing load. While ceramics can handle high loads in compression, 
they are brittle and perform poorly in tension and torsion. For this reason, MPC and CPCs are 
primarily used in low- semi-load or non-load bearing applications. The clinical success of bone 
cements so far has been governed by the setting and handling characteristics as well as by the 
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mechanical strength of the scaffolds following setting. Therefore, the level of strength achieved 
by MPCs is one of the greatest attractions, with researchers frequently reporting strengths greater 
than 50 MPa (Table 1-3). The most common mechanical test for bone cements is uniaxial 
compression testing performed on cylindrical or cuboidal samples. It is sometimes difficult to 
compare compressive strengths reported by various researchers because additional factors, such 
as compaction, dry or wet setting environment, and dry or wet testing conditions drastically 
affect the strength of cements. Compaction will increase the strength of the product by reducing 
the porosity and is not advised for bone cement research because similar compaction is not 
realistic in a clinical setting [98]. Setting under a humid environment or when immersed in 
aqueous solution will reduce the strength in comparison to a dry environment, but is advisable 
because humidity more closely mimics in vivo conditions.   When conducting direct 
comparisons, many researchers find higher initial compressive strengths for MPCs than CPCs. 
Highly dense sintered HA ceramics may achieve strengths up to 150 MPa under laboratory 
conditions. On the other hand, macroporous HA cements and commercially available HA 
cements generally display strengths below 30 MPa at 40 % or more porosity [6, 93]. Brushite 
cements rarely display strengths above 20 MPa without the incorporation of macropores [93]. 
Comparatively, MgP cements have routinely demonstrated strengths between 40-85 MPa [36, 
37, 56, 57, 99]. Frequently, this advantage is not retained with extended incubation in vitro or in 
vivo, which is likely due to the higher solubility of the crystalline phases present in MPCs [31, 
34, 36, 85]. However, others note an increase in strength following in vitro incubation, which 
may be attributed to further completion of the cementing reaction [29, 38, 88].  Factors which 
may affect the strength evolution of bone cements include the ceramic to salt ratio, P:L, particle 
size, additives and porosity [52]. Klammert et al reported that grinding time, and thus D50, of 
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TMPA powder when mixed with monocalcium phosphate monohydrate (Ca(H2PO4)2·H2O 
,MCPM) affected the wet compressive strength of the resulting cement increasing from 10 MPa 
to a maximum of 40 MPa [60]. However, other research indicates that while the particle size may 
affect the rate of strength evolution, it does not play a large role affecting the final strength [52]. 
It is well recognized that the strength of MPC is sensitive to the P:L used in the cement [52]. 
Within the bounds of workable putty viscosities, a decrease in P:L results in decreased strength 
of the cement, a trend which is observable in the analysis of compression data in Table 1-3. 
Moseke et al found that P:L of a 3.5 M DAHP solution with TMPA powder moderately affected 
the cement strength: cements at 1:1 had a compressive strength of only 20 MPa, while cements 
the strongest cement, at 56 MPa, were those at 2:1 [62].  
In 2014, Kanter et al created Sv cements from TMPA powder mixed with a solution of 
3.0 M DAHP/0.5 M MAHP [78]. The cements achieved strengths of 57-65 MPa, significantly 
greater than HA cements (27 MPa) or DCPD cements (10-34 MPa) assessed in the same study. It 
is important to note that the MPCs had porosity less than 10 % while CPCs had porosities 
between 30-45 %. Similarly, Wang et al determined that P:L affected the strength of a cement 
comprising of MgO + MKHP powders, reducing it from 22 MPa at 4:1 to 7 MPa at 1.5:1 while 
simultaneously increasing the porosity increased from 11 % to 23 % under the same range [37].  
Porosity plays a complicated role in the bone cement field. For many biomaterial 
applications, the inclusion of cell-sized open porosity is highly encouraged because it is shown to 
improve implant integration, increase degradation rates and reduce the rate of implant rejection 
[12, 22, 100]. However, particularly for ceramics, the inclusion of large pores, historically seen 
as defects, drastically reduces the mechanical strength of the product [12, 93, 101]. This makes 
the design of porous bone cements a delicate balance of desired properties. Additionally, the 
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level of porosity preferred may vary depending upon the application. For example, Mestres et al, 
in developing MPCs for endodontic applications, desired low open porosity because this yields 
lower degradation and leakage rates [38]. The porosity of MPCs is frequently lower than DCPD 
cements, ranging from 5-25 % [37, 38, 74]. Vorndran et al assessed the porosity of cements in a 
series of MgxCa3-x(PO4)2 with 3.5 M DAHP approximately following a linear curve fit of 
ln(strength), with increasing strength with decrease in porosity as shown in Figure 1-3 below 
[87]. The trend was not perfectly predictive, and some differences observed were attributed to 
differences in the microstructure at the same porosity levels. 
Figure 1-3 Relationship between porosity and ln(compressive strength) calcium-magnesium phosphate 
cements, from Vorndran at al [87]. 
While uniaxial compression testing is the predominant strength measurement method 
accepted for MPCs, and ceramics in general, other measures of cement mechanical resilience 
may be important to consider. When implemented clinically, bone cements do not undergo 
25 
strictly compressive loading. Instead, the cement may be expected to perform adequately under 
compression, tension and shear forces, the magnitude and importance of which are determined 
by the defect site [13]. For this reason, testing for screw pullout strength, stiffness or elastic 
modulus, or push-out strength in dental applications may become crucial to understanding the 
performance of the cement. Ideally, both the strength and elastic modulus of the cement implant 
would be in agreement with the surrounding bone or tooth tissue. Mestres et al observed the 
push-out strength of magnesium cement formulations (MgO with MAHP or MNaHP) in 
explanted teeth to be higher than that of commercial mineral trioxide aggregate (MTA), a widely 
used commercial Portland cement derivative [28, 38].   
1.3.6 Adhesion  
One of the greatest innate attributes of some MPCs which is not perceived spontaneously in 
CPCs are their adhesive capabilities, a clinical need which is currently filled with polymer 
formulations, particularly PMMA [102]. Indeed, this property helped launch the OsteoCreteTM 
formulation, from Bone Solutions Inc., through FDA approval which built interest in MPCs 
according to BSI President Drew Diaz (personal communication, January 30th, 2015).  
OsteoCreteTM MPC has been investigated in tendon-to-bone fixation, bone flap securing, screw 
fixation and bone-to-bone adhesion, showing improved adhesion and healing in nearly all 
circumstances [73, 103-106]. Research comparing the OsteoCreteTM formulation with other 
common MPC formulations has not been completed to determine whether most MPCs indeed 
display this adhesive capability or if this aspect is unique only to the OsteoCreteTM system.   
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1.3.7 Clinical Considerations 
For clinical implementation an MPC must achieve more than adequate mechanical 
strength and in vivo response. The commercial product must be manufactured, packaged, 
sterilized and implanted under realistic conditions. The cement materials need to be stable for 
extended shelf life. Because MPCs undergo acid-base reactions, the reacting components should 
ideally be kept separate, such as delivering the salt in solution form upon mixing. For 
formulations which this salt is delivered in powder form, it is imperative that the product remain 
dry until it is ready for use, else the components react prior to opening the package. Sterilization 
is another critical clinical concern often not assessed in academic research. All cement 
components must undergo stringent, often destructive, sterilization methods, such as γ 
irradiation. Although ceramics and salts are likely to be inert to these destructive sterilization 
methods, additives such as polymers or drugs may not be so resilient. Zeng et al used cobalt 60 
irradiation for sterilization of cement pieces after reaction, while Kanter et al used γ irradiation to 
sterilize cement powders and autoclaving to sterilize reacting liquids prior to in vivo 
implantation, each with no negative effects reported [78, 107].  
Thermal evolution during the cementing reaction is an additional clinical concern. A high 
temperature exothermic reaction observed during the setting reaction can result in tissue necrosis 
and implant failure. Clinically accepted maximum temperatures are expected to be in the 45°C 
and below range [108]. For MPCs, controlling the maximum temperature frequently means 
controlling the reaction rate. Mestres et al inferred that while a finer salt powder did not 
necessarily result in earlier temperature evolution during the setting reaction, the finer salt 
powder resulted in higher maximum temperature levels, up to 80 °C [29]. Moseke et al on the 
other hand, observed a maximum temperature 54 °C for a cement of TMPA+ 3.5 M DAHP while 
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Wang et al determined that decreasing P:L and increasing calcining temperatures reduced the 
maximum temperature reached, in the range of 35-65 °C for a cement of MgO + MKHP [37, 62].  
Zhou et al decreased the setting temperature of a cement of MH+PA by pre-reacting the cement 
under microwave irradiation, grinding the resulting cement, and then mixing that powder with 
deionized water. The setting temperature for the cement following this process was reduced from 
60 °C to room temperature [39].  
1.4 CEMENT SYSTEM MODIFICATIONS 
Modifications to basic cements systems are very common, in both the civil engineering 
applications as well as biomedical engineering applications of magnesium cements. 
Modifications to basic formulas may include combination of systems, typically with calcium-
containing compounds for biological reasons, composite systems, or the addition of reaction 
retardants and pore formers.   
1.4.1 Reaction Retardants 
Acid-base reactions may be rapid at times and thus resulted in very short setting times (Table 1-
3). When other processing controls, such as changes in particle size and P:L, are not sufficient to 
slow the reaction, retardants such as Borax and citrates may be added, with borax being the most 
common.  Mestres et al confirmed that increasing additions of borax decreased the maximum 
temperature evolution and delayed the setting reaction for MgO+MAHP or MNaHP, but was 
more effective with the MAHP [29]. The addition of 3 % borax was determined optimal based 
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on the maximum temperature and setting times for this series of cements. In later studies, 
Mestres et al utilize 1 and 6 % borax easily tailoring the setting time of their cement system as 
desired [28].  
Some researchers have also inferred that adding retardants reduces the maximum 
temperature reached while others have found that it may increase the maximum temperature. 
Moseke et al utilized the supplementation of DAC as a reaction retardant in a TMPA+ 3.5 M 
DAHP solution MPC [62]. The increase in setting time was proportional to the citrate content, 
with proportions of 2.0M and greater (of the 3.5 M total salt concentration) resulting in setting 
times longer than 60 minutes. Proportions of 0.5 M, 1.0 M and 1.5 M improved the setting time, 
within clinical constraint, as well as improving the injectability of the cement. However, these 
same additions increased the maximum setting temperature, from 54 °C up to 73 °C as well as 
decreasing the compressive strength of the cement. Pijocha et al analyzed the addition of calcium 
sulfate hemihydrate (CaSO3·1/2H2O, CSH) or sodium pyrophosphate (Na4P2O7, SPP) as reaction 
retardants, effectively reducing the maximum temperature from 88 °C to 38 °C and below. The 
effect of these retardants on other cement properties was not however reported [90].  
1.4.2 Pore Formers 
Porosity is a double-edged sword in ceramic bone cements: it is necessary for biodegradation, 
cellular infiltration and implant integration; however the strength of a ceramic or cement is 
inversely proportional to its largest defects [12, 93, 100]. Some level of porosity is always 
present in MPCs, as discussed above, however the addition of intentionally constructed 
macroporosity could prove beneficial to MPC implants. There are numerous ways to create 
porosity in a cement scaffold, including the use of 3D printing for pre-constructed (non-
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injectable) cements  and water soluble porogens  [109, 110].  Klammert et al used 3D printing to 
create porous MPC scaffolds, utilizing TMPA powder and 0.75 M MAHP/ 0.75 M DAHP 
solution as the binder [32]. Including DAHP salt in the powder phase as well as incubation of the 
scaffold in reacting solution after printing increased the compressive strength of the printed 
scaffold. However, the porosity of the structures was not reported nor correlated with other 
cement properties [61].  Beyond this report, the addition of pore formatting agents has not been 
explored in MPCs. In the CPC field, a wide variety of pore formation methods has been used, 
including the addition of sugar crystals such as mannitol, salt crystals and gas pore evolution 
[111-114]. Although considerable amounts of macropores can be formed using these processes, 
some techniques, such as 3D printing and gas evolution, may not be suitable for use with an 
injectable cement paste. Moreover, the rapid dissolution of highly water soluble pore formers, 
prior to the complete setting of the cement, can result in mechanically inferior implant or 
fragmentation of the partially set putty. Therefore, the use of slowly degrading biocompatible 
polymeric microspheres and fibers as pore formers have been proposed for CPCs [115-119]. 
These pore-forming agents have been successful in improving CPC integration and resorption in 
vivo and may be utilized in MPCs as well [120-122].   
1.4.3 Radio-opaque Additives 
The ability to non-destructively, non-invasively track the progress of cement implants is highly 
desirable for clinicians. Radiographic evaluation is a tool to achieve this goal, but in order for a 
clinician to track the implant it must be radio-opaque [123]. This analysis is particularly common 
in the dental field to track the state of procedures such as root canals. Barium sulfate and 
zirconium dioxide are common radiopacifiers in bone cements but their addition may be 
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detrimental to other cement properties [77, 124]. For this reason, some attempts have been made 
at utilizing more biologically neutral radiopacifiers, such as strontium carbonate [124].   Mestres 
et al add up to 15 % Bi2O3 to an MPC of MgO+MAHP or MNaHP in order to increase the 
radiopacity, and determined that 10 % addition displayed sufficient contrast, in comparison to 16 
% currently contained in commercial dental MTA [38].  
1.4.4 Combination of Systems 
The most common combination systems with magnesium phosphate cements are CMPCs, or 
combinations with well-known calcium phosphate cements, both because of the known 
bioactivity of CaPs as well as the more extensive knowledge of CPCs in research and 
development. CMPCs are created by generating substituted ceramic powders, particularly in the 
MgxCa3-x(PO4)2  system, or by simply mixing together an MPC formula with a CaP filler or CPC 
formula, such as the addition of HA to an MPC cement [87, 90]. Frequently, CMPCs are found 
to have a better combination of mechanical strength and cytocompatibility or biocompatibility 
than MPC or CPC formulations. Klammert et al found a cement of MgxCa3-x(PO4)2  and MCPM 
mixed with 0.5 M citric acid (C6H8O7, CA) resulted in the formation of DCPD and Nb, with the 
amounts varying based on X [60].  Vorndran et al made a series of cements of MgxCa3-x(PO4)2 
with 3.5 M DAHP solution. The cement of Mg2.25Ca0.75(PO4)2 displayed the highest compressive 
strength, up to 80 MPa, as well as the greatest cell number, but cement of TMPA had the highest 
cell activity [87]. Wu et al generated combination systems of MgO + DAHP mixed with TTCP + 
DCPA. They found that 1:1 combination of the two systems, at a P:L of 8:1, resulted in the 
highest compressive strength, of 91 MPa [58]. Other combination systems explored include 
reacting MgO + MCPM, which yields TMPA + TCP as cementing products instead of reactants, 
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or the addition of CSH which both contributes to the cementing reaction, converting to calcium 
sulfate dehydrate (CaSO4·2H2O, CSD) as well as acts as a reaction retardant [84, 88, 90].  Zeng 
et al assessed porous granules of MPC, CPC and MCPC for cell proliferation and osteogenic 
differentiation of bone marrow stromal cells as well as the functionality of maxillary sinus floor 
surgery on rabbits [107]. They determined that the MCPC enhanced cell proliferation and 
differentiation over MPC as well as formed more bone than either CPC or MPC.  
Another option to alter cement properties and improve bioactivity of the resulting cement 
is through the substitution of alternative anions and cations in the MgO and TMPA.  Many trace 
elements such as Sr, Cu, Zn, and Si are present in the human body and are known for their role in 
bone metabolism [40, 125]. Release of these ions from the scaffold after exposure to a 
physiological environment favorably affects both osteogenesis and angiogenesis. The inclusion 
of such additives has been widely studied in the calcium phosphate field but has not been explore 
in MPCs.  
1.4.5 Composite Systems 
Composite systems of MPCs are a particularly under-explored area of MPC development. 
Based on the extensive knowledge gathered surrounding CPCs and related cements, a variety of 
MPC composite systems can be envisioned and should be explored. Composite systems, 
particularly composites with biopolymers and biological macromolecules are of particular 
interest because the addition of such materials has the potential to improve cement properties, 
such as degradation rate or elastic modulus, which are not ideal in MPCs alone. Combination of 
systems which would be of interest to explore include composites with bio-glasses and metals, 
composites with synthetic degradable polymers or natural biopolymers such as collagen, silk, 
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alginate, in fiber or microparticulate forms, composites with growth factors (GFs), biomolecules 
and drugs, and multi-level composites with growth factors (GFs), biomolecules or drugs 
entrapped microparticles or reinforcing fibers of biopolymers [126-134].  
1.5  IN VITRO PROPERTIES   
1.5.1 Dissolution and Degradation 
 Biodegradability, through dissolution, cell-mediated resorption, or a combination of these two 
mechanisms, is often considered a mandatory requirement for bone cements. Many researchers 
report dissolution at 37 °C in aqueous solution, such as phosphate buffered saline or Ringer’s 
solution, as an indication of solubility-mediated dissolution. While this measure does not directly 
translate to degradation rate in vivo it is a good indication of comparative rate of dissolution 
between compositions or in comparison to calcium phosphate controls. It can also be used to 
draw correlations between ionic concentrations in solution and cellular response to the scaffold. 
Because the higher dissolution rates of MPCs than CPCs is one of the greatest advantage of 
MPCs, most researchers report MPC dissolution as it compares to the HA or DCPD CPCs. 
Relative dissolution of cements typically follow the decreasing trend of HA < DCPD < MgP 
cements [58, 59].  MPCs may degrade more slowly than other calcium-based formulations, such 
as calcium sulfate cements [88]. In the case of CMPCs, the ratio of CaP to MgP is assessed as it 
relates to the degradation rate, where again the dissolution follows the decreasing trend of CPC < 
CMPC (High CaP) < CMPC (High MgP) < MPC  [84].  For example, Wu et al generated 
combination systems forming Sv and HA [58]. The in vitro degradation of these systems, 
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measured by weight loss, was dependent upon the ratio of MPC to CPC, with increasing MPC 
increasing the weight loss over a 3 month period, as shown in Figure 1-4 [58].  Both of these 
trends are easily attributed to the respective solubility of magnesium and calcium phosphate 
phases [30]. The inclusion of other additives, such as reaction retardants and pore formers, may 
alter the dissolution profile of MPCs [85, 135, 136]. In some instances, such as the dental MTA 
replacement analyzed by Mestres et al, there is a desire for lower dissolution rates [38]. It is 
important to note that the formulations studied by Mestres et al were relatively of low porosity 
which contributed to the low dissolution rates. 
Figure 1-4 Weight loss of MPC, CPC and combination systems, from Wu et al [58]. 
For the resorption of DCPD CPCs, dissolution-mediated degradation is combined with cell-
mediated degradation, while for HA CPCs, cell-mediated degradation is the primary source of 
implant resorption [137, 138].   Grossardt et al analyzed both dissolution and cell-mediated 
resorption of a TMPA+Sv cement created with 3.5 M DAHP with RAW 264.7 monocytes, 
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which would form osteoclasts in vivo [74]. These samples were incubated with and without 
RAW cells, and the ion concentrations in media were assessed as a measure of dissolution. 
Results indicated that Sv MPCs resorbed three fold faster than DCPD CPCs; however this 
resorption was mainly dissolution-mediated while DCPD CPC resorption is a mix of dissolution 
and cellular activity and HA CPC underwent almost strictly cell-mediated resorption. When 
discussing the desired dissolution rate of bone cements, there is not a true ‘correct’ rate of 
degradation, as the desired rate is dependent upon the defect site as well as other clinical 
considerations, such as patient age and additional trauma at the implant site. However, it is a 
mandatory requirement that the degradation and resorption kinetics of the degradable scaffolds 
have to be controlled in such a way that the bioresorbable scaffold retains its physical properties 
and strength until the tissue engineered transplant is remodeled by the host tissue [139, 140].  
Another consideration for bone cements is the pH of the cement in vitro or in vivo 
because it can affect the viability of the surrounding cells. MPCs are typically neutral to slightly 
basic in vitro, a notable advantage over acidic DCPD cements [19, 29, 84].   Klammert et al 
observed that cements of Mg2.25Ca0.75(PO4)2 + MCPM reacted with citric acid displayed a 
physiological pH throughout the 21 days of testing [60]. Kanter et al also perceived that Sv 
cements during setting exhibited an approximate pH of 7.5 but reduced over 30 minutes to 
around 4.5 pH [78]. In addition to a variety of other properties, a physiologic setting pH is often 
desired to enable the viable incorporation of biologics or drugs, which tend to be unstable at 
higher and lower pH values [24, 141, 142]. 
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1.5.2 Cytocompatibility 
Cytocompatibility of MCPs with osteoblastic and osteoclastic cells is frequently 
completed in conjunction with material physiochemical evaluations. Most common are 
assessments of MPCs with osteoblast cell lines, MC3T3-E1 and MG63, or bone marrow stromal 
cells.  Osteoblasts predominantly display higher proliferation and cellular activity on MPCs or 
CMPCs in comparison to CPCs [58, 60, 84, 87, 91]. Ewald et al found that MG63 cells displayed 
high cell number and cellular activity on Sv cements in comparison to CDHA or DCPD cements, 
as shown in Figure 1-5 [86]. Determination of osteogenic response to MPCs is not consistent, 
with some authors reporting higher expression of alkaline phosphatase (ALP) and osteogenic 
genes while others report lower expression in comparison to CPC or other control substrates 
[84]. For example, in the same study as above, Ewald et al studied protein production for several 
osteogenic proteins, including ALP, collagen, and osteocalcin, on Sv, DCPD and CDHA 
cements. They ascertained that protein production  on Sv cements were higher than the 
polystyrene controls but lower than DPCD and CDHA cements [86].  Klammert et al also 
observed that cements of Mg2.25Ca0.75(PO4)2 + MCPM + CA displayed slightly inferior ALP 
activity than titanium controls with MC3T3-E1 cells [60]. Zeng et al assessed extracts from 
porous granules of MPC, CPC and CMPC for cell proliferation and osteogenic differentiation of 
bone marrow stromal cells [107]. They determined that cell proliferation was highest on MPC 
but that CMPC had higher ALP and osteocalcin (OCN) expression. Similarly, Jia et al confirmed 
that a cement of MgO + MCPM supported higher proliferation of MG63, as well as higher ALP 
expression after 4 days, than CPC controls [84]. Importantly, Yu et al determined that cements of 
MgO+MAHP displayed no carcinogenicity or mutagenicity in a variety of tests including 
unscheduled DNA synthesis, Ames mutagenicity test and micronuclei test [36]. 
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Figure 1-5 MG63 cell growth and activity on CDHA, DCPD and Sv cements, from Ewald et al [86]. 
Observing a wider body of work, the role on magnesium or magnesium substrates on 
osteogenic differentiation and gene expression may be explored in the MPC context. Research 
indicates that magnesium may stimulate osteogenic expression, matrix production and mineral 
deposition, however these results are concentration dependent [41, 43].   Yoshizawa et al studied 
the effect of MgSO4 concentration, thus free magnesium ions, on human bone marrow stromal 
cells (hBMSCs) in maintenance and osteogenic media, shown in Figure 1-6 [41].  The authors 
showed that cell number was concentration, time and media dependent (Figure 1-6a) with 
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increasing magnesium ion concentration increasing cell number [41]. They also showed that an 
elevated magnesium ion concentration (10 mM over 0.8 mM controls) enhanced collagen X, 
VEGF, PGC-1α, HIF-1α and HIF-2α protein expression (Figure 1-6b) [41].  The high 
cytocompatibility combined with possibility of elevated osteogenic activity likely indicates that 
the presence of a CaP scaffold is not needed in order to effectively rebuild boney tissue. 
Figure 1-6 Effect of elevated magnesium ion concentration on hBMSCs indicating (A) increased 
proliferation at 10 mM Mg concentration in maintenance and osteogenic media and (B) enhanced protein 
expression at 10 mM Mg concentration (mean fold change compared to 0.8 mM concentration), from 
Yoshizawa et al [41]. 
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As mentioned above, elevated levels of magnesium have been shown to temporarily 
suspend the formation of osteoclasts from monocytes [44-46]. Grossardt et al observed that with 
RAW 264.7 monocytes that Sv cements supported higher cell number and cell activity than 
DCPD cements [74]. Grossardt also determined that RANKL-supplemented RAW 264.7 cells on 
Sv surfaces did not stain positive for TRAP, but did express CT-R, an osteoclast-specific protein. 
These are contradictory results, indicating that while the cells were very active, they have not 
formed mature polynucleated osteoclast cells as anticipated.  The implications of suspended 
osteoclast formation on bone tissue scaffolding of any sort are not immediately obvious. 
Although a scaffold interrupting the natural bone growth process may not be ideal, many patients 
currently take medications in order to slow bone resorption to decrease their rate of fractures and 
some research has been conducted to assess the delivery of such a medication in a CPC 
formulation [143]. Janning et al inferred that locally restricting osteoclast proliferation increased 
bone formation [44]. Given the resorption properties of MPCs, osteoclast activity is not required 
from MPC degradation, nor is it an absolute requirement for new bone growth. Thus it is likely 
that the temporary suspended osteoclast formation may ultimately be beneficial to MPC 
implants, allowing for a more rapid rate of new bone ingrowth.  
1.5.3 Antibacterial Properties 
Another possible property inherent to MPCs which is desired, and often added to CPCs, is 
antibacterial activity. While CPCs have antibiotics such as vancomycin added to the cement 
formulation, some MPCs may be naturally antibiotic [144, 145]. Mestres et al observed cements 
of MgO + MNaHP salt or MNaHP/MAHP salt mixture exhibited bactericidal effects on S. 
sanguinis bacteria, while cements reacted with only MAHP salt exhibited growth inhibition but 
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no bactericidal effects [29]. The bactericidal effects were attributed to a combination of pH 
increase (up to 9.91) while the growth inhibition was attributed to acidic conditions and the 
release of Mg2+ ions and reactive oxygen species from the remaining MgO. In a later study 
Mestres et al determined the antibacterial activity against three strains of bacteria: E. coli, P. 
aeruginosa and A. actinomycetemcomitans [28]. As shown in Figure 1-7, the authors observed 
that incubation extracts from both cement formations were most effective against A. 
actinomycetemcomitans and least effective against E. coli, with only aged MNaHP being 
effective against E. coli [28]. These results again were attributed to the change in pH and 
osmolarity of the solution. For comparison, in dental applications Ca(OH)2 is frequently used, 
which displays a pH of 12.5, so the alkalinity is not likely to be a concern in this field. If the 
alkalinity and ion release from MPCs is not detrimental to the implant performance, innate 
antibiotic nature of MPCs may be particularly useful in high bacterial density prone sites such as 
dental reconstruction. 
Figure 1-7 Viable bacteria following exposure of incubation extracts of MPCs tested on three different 
bacteria with fresh and aged extracts, relative to PBS controls,  from Mestres et al [28] .
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1.6 IN VIVO STUDIES AND CLINICAL APPLICATIONS   
Current in vivo assessments of MPCs or CMPCs are somewhat limited, but the results are highly 
encouraging.  When implanted in boney sites such as the femur condyle defects in rabbits, MPCs 
consistently show higher ingrowth of new bone than CPCs, with little to no inflammation or 
foreign body response. Yu et al implanted fully reacted plugs of cement of MgO + MAHP  in the 
muscle and femur condyle of rabbits [36]. In the condyle defect, they observed that within 1 
month or less, the interface of the implant and bone was clear, but after 3 months, the interface 
was not clear, and by 6 months the implant was replaced by new woven bone which was partly 
transformed into lamellar bone. They also measured the blood levels of magnesium phosphate 
and calcium and observed that the cement did not change the metabolic levels of these ions. Wu 
et al implanted preset samples HA CPC and Sv+HA CMPC into holes drilled in the femur of 
rabbits [58]. They reported substantially greater degradation of the CMPC implant, as well as 
higher new bone volume, 85 % for the Sv+HA system versus less than 10 % for the HA system. 
Zeng et al also assessed porous granules of Sv MPC, HA CPC and Sv+HA CMPC systems for 
the functionality of maxillary sinus floor surgery on rabbits [107]. They observed that the CMPC 
formed more bone than CPC or MPC. The addition of bone marrow stromal cells with the 
cement granules resulted in even greater bone growth and scaffold dissolution. Kanter et al on 
the other hand, implanted Sv cements from TMPA + 3.0 M DAHP / 0.5 M MAHP in the femoral 
condyle of adult sheep, the CT results of which are depicted in Figure 1-8 [78]. They determined 
that after 10 months the porosity of Sv cements increased above 20 % but underwent a 
substantial reduction in strength. The Sv cement was determined to be more favorable for bone 
regeneration than DCPD or HA cements, degrading more substantially and resulting in more new 
bone growth than the CPC cements. The loss of mechanical strength following implantation in 
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vivo is however, a consistent trend but has not negatively affected the functionality of the MPC 
implants [31, 34, 78]. For example, Yu et al implanted the same MPC scaffolds intramuscularly 
in rabbits, which displayed significant surface changes with time as well as reductions in 
compressive strength, from 85 MPa initially to 25 MPa after 3 months [36]. In addition to these 
formulations, the OsteoCreteTM MPC formulation has been studied in a variety of animal models 
and defects, including cranial defects in rabbits, securing dental implants in dogs, and metacarpal 
and metatarsals in horses [103, 105, 146]. OsteoCreteTM has demonstrated improved adhesion 
and healing in nearly all surgical sites explored. 
Figure 1-8 Results of Sv and brushite cement implantation in sheep femoral condyles for 10 months, 
showing a) x-ray, B) macroscopic images, C) µ-CT slices and D) histological section stained with toluidine 
blue and basic fuchsin, from Kanter et al [78]. 
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 There thus is a broad range of potential uses for ceramic bone cements, including dental 
filling, adhesion, and void filling. Clinical applications for ceramic bone cements may include 
orthopedic, vertebroplasty, maxillofacial surgery, endodontic treatments, filler agents in dental 
pulp capping and root canals.  The implementation of MPCs for these applications depends upon 
a wide variety of property performance metrics. Some applications have been demonstrated to be 
successful with MPCs, as signified by the FDA clearance of OsteoCreteTM for long bone and 
pelvic applications. 
1.7 DESIGNING A BETTER MAGNESIUM BONE CEMENT 
Although MPCs display greater mechanical strength than CPCs, the strength and elastic modulus 
of MPCs at this time remains inferior to native bone. For this reason, clinical use of MPCs is 
expected to remain predominately relegated to semi-load or non-load bearing applications, 
similar to commercial CPC products. With this in mind, the commercial viability of MPCs 
hinges on their unique advantages over CPCs. In addition to the increased mechanical strength, 
MPCs have shown more rapid degradation and subsequent bone in-growth in vivo than CPCs 
counterparts, a propensity for inherent antibiotic ability, and significantly finer control over 
setting times than CPCs, as well as the adhesive capabilities demonstrated by the OsteocreteTM 
formulation demonstrating the slight positive edge of MPCs over the ubiquitous CPCs [29, 36, 
78, 104].  
From a clinical perspective, certain characteristics are crucial for ease of use and product 
performance that all need to be addressed for commercial implementation, including 
injectability, porosity and dissolution. The adhesive capabilities of MPCs, which are not inherent 
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to CPCs, can be extremely useful for simple or compound fracture manipulation. These 
situations, as well as many others, require an injectable formulation. However the injectability of 
MPCs, inherent or additive-induced, has not been thoroughly explored. Many additives which 
improve injectability also act as cohesion promoters, and may therefore improve the cement 
paste stability in the presence of bodily fluids, another crucial requirement for clinical 
implementation [14, 17].  
An added unique advantage of MPCs are their higher solubility than CPCs, resulting in 
more rapid in vivo resorption and cellular infiltration than CPCs. This may be improved further 
through the addition of pore formers which promote rapid cellular infiltration and fluid transport. 
Although a variety of pore forming techniques have been explored with CPCs, there is still no 
clinically available CPC which is both porous and injectable, and very few FDA approved CPC 
formulations are indeed injectable. This lack of clinical accessibility may be due to poor 
handling characteristics of porous CPCs, including long setting times and insufficient mechanical 
integrity. As MPCs have shorter setting times, higher mechanical strengths and greater 
dissolution than CPCs, the development of porous, injectable MPCs formulations have the 
opportunity to gain clinical favor for many difficult applications wherein CPCs may be 
considered inadequate.  
The formation of new bone on and around an implant can be strongly dependent on the 
release of ions from the degrading implant. A high level of magnesium is known to stimulate 
new bone growth in vitro and in vivo, with several recent studies on magnesium alloy implants 
demonstrating enhanced bone growth around the corroding implant [41, 43, 147].  In addition to 
magnesium, various other cations and anions are implicated in new bone formation, and the 
study of ion-doped MPCs has the potential to show even greater bone growth while maintaining 
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suitable handling, setting and mechanical characteristics clinically necessary for implementation 
[40, 97, 125].  
In addition to the scientific rigors of product development, MPCs will face societal 
hurdles entering the market place. The market is conservative in many respects. Although the 
limitations of CPCs are widely known and criticized, clinicians are often reluctant to use a new 
product which differs significantly from what is currently used. When this difference is 
manifested in the chemical make-up of the implant, a large body of clinical study evidence is 
required to build trust in a new product’s safety and efficacy. With time however, the unique 
capabilities of magnesium phosphate cements, including adhesive and antibacterial features, can 
overcome these hurdles, ultimately improving clinical care in applications wherein calcium 
phosphate cements may not be deemed capable of performing.   
1.8 SPECIFIC AIMS 
Ceramic granules and cements for dental and craniofacial applications have been primarily 
developed with the intent to fill voids in bony tissue and prevent additional bone recession while 
promoting new bone growth. The primary series of materials studied thus far are composed of 
hydroxyapatite. In many cases, apatite implants are considered non-resorbable and thus suffer 
from similar maladies as other permanent foreign implants.  
Bone cements based on magnesium oxide and magnesium phosphate have the potential to 
fill the needs not satisfied by these calcium phosphate implants, demonstrating higher 
mechanical integrity and greater resorbablilty in vivo than apatite cements. However, the body of 
knowledge related to these materials is scant and undeveloped in comparison to the calcium 
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phosphate literature. It is hypothesized that magnesium phosphate substrates and cements will be 
simple and straight forward to generate in a laboratory environment and will demonstrate 
cytocompatibility comparable to calcium phosphate controls, while maintaining adequate 
strength under aqueous conditions thus demonstrating increased bone-forming capacity.  
Accordingly, five specific aims have been formulated to evaluate this hypothesis. 
Specific Aim 1 
Synthesize trimagnesium phosphate cement precursors and perform materials 
characterization and cytocompatibility assessment to determine viability of the base materials. 
Specific Aim 1 is the subject of Chapter 2. 
Specific Aim 2 
Evaluate the effect of trimagnesium phosphate crystallinity (amorphous, semi-crystalline 
and crystalline) on the cementing reaction and the materials characteristics of the resulting 
cement.  Specific Aim 2 is the subject of Chapter 3.  
Specific Aim 3 
Assess the effect of reacting solutions of potassium phosphate, sodium phosphate and 
ammonium phosphate with crystalline trimagnesium phosphate on the ensuing cement forming 
reactions and evaluate cytocompatibility of the resulting cement. Specific Aim 3 is the subject 
of Chapter 4.  
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Specific Aim 4 
Evaluate the effect of porogen addition to a model cement system to investigate alteration 
of the mechanical behavior, increase the porosity and improve the cellular interaction with the 
resulting cement. Specific Aim 4 is the subject of Chapter 5.  
Specific Aim 5 
Evaluate the effect of biodegradable polymer fiber reinforcement addition to a model 
cement system to explore the improvement in fracture toughness while also providing cell sized 
porosity. Specific Aim 5 is the subject of Chapter 6.  
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2.0  SPECIFIC AIM 1: SYNTHESIS OF AMORPHOUS AND CRYSTALLINE TRI-
MAGNESIUM PHOSPHATE AND OSTEOBLAST AND OSTEOCLAST VIABILITY 
ASSESSMENT 
2.1 INTRODUCTION 
Historically, for patients in need of bone repair or replacement, synthetic substitutes may be 
chosen over naturally derived materials, such as allografts and autografts, due to the mass 
production capacity and lower immunogenicity of synthetic materials [1, 148]. Ceramic implants 
are often the primary choice simply for their mechanical durability similar to bone. These 
materials include bioglasses, zirconium oxides, aluminum oxides, and calcium oxides or 
phosphates; however the implementation of ceramic scaffolds may be hindered a variety of 
considerations [149-151]. 3D printed implants require extensive planning and invasive surgical 
procedures, particulate fillers offer limited mechanical stability, while bone cements, which 
require less invasive surgery either exhibit low strengths or are too slow to achieve desired 
strengths, risking premature failure [11, 20, 109, 152]. With many of these implant options a 
major concerns is the lack of resorbability which may result in implant rejection or chronic 
infection, as well as poor integration with host tissue.  A common choice of synthetic implant are 
calcium phosphate (CaP) based grafts since these materials are chemically similar to the mineral 
component of native bone tissue, however even these implants are less than ideal [10].  CaP 
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implants resorb too slowly, necessitating extremely long periods of time for the implant to be 
replaced by native bone [23, 24]. 
In addition to calcium, many other ions such as magnesium, silicon, zinc, potassium and 
copper play important roles in bone regeneration. These include regulating metabolic processes, 
modulating osteoblastic differentiation, increasing osteoblastic cell adhesion, and promoting 
angiogenesis [40]. Magnesium has been shown to play a role in calcification, mineral 
metabolism, HA crystal formation and increased bone cell adhesion, proliferation and 
differentiation, thus the utilization of magnesium-based implants is acceptable from a biological 
standpoint, however only recently have the mechanisms behind the effect of magnesium ion 
levels on osteoblast viability been investigated, and this work is still in the early stages [19, 34, 
41]. 
Due to the promising results of magnesium for bone regeneration, the use of 
magnesium phosphate (MgP) based materials has been proposed for clinically adoptable 
implants [29-31].  Currently, the body of published research regarding magnesium 
phosphates for biomedical applications is limited both in variety and depth of study.   The 
majority of current studies of individual magnesium phosphate phases tend to focus 
solely on materials synthesis and characteristics without thorough in vitro evaluation of 
cell response to the material [33, 153, 154]. Studies which do focus on cytocompatibility 
often have little detail regarding materials characteristics and are frequently combined with 
calcium phosphates which convolute the implications of the presence of magnesium 
phosphate [55, 58, 155-157].  In two recent studies, researchers have synthesized MgPs and 
amorphous magnesium phosphate nanoparticles for biomedical applications [30, 39].  In each 
study, the non-toxicity of MgPs on relevant cell lines was demonstrated. However, neither of 
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these studies demonstrated the capability of MgPs to support osteogenic differentiation on bulk 
samples or explored osteoclastic resorption directly on the MgP scaffolds.   
The study explores the materials characteristics and inherent cytocompatibility of 
amorphous magnesium phosphate and crystalline tri-magnesium phosphate, Mg3(PO4)2. The 
comparison of amorphous and crystalline embodiments of magnesium phosphate is of particular 
interest due to the anticipated differences in stability, solubility and reactivity resulting from 
varying the crystallinity of the scaffold, which may result in differences in cellular viability 
on the substrates.  The focus of the current work was to explore the synthesis and 
cytocompatibility of amorphous and crystalline MgPs, the spontaneous mineralization of the 
amorphous MgP in vitro and the mineralization-assisted increase in cytocompatibility of the 
amorphous MgP material.  The mineralization of biomaterial surfaces in aqueous solutions, 
such as cell culture media, has been widely observed to improve the in vitro cytocompatibility 
and in vivo biocompatibility and osseointegration of a variety of materials including hydrogels, 
electrospun polymers, glass fiber composites and metallic implants, including the 
mineralization of magnesium phosphate on gellan gum hydrogel [158-164]. This study thus 
evaluates the synthesis of MgPs and aims to characterize the materials properties as well as 
in vitro mineralization of the amorphous MgP pellet surfaces. Cytocompatibility with 
osteoblast-forming and osteoclast-precursor cell lines is also assessed in order to evaluate 
whether amorphous magnesium phosphate or crystalline tri-magnesium phosphate are 
favorable candidate materials for bone void repair applications.   
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2.2 MATERIALS AND METHODS 
2.2.1 Materials Synthesis 
Magnesium phosphate (MgP) powders were synthesized through an aqueous precipitation 
reaction between magnesium chloride and tri-sodium phosphate (Sigma Aldrich). The reactants 
were dissolved separately in deionized water at concentrations of 0.3 M and 0.2 M respectively. 
The magnesium containing solution was then pipetted into the phosphate containing solution, at 
room temperature, resulting in precipitation of magnesium phosphate following the reaction in 
Equation 2-1:  
Equation 2-1 
3Mg+ + 2PO43- Mg3(PO4)2 
The solution was centrifuged at 19,500 rcf for 5 minutes and the supernatant liquid was 
discarded. The resulting precipitate was rinsed in deionized water and then centrifuged in 
triplicate to remove the excess sodium and chloride ions. Finally, the precipitate was rinsed in 
acetone, centrifuged and the solid was collected. The precipitate was dried overnight at 60 °C 
and stored in sealed containers under ambient conditions before further testing.  
2.2.2 Materials Characterization 
Crystalline phases were identified using X-ray diffraction (XRD, Philips X-Pret PRO 
diffractometer) equipped with Cu Kα radiation and a Si-detector (X’celerator). The X-ray 
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generator was operated at 45 kV and 40 mA at a 2θ range of 10-90 degrees.  Thermogravimetric 
analysis and differential scanning calorimetry (TGA and DSC, Netzsch STA 409 PC Luxx) were 
used to identify the level of hydration and temperature of crystallization. The as-synthesized 
powder was heated at a rate of 10 °C/min to 1000 °C under argon. The particles formed were 
observed via scanning electron microscopy (SEM, JEOL, JSM-6610LV). Samples were sputter 
coated with palladium (Cressington sputter coater 108A) prior to imaging. Energy dispersive 
spectroscopy (EDS) was used to identify the relative atomic content of the synthesized powder. 
Fourier transform infrared spectroscopy (FTIR, Nicolet 6700 spectrophotometer, Thermo 
Electron Corporation) with a diamond ATR Smart orbit was used to identify the differences in 
molecular chemical linkages between amorphous and crystalline precipitates. FTIR spectra were 
obtained at a resolution of 1.0 cm-1 averaging 64 scans in the 400 – 40000 cm-1 frequency range.  
High-resolution transmission electron microscopy (HRTEM, JEOL JEM-2100F with Gatan GIF-
Tridiem) was operated at 200 kEV to obtain high-resolution images to confirm the crystallinity 
and assess the individual particles. For HRTEM, the particles were suspended in ethyl alcohol 
and pipetted on copper grids with holey carbon film. The sample grids were subsequently air-
dried before imaging. 
2.2.3 In Vitro Sample Preparation 
To prepare samples for in vitro testing, MgP powders were thermally treated, pressed into 
pellets, and then sintered through additional thermal treatment to circumvent extensive weight 
and volume changes during thermal treatment. To create amorphous magnesium phosphate 
pellets, the powder was heated to 200 °C for 6 hours in air, pressed into pellets and then again 
heated to 200 °C for 6 hours in air to sinter the pellets, termed as “ATMP” pellets. To create 
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crystalline TMP pellets, the as-prepared powder was heated to 750 °C for 4 hours in air, pressed 
into pellets and then again heated to 750 °C for 4 hours in air to sinter the pellets, termed as 
“CTMP” pellets. The pellet size was 13 mm diameter x 2 mm thick and were pressed using a 
Carver hand press set to 10,000 psi.  . For a positive control β-tricalcium phosphate (β-TCP, 
HIMED Inc, Old Bethpage, NY) powder was also pressed into pellets of the same size and 
sintered at 1000 °C for 4 hours. 
2.2.4 In Vitro Dissolution and Mineralization 
Substrates were sterilized by rinsing in ethanol for 15 minutes then drying under exposure to UV 
light for 1 hour per side. Each substrate was soaked in 2 mL of α-MEM growth media (MEM α, 
Gibco, Grand Island, NY) containing 0 %, 10 %, and 20 % fetal bovine serum (FBS) and 1 % 
penicillin/streptomycin (P/S) antibiotics, under standard growth conditions of 37 °C, 5 % CO2 
and 95 % relative humidity.  The different concentrations of FBS in media were used to assess 
the role that FBS may play on the surface changes and mineralization. The in vitro dissolution 
characteristics of ATMP, CTMP and β-TCP substrates were characterized by assessing ionic 
concentrations of magnesium and calcium within the collected supernatant cell culture media 
through inductively coupled plasma optical emission spectroscopy (ICP-OES, iCAP duo 6500 
Thermo Fisher). The media was collected at numerous time points through 7 days of incubation. 
All media was removed at each time point and media was not changed between time points to 
allow for sequential and cumulative release measurements. Collected media was diluted in 0.03 
M Tris buffer solution and analyzed by ICP-OES with the culture media used as standard to 
compare against. Calcium ion concentrations were measured in order to compare the TMP 
substrate ion release to the ion release from the β-TCP control.  Following incubation in cell 
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culture media, the substrates were dried for observation under SEM. The mineral formed was 
characterized by collecting the particles grown on the surface and analyzing them using SEM 
coupled with EDS, FTIR and HRTEM, as described above. 
2.2.5 Cell Culture 
Murine MC3T3 –E1 pre-osteoblast cells and RAW 264.7 macrophage cells were utilized for cell 
culture studies. Cells were cultured at 37 °C, 5 % CO2 and 95 % relative humidity in α-MEM 
(MC3T3-E1 cells) or DMEM (RAW264.7 Cells) growth media containing 10 % FBS and 1 % 
P/S.  The substrates were sterilized as previously described, soaked in culture media for 24 
hours, then seeded with MC3T3 cells at a density of 40,000 cells/well or RAW cells at a density 
of 50,000 cells/well in 24-well plates.  The media was changed every other day throughout 
testing.  
2.2.6 Osteoblast Assessment 
Cell viability was assessed using Live/Dead staining (Invitrogen, Live/Dead Staining Kit). The 
Live/Dead assay was performed on days 1 and 5 post seeding according to the manufacturer’s 
protocol.  Imaging was performed using fluorescence microscopy (Olympus CKX41). 
Following imaging, cells were fixed using a 2.5 % glutaraldehyde solution and subjected to 
alcohol dehydration and mounted for SEM imaging under the previously stated conditions.   
Cell viability directly cultured and indirectly cultured was assessed using the MTT 
activity assay (Vybrant® MTT Cell Proliferation Assay Kit).  For the MTT assay, the cells were 
subjected to fresh media, 500 μL each, with 50 μL of 12 mM MTT (3-(4,5-Dimethylthiazol-2-
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yl)-2,5-diphenyltetrazolium bromide) solution and incubated for 4 hours. After incubation, 500 
μL of sodium dodecyl sulphate was added and incubated for 18 hours to lyse cells and solubilize 
formazan.  After solubilization, 200 μL of solution from each sample was transferred to a 96 well 
plate and the absorbance of the sample was measured using Synergy2 Multi-Mode Microplate 
Reader (Biotek, USA) at an emission wavelength of 570 nm.  Due to concerns surrounding Mg2+ 
interaction with MTT as reported in the literature, the reported values are normalized by 
background readings for each material [165]. However, significant differences between 
backgrounds were not observed. An indirect method of culture was also employed to distinguish 
between the effects of ions dissolved from the samples in media and surface morphology on the 
osteoblast viability. The pellets were incubated in 2 mL of culture media supplemented with FBS 
and P/S for 48 hours. This supernatant media was then collected and MC3T3 cells cultured on 
tissue culture plastic (96 well plates) were exposed to this media for 1 and 5 days, replacing with 
new supernatant every 48 hours. Cells were exposed to the fully concentrated supernatant as well 
as supernatant diluted into fresh culture media to 25% of the original concentration. MTT 
activity assay were then completed similar to the protocol above. 
Osteoblast maturation was assessed by measuring alkaline phosphatase (ALP) activity. 
MC3T3-E1 cells were cultured on substrates for 7 days in growth media (α-MEM with FBS and 
P/S). After 7 days cells were cultured in osteogenic media. Osteogenic media was prepared by 
supplementing the growth media with 100 nM dexamethasone, 50 µM ascorbic acid and 10 mM 
β-glycerophosphate and cultured for an additional 3, 7 and 14 days. After culture for these time 
points, samples were rinsed with PBS then incubated in CellLytic cell lysis buffer, 0.5ml per 
well, for 30 minutes on a shaker to lyse the cells. The supernatant was collected, centrifuged and 
stored at -20°C until testing. For determination of ALP activity, Sigmafast p-nitrophenyl 
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phosphate (pNPP) and Tris Buffer tablets were used.  200 µL of pNPP buffer solution was mixed 
with 20 µL of lysis extract and incubated for 2 hours at 37°C. 0.3 N NaOH solution was added to 
stop the reaction, and the absorbance was read at 405 nm using the plate reader. The total protein 
concentration was determined, utilizing a Pierce BCA Protein Assay kit according to the 
manufacturer’s protocol.  The ALP activity was normalized by the total protein content for each 
sample. 
2.2.7 Osteoclast Assessment 
The proliferation, maturation, and activity of RAW 264.7 monocytes into osteoclast-like cells 
were assessed through SEM imaging and fluorescent staining of cellular actin and nuclei.  RAW 
cells were seeded on substrates in 24 well plates with 1 mL of media per well. The cells were 
cultured for 24 hours after seeding in growth media, after which cell culture media was 
supplemented with 50 ng/mL RANKL (BioLegend, San Diego, CA) to induce differentiation 
into poly-nucleated osteoclast-like cells. The media containing RANKL was replenished every 
other day.   The cells were rinsed with PBS and fixed using a 4 % paraformaldehyde solution.  F-
actin was stained using phalloidin–Tetramethylrhodamine B isothiocyanate (phalloidin-TRITC, 
Sigma Aldrich) and the nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI) 
(Applichem) according to the manufacturer’s instructions. Imaging was completed using 
fluorescence microscopy as previously described. Subsequently, the cells were subjected to 
alcohol dehydration and mounted for SEM imaging, under the previously stated conditions.  
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2.2.8 Statistical Analysis 
Statistical calculations were performed using IBM SPSS Statistics 20 statistical analysis 
program.  For TGA/DSC the mean and standard deviation was expressed for a total of seven 
independent samples. For all other quantitative assessments, including ionic content via ICP-
OES, MTT viability assay and ALP activity assay, the mean and standard deviation was assessed 
for a sample size of three per sample. Statistically significant differences were assessed through 
one-way ANOVA with Tukey’s post hoc testing where significance was set at p<0.05.  
2.3 RESULTS 
2.3.1 Materials Synthesis and Characterization 
The purpose of this study was to synthesize crystalline and amorphous magnesium phosphate 
phases, characterize the synthesized powders, and evaluate their biological response in vitro. For 
the majority of the materials testing, a total of seven batches of synthesized materials were 
analyzed in order to ensure repeatability.  The x-ray diffraction results of the as-synthesized 
powder and thermally treated powders can be seen in Figure 2-1a. Diffraction data indicates that 
the native as-synthesized powder is indeed amorphous.  Similar to the as-synthesized material, 
the material thermally treated to 200 °C for 6 hours in air was also shown to be amorphous in the 
bulk. The material heat treated to 750 °C for 4 hours in air, above the exothermic reaction 
temperature seen in DSC, was however as expected was identified to be crystalline Mg3(PO4)2
(TMP, ICCD Card 00-033-0876). To understand the crystalline phase evolution during thermal 
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treatment of the amorphous phase, TGA/DSC was also conducted, the results of which are 
shown in Figure 2-1b.  DSC analysis conducted in argon indicates a broad endothermic reaction 
with an average reaction onset and end between 90-212 °C and a sharp exothermic peak with an 
average onset and end temperatures between 657-689 °C. The TGA plot shows an average 
weight loss of 30.4 % with approximately 24.2 % occurring within the bounds of the 
endothermic peak seen between 90-212 °C and the remaining weight loss occurring gradually 
throughout the temperature range of thermal treatment.  
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Figure 2-1 Basic material characterization showing (a) XRD of the as synthesized powder and the 
powder thermally treated to 200 °C and 750 °C with reference pattern of Mg3(PO4)2 (ICCD Card 00-033-
0876) and (b) TGA/DSC of the as synthesized powder. 
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In Figure 2-2a are shown representative SEM images of the native, as-synthesized 
precipitate and the precipitate after thermal treatment to 750 °C for 4 hours in air. No qualitative 
difference can be seen in the particle size and geometry between the as-synthesized and the 
crystallized particles, with both native and thermally treated powders showing the flat, plate-like 
particles with a wide distribution of particle sizes.  An EDS spectrum was used to identify the 
elemental composition of the powders (data not shown). The measurements showed an average 
Mg/P ratio of 1.48 ± 0.04, confirming the nearly stoichiometric nature of the tri-magnesium 
phosphate present in the as-synthesized amorphous material. Representative HRTEM images of 
the as-synthesized and thermally treated powders are shown in Figure 2-2b. The low-
magnification image of the as-synthesized powder indicates that the particles seen in SEM are in 
fact, agglomerates of much smaller spheres of amorphous material. High magnification images 
of the as-synthesized and thermally treated powders and fast Fourier transform (FFT) pattern 
insets (2-2b center and right, respectively) confirm that the precipitated TMP is amorphous and 
forms a highly disorganized crystalline material under the thermal treatment parameters. Given 
this characterization information, subsequent in vitro testing was completed on powders treated 
to 200 °C (ATMP) and 750 °C (CTMP).  XRD of sintered pellets confirmed that pellets 
thermally treated to 200 °C remained amorphous and pellets thermally treated to 750 °C retained 
the same crystalline TMP form (data not shown), confirming the stability of the amorphous and 
crystalline powders under the extended thermal treatment required for pellet generation. 
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Figure 2-2  Electron microscopy of synthesized Mg3(PO4)2 powders displaying (a) representative SEM 
images of the as-synthesized and thermally treated powders (scale bar is 10µm) and (b) TEM images of the as 
synthesized powder at low magnification (scale bar is 40 nm) at left and images of the as-synthesized and 
thermally treated powders at high magnification (scale bar is 2 nm).  Insets show diffraction patterns of the 
respective samples. 
2.3.2 In Vitro Dissolution and Mineralization 
In vitro dissolution and surface mineralization of the pellets was studied in order to understand 
the media and surface environment to which cells are exposed to. Pellets of ATMP, CTMP and 
β-TCP were immersed in the growth media and the media was collected at numerous time points. 
ICP-OES was then used to determine the ionic concentrations of magnesium and calcium in the 
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media in order to evaluate the dissolution of substrates under in vitro conditions.    ICP-OES 
measurements show that the ATMP released much higher levels of magnesium ions than CTMP, 
up to 9 mM with ATMP versus 3 mM with CTMP  (Figure 2-3a, top) after 125 hours of 
immersion, while magnesium ion concentrations in β-TCP controls remained the same as the 
media samples (p<0.001). Measurements of calcium ion concentration (Figure 2-3a, bottom) 
showed an interesting trend of calcium ion level reduction over time. All three materials showed 
some calcium level reduction in media (p<0.01 beyond 1 hour for ATMP and CTMP, p<0.01 for 
β-TCP beyond 12 hours), however the reduction in Ca levels for ATMP was significantly higher 
than CTMP or β-TCP (p<0.01 beyond 1 hour).  
Figure 2-3 In vitro dissolution of pellets showing (a) the released ion concentrations of magnesium (top) 
and calcium (bottom) into the media and (b) SEM of pellet surfaces: as-synthesized and after 14 days in 
media (scale bar is 10 µm). 
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SEM images of the pellet surfaces prior to media exposure and after two weeks of media 
incubation can be seen in Figure 2-3b. The images indicate that the surface of β-TCP and CTMP 
remain relatively unchanged throughout this time period while the ATMP surface undergoes 
significant morphological changes. The ATMP surface promotes the growth of rosette-like 
crystal features. Images of the surface of ATMP pellets incubated for 14 days in culture media 
with 0 % and 20 % FBS, shown in Figure 2-4a, also show significant changes in morphology. 
The change in ATMP surface morphology when incubated in 0 %, 10 % and 20 % FBS are quite 
different, indicating the critical role FBS may play in the dissolution and formation of the rosette 
type morphology.  In order to determine the nature of the surface growth, granules of the rosette 
shaped growths were scraped from the surface and analyzed. FTIR spectra of the ATMP powder, 
CTMP powder, FBS and the scrapings of the rosette growth collected from the surface of the 
ATMP can be seen in Figure 2-4b.   
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Figure 2-4 SEM images of ATMP pellets (a) after 14 days of incubation in culture media with 0 % and 
20 % fetal bovine serum (FBS, scale Bar is 5 µm) and FTIR spectra (b) of ATMP and CTMP powders, FBS, 
and ATMP pellet scrapings. 
FTIR spectra of the CTMP powder shows numerous sharp peaks  between 900-1200 cm-1 
and  450-700 cm-1 which correspond with various PO43- adsorption bands;  ʋ2 (480 cm-1),  ʋ4 
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(575 & 590 cm-1),  ʋ1 (960 cm-1) and  ʋ2 (1000 cm-1), respectively [166].   ATMP powder 
spectra show broad peaks around 1000 cm-1 and 600 cm-1. These bands are the result of the 
various PO43- bands which lack the splitting and definition of specific bonds corresponding to the 
crystalline state due to the amorphous nature of the TMP powder. Scrapings of the rosette growth 
show that there appears to be minor increased organization of phosphate bonds around 1000 cm-1 
but the linkages do not achieve distinguishable states corresponding to the various conformations 
(bending and stretching) which are seen in the fully crystallized CTMP material and are not truly 
indicative of crystallization.  The spectra also show adsorbed water (broad peak 2700-3500 cm-1) 
as well as numerous broad bonds associated with carbon-oxygen bonds.  These carbon-oxygen 
bands can be attributed to the carbonate ions substituted into the phosphate structure, wherein 
bonds at 850 cm-1 and between 1400-1650 cm-1 could represent the carbonate substitution for 
hydroxide or phosphate typically seen in the apatite structure [166]. The broad peaks between 
3000-3500 cm-1 is attributed to the adsorbed water. Finally, the weak peak seen at 3500 cm-1 as 
well as the peak observed at 700 cm-1 may be attributed to OH- stretch which would be indicative 
of the formation of the characteristic apatite-like structure [166].   The amorphous nature of the 
surface growth requires the use of additional characterization techniques to further distinguish 
the specific role of various ions or compounds contributing to the growth of the final product.    
Figure 2-5a shows the SEM image of the ATMP pellet surface during the early stages of 
the rosette structures formation. This image shows that the rosette structures indeed grow onto 
the surface of the pellet as opposed to growing within the culture media and depositing on the 
pellet surface.  In Figure 2-5b and c are low and high magnification HRTEM images 
(respectively) of collected rosette scrapings from an ATMP pellet surface after incubation. The 
image in Figure 2-5c and corresponding FFT pattern (insert) indicate that although the habitual 
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rosette morphology would imply the formation of a crystalline product, the structures in fact is 
amorphous.    EDS measurements shown in Figure 2-5d, while not reliably quantitative, indicate 
that the isolated products are composed of phosphorous, oxygen and magnesium with a 
significant amount of calcium, suggesting that these rosette morphologies are likely calcium-
substituted magnesium phosphates. 
Figure 2-5 SEM image of early rosette formation (a) at 24 hours of incubation (scale bar is 1 µm), TEM 
images of pellet scraping at low magnification (b, scale bar is 20 nm) and high magnification (c, scale bar is 5 
nm) with inset containing the diffraction pattern for the particle, and EDS elemental analysis from the 
particle (d).
2.3.3 In Vitro Cytocompatibility 
Viability of MC3T3-E1 murine pre-osteoblasts was characterized using Live/Dead staining as 
well as the MTT viability assay. Live/Dead staining at days 1 and 5 post seeding can be seen in 
Figure 2-6. The cellular attachment on ATMP and CTMP substrates qualitatively showed cell 
densities similar to the β-TCP control at day 1. At day 5 however, ATMP and β-TCP substrates 
showed significant proliferation from day 1. In contrast, the CTMP substrates showed only 
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minor changes in live cell density after day 5. MTT assay results of direct and indirect cell 
cultures, seen in Figure 2-7a, showed that there are differences in cell activity levels between 
substrates, similar to the trends visualized in the Live/Dead staining. Day 1 results show that 
with direct cell seeding, ATMP and CTMP are significantly lower than β-TCP and not 
statistically different from each other (p<0.05) while with the indirect culture the ATMP surface 
exhibits viability that is lower than the CTMP. Day 5 analysis shows that with direct seeding, β-
TCP is slightly higher than ATMP (p=0.061) while CTMP is now much lower than both β-TCP 
and ATMP (p<0.05).  Day 5 indirect cultures show an even greater difference between ATMP, 
and the CTMP and β-TCP (p<0.05). Dilution of the extract appears to negate the cellular activity 
differences observed in the cultures. 
Figure 2-6 Live/Dead staining of MC3T3 osteoblasts, left to right are βTCP, ATMP and CTMP at days 
1 and 5 post seeding (top and bottom respectively, scale bar is 200 µm). 
In Figure 2-7b-d can be seen representative SEM images of fixed cells on the surface of 
βTCP, ATMP and CTMP pellets. Figure 2-7c shows that the MC3T3-E1 cellular cytoplasmic 
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extensions appear to be preferentially attached to the rosette formations on the surface of the 
ATMP pellet, as indicated by the arrows in the images.  Alkaline phosphatase activity is shown 
in Figure 2-7e. Results indicate that MC3T3 cells show an earlier increase in ALP activity on the 
ATMP pellets than on the β-TCP or CTMP pellets. At 7 days of culture in osteogenic media, a 
total of 14 days of culture, ALP activity presented on ATMP pellets was statistically higher than 
the β-TCP (p=0.004) and CTMP (p=0.001). By 14 days of culture in osteogenic media, β-TCP 
achieved ALP levels similar to ATMP and the tissue culture control (p>0.5) while the CTMP 
substrates never achieved increased ALP activity levels (p<0.05).  
SEM images of RAW 264.7 cells fixed on substrates after 8 and 11 days of culture in 
media supplemented with RANKL can be seen in Figure 8. β-TCP substrates show significant 
proliferation of monocytes and the formation of polynucleated cells at Day 8 with pseudopodia 
extensions of these cells at Day 11. After 8 and 11 days of culture both ATMP and CTMP show 
substantial proliferation and attachment of monocytes to pellet surfaces but the samples give no 
indication of the formation of polynucleated cells. In Figure 2-9 are displayed images of actin 
and nucleus staining of RAW cells.  Images indicate that monocytes grown on tissue culture 
plastic controls rapidly form polynucleated cells, as seen in the Control, Day 8 image. The 
Control Day 11 image shows strong actin ring formation surrounding polynucleated cell, which 
is indicative of true osteoclast cell formation. β-TCP substrates show formation of some 
polynucleated cells at Day 8 and pseudopodia extensions of these cells at Day 11. Similar to 
SEM image results collected after 8 and 11 days of culture both ATMP and CTMP show 
significant proliferation of monocyte and although there are clusters of monocytes, there is no 
indication of the formation of polynucleated osteoclast-like cells.  
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Figure 2-7  MTT viability results of direct and indirect MC3T3 cell culture (a), SEM images of fixed 
MC3T3 cells on βTCP, ATMP and CTMP pellets 24 hours after seeding (b-d, scale bar is 50 µm) showing 
preferential attachment to surface growth particles (indicated by the arrows) on the ATMP scaffold, and 
ALP activity of MC3T3 cells cultured on pellets in osteogenic media (OM) (e). *Units of ALP are 
[(µmol/hr)/(µg protein)/cm2 surface area]. 
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Figure 2-8 SEM Images of RAW 264.7 cell morphology on pellet surfaces after 8 and 11 days of culture 
in media supplemented with RANKL (scale bar is 25 µm). 
Figure 2-9 Actin-Nucleus staining of RAW 264.7 cells at days 8 & 11 of culture in media supplemented 
with RANKL (scale bar is 50 µm). 
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2.4 DISCUSSION 
Magnesium, one of the most common metals in the body, is implicated in more than 300 
enzymatic reactions, and shares many chemical similarities with calcium [167-169]. For this 
reason, many researchers have begun assessing the potential benefit of partially or fully 
substituting magnesium in calcium phosphate based implants intended for bone regeneration, 
since 50-60 % of the body’s magnesium is stored in bone [167]. The work in this paper operates 
on the notion that calcium phosphates or biologics such as BMP-2 are not necessary for an 
effective bone repair scaffold. All necessary chemical and mechanical signaling for bone repair 
can be achieved through strong constructs with ion-based cell regulation; in particular the use of 
magnesium phosphate is attractive as magnesium is known to upregulate cellular proliferation 
and osteoblast activity [34, 40, 41]. As research in this field progresses, new embodiments, 
synthesis methods, and insight into the biological activities of magnesium phosphates are being 
discovered which will increase the breadth and depth of knowledge of these lesser studied 
materials. The aqueous precipitation of magnesium phosphates is not a new phenomenon, 40-41 
but has recently been revisited by a few authors including Tamimi et al with the purpose of 
relating the spontaneous precipitation to biologically relevant conditions [30, 170, 171].  Tamimi 
et al found that, at 37 °C and pH below 8.0, under physiological concentrations with 10x 
physiological concentrations of magnesium and phosphate ions, mineral precipitation did not 
occur. Under other pH, temperature and ion concentration ranges, copious precipitation however 
occurred, most frequently resulting in the formation of crystalline tri-magnesium phosphate with 
various levels of bonded water. These minerals where shown to be non-toxic. More recently, 
Zhou et al reported a method of microwave synthesis of amorphous magnesium phosphate 
nanoparticles, which transformed to Mg3(PO4)2•8H2O when incubated in cell culture media 
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while Douglas et al reported the formation of a mixture of amorphous magnesium phosphate and 
Mg3(PO4)2•8H2O on a hydrogel scaffold which showed improved cytocompatibility over 
calcium phosphate mineralization on the same hydrogel [33, 164].  However, beyond this recent 
study, no studies characterizing amorphous magnesium phosphate have been published.  
The aqueous precipitation method used in this study is at higher ionic concentrations than 
those utilized by either Tamimi or Zhou. This high concentration, room temperature aqueous 
precipitation of magnesium phosphate powder was demonstrated to be a simple, reliable method 
of formation of the phosphate.  Spontaneous precipitation of amorphous magnesium phosphate 
(ATMP) from MgCl2 and Na3PO4 solutions occurred in a highly basic environment. The 
precipitate remains amorphous while in solution, and rapid rinsing and drying of the powder is 
deemed necessary to stabilize the amorphous material. Once dried, the amorphous powder is 
stable under ambient conditions, similar to amorphous calcium phosphate (ACP) [172]. Thermal 
treatment above 600 °C in air for extended time however, is required to transform the material 
into crystalline Mg3(PO4)2. The combination of TGA, DSC and XRD results shown in Figure 2-
1a and 2-1b indicate that the low-temperature endothermic reaction seen in DSC corresponds to 
the loss of water from the precipitate structure while the high temperature exothermic reaction 
corresponds to the transition of the TMP precipitate from amorphous to crystalline phase of 
TMP. The loss of water and the corresponding temperature induced phase transition results in the 
formation of crystalline anhydrous Mg3(PO4)2 after thermal treatment.  
While the SEM images of the TMP powder, Figure 2-2a, show flat, plate-like particles, 
HRTEM images in Figure 2-2b (left) indicates that the as-synthesized bulk particles are 
agglomerates of much smaller, spherical particles which appear to be in the range of 50 nm. The 
thermal treatment of these agglomerates results in numerous randomly oriented microcrystalline 
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regions within a single particle, Figure 2-2b (right). The agglomeration of nanoparticle sized 
precipitates into larger particles has been the subject of thorough study by Matijević et al as well 
as many others [173, 174]. Matijević et al’s work indicates that the agglomeration of 
nanoparticle precipitates into micron-sized particles of seemingly crystalline shapes is not 
unusual and may be controlled by synthesis parameters such as ion concentrations, pH and 
agitation rate [173, 174].  Such parameters could be further controlled during the TMP synthesis 
and result in greater control over the size, morphology and polydispersity of the as-synthesized 
TMP particles. Powder characteristics of particle size and morphology have direct implications 
towards the reactivity and stability of the bulk material and would be of high interest to study 
moving forward.  
Many implanted materials are designed to be replaced by native tissue through 
dissolution and degradation. This rate of implant removal is controlled by numerous material and 
implant properties.   While these mechanisms are often desired, overly-aggressive reactions may 
result in implant failure and localized or systemic toxicity.  The in vitro dissolution patterns 
(Figure 2-3a) shown by the ATMP and CTMP indicate sustained release of magnesium from 
both substrates during incubation as well as calcium removal from the media. The higher 
magnesium release shown by the ATMP over the CTMP is as expected, as amorphous materials 
are generally more soluble than their crystalline counterparts due to the disordered nature of the 
amorphous structure [175].  It should be noted that in measuring the dissolution of the pellets in 
vitro, the intention is to draw connections between relative dissolution rates and cellular activity, 
and not to predict clinical dissolution rates. Though the ion concentrations are not at median 
lethal dose 50 % (LD50) levels, it could be anticipated that the high level of magnesium 
concentration in ATMP cell culture should result in lower osteoblast viability in comparison to 
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the CTMP culture [47, 176]. However the direct opposite is observed: the ATMP displays 
markedly better MC3T3 viability over time than the CTMP.  Live/Dead staining (Figure 2-6) and 
MTT viability tests (Figure 2-7a) indicate that ATMP is more cytocompatible over time than 
CTMP. To test the hypothesis that the increased magnesium ion concentration in ATMP should 
be detrimental to osteoblast viability, the indirect method of culture was employed, utilizing 
media extracted after pellet incubation. The indirect culture shows the anticipated results, with 
fully concentrated extracts from ATMP showing statistically lower viability than the CTMP 
extracts, especially after 5 days of culture (Figure 2-7a).    
The differences seen between ATMP and CTMP in the direct versus indirect cultures 
imply that there is some other factor, such as surface chemistry or mechanotransduction, 
modulating the osteoblast cell viability on the ATMP. Herein the effect of the surface 
morphological changes observed on the ATMP which are not observed on the CTMP is 
concluded to be this modulating effect.  The surface growth documented on ATMP (Figures 2-
3b, 2-4a and 2-5a) is seen in the SEM images of fixed MC3T3 cells (Figure 2-7c). These 
representative images appear to show that the osteoblast cellular cytoplasmic extensions are 
preferentially elongated and attached to the rosette nodules grown on the ATMP surface. This 
indicates that the surface mineralization on the ATMP is directly affecting the osteoblast 
viability.   It is difficult to elucidate beyond this whether the improved viability is due to 
physiochemical or mechanical cues, although it is likely due in part to both.  
This spontaneous mineralization, and resulting increase in cytocompatibility, is of 
particular interest because past studies have shown that in vitro mineralization of synthetic 
biomaterials’ surfaces results in increased cytocompatibility in vitro and biocompatibility in vivo 
[158, 160, 162, 163, 177-180]. Many researchers purposely mineralize the surface of 
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biomaterials and spontaneous mineralization is seen by many as inherently valuable [177, 180].  
The rosette formations seen on ATMP pellet surfaces are nearly identical to calcium phosphate 
and hydroxyapatite mineralization habits seen on a wide variety of biomaterials [177, 181]. The 
visualized rosette morphology classically resembling apatite, in addition to the ICP results, 
showing calcium ion consumption from the media, and the EDS observations, showing calcium 
ion presence in the rosette structure all indicate that the rosette formations can be anticipated to 
have a hydroxyapatite framework highly substituted with magnesium.  However, the formations 
were shown to be amorphous in nature.  Magnesium, especially at high substitution levels, is 
known to stabilize amorphous calcium phosphate during synthesis and under in vitro conditions, 
suspending the formation of crystalline hydroxyapatite [155, 168, 182-184]. Additionally, results 
show that the level of fetal bovine serum plays a role in stabilizing the rosette morphology of the 
ATMP surface growth (Figure 2-4a).  Though the presence of FBS-provided compounds, such as 
amino acids and growth factors, may contribute to the development of a particular growth 
morphology of the substrate, it is not specifically resolved in the FTIR spectra (Figure 2-4b). It is 
possible that there are proteins adsorbed to the surface of the mineralized growth but that the 
concentration is too low for proper detection with the methodology utilized.   
The effect of this rosette growth on osteoblast cells may be significant. Not only does the 
cytocompatibility of the amorphous magnesium phosphate pellets improve over the CTMP 
pellets, the early stage of differentiation of MC3T3 cells into osteoblasts, as measured by the 
increased ALP activity on ATMP substrates (Figure 2-7e) at earlier time points than β-TCP 
controls maybe both attributed in part to the rosette growth.  The result is that the ATMP 
material achieves high levels of cellular proliferation and more active differentiation than even 
the β-TCP control. This is in contrast to what has been seen in some cell culture on magnesium 
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phosphate minerals and cements, which displayed decreased osteoblast gene expression, 
including ALP, in comparison to calcium phosphate analogs [30, 86].  Studies have shown that 
magnesium doping into calcium phosphates or magnesium ion supplementation in vitro can 
increase osteoblast differentiation, and it is likely that the calcium rich surface mineralization is 
reducing the effect of direct magnesium phosphate interaction [60, 185-187].  In contrast, the 
lack of differences in viability and differentiation of RAW 264.7 monocytes into osteoclast-like 
cells on the ATMP and CTMP indicates that the differentiation appears to be affected by only the 
presence of a high level of magnesium and not the surface mineralization. Though the mineral 
layer may restrict physical contact with magnesium phosphate substrate, the magnesium ion 
concentration which the RAW cells are exposed to is high with both the ATMP and CTMP 
substrates.  SEM images of RAW cells grown on substrates with RANKL supplementation 
(Figure 2-8) indicate that all substrates facilitated active monocyte proliferation. However, while 
RAW cells actively form osteoclast-like polynucleated cells on β-TCP, there is almost no 
indication of polynucated cells observed on ATMP or CTMP substrates during the period 
studied. Previous studies have shown that magnesium ions appear to temporarily suspend the 
formation and differentiation of precursor monocytes into mature osteoclasts but that magnesium 
does not affect the viability and function of mature osteoclasts [44, 45, 74, 188].  Because of the 
number of factors affecting osteoclast studies, osteoclast-substrate studies are often controversial 
and more precise, controlled studies would be highly beneficial to understanding the relationship 
between magnesium ions, magnesium phosphates, effects of surface composition, microstructure 
and particle size on osteoclast cells  [189].  
The early differentiation of osteoblasts and suspended formation of osteoclasts may have 
a positive effect on the integration of the material into bone. Due to the reactive nature of the 
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amorphous magnesium phosphate, and the resulting spontaneous mineralization of ATMP in 
vitro, this material is likely to generate implant substrates which are more bioactive and 
osteoconductive than the more common inert materials. The high solubility but lower anticipated 
cell-mediated resorption of the amorphous magnesium phosphate, along with the increased 
osteoblast activity, could result in more rapid formation of new bone tissue in vivo. Future work 
exploring the in vivo reactivity, degradation and bone formation would be interesting to 
determine whether in vitro results presented here correspond well with in vivo mineralization of 
similar amorphous, apatite-like formations as well as possibly demonstrating a favorable effect 
of the amorphous magnesium phosphate and surface mineralization on osteoblast and osteoclast 
activity. These studies are currently being planned and will be reported in the near future. 
2.5 CONCLUSION 
Amorphous magnesium phosphate was successfully generated through an aqueous precipitation 
method and subsequent thermal treatment resulted in crystalline tri-magnesium phosphate. Pellet 
substrates of the amorphous magnesium phosphate were significantly more soluble in vitro and 
showed higher levels of osteoblast viability and differentiation than the crystalline tri-magnesium 
phosphate phase. Under in vitro cell culture conditions, the amorphous magnesium phosphate 
substrate induced spontaneous growth of calcium-rich amorphous phosphate rosettes 
morphologically similar to crystalline hydroxyapatite mineralization on the pellet surface. The 
increased osteoblast viability is attributed to the synergistic effects of high solubility of the 
material, the high magnesium concentration seen by the osteoblasts, and the serum protein 
mediated apatite-like mineralization on the material.   Both amorphous magnesium phosphate 
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and crystalline tri-magnesium phosphate supported extensive monocyte proliferation but 
suspended osteoclast formation. The combination of high solubility, spontaneous mineralization, 
increased osteoblast proliferation and differentiation and suspended osteoclast formation 
indicates that amorphous magnesium phosphate may be a unique material to explore for bone 
repair implant applications, in particular acid-base reacting bone cement style applications.   
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3.0  SPECFIC AIM 2: SYSTEMATIC ASSESSMENT OF SYNTHESIZED TRI-
MAGNESIUM PHOSPHATE POWDERS (AMORPHOUS, SEMI-CRYSTALLINE AND 
CRYSTALLINE) AND CEMENTS FOR CERAMIC BONE CEMENT APPLICATIONS 
3.1 INTRODUCTION 
Bone substitutes are widely used in patients who require implantation to repair or remodel bone 
defects. These bone substitutes can range from synthetic materials such as metals and polymers 
to natural polymeric and biologic materials including allografts and autografts [1, 3]. Calcium 
phosphate based synthetic grafts are an excellent choice of bone replacement systems because 
these implants mimic the chemistry of the mineralized portion of human bone and have shown 
excellent biocompatibility [10, 24]. Currently, there are calcium phosphate based bone cements 
clinically available; however these products are less than ideal. Optimal bone cements should 
display high biocompatibility and osteoconductivity, strengths similar to natural bone, resorption 
rates in line with rapid bone remodeling, and clinically appropriate mix-ability, injectability, and 
setting times [10, 141, 190]. Brushite (CaHPO4) based calcium phosphate bone cements, 
although readily resorbable, tend to display prohibitively fast setting rates and compressive 
strengths lower than natural bone. Hydroxyapatite (Ca5(PO4)3(OH)) based calcium phosphate 
bone cements are capable of achieving higher strengths, but set very slowly and require several 
years to resorb and allow for bone remodeling [23, 24].    
79 
Recently it has been proposed that magnesium phosphate cements may pose a more 
clinically favorable option to traditional calcium phosphate cements [29]. Preliminary studies 
have shown that magnesium phosphate based cements display higher strengths, better setting 
times and faster resorption rates than calcium phosphates, while maintaining a high level of 
biocompatibility [28, 29, 31, 34, 36, 38, 39, 62, 191]. However, in contrast to calcium 
phosphates, the intensity and depth of study into these cement systems is still limited to only a 
few phases and remains to a large extent unexplored with inconsistent evaluation.  
The following study explored the cementing characteristics of amorphous and crystalline 
tri-magnesium phosphate (TMP), Mg3(PO4)2 ceramic which was synthesized and assessed in 
Chapter 2. Trimagnesium phosphate is a potential bone cement precursor material critical to the 
cementing reaction. It is important to study the precursor reactants as these material properties 
correlate to the final cement product since the material properties affect reaction kinetics, cement 
formulation and final product properties.   Recent studies into magnesium phosphate cements 
have developed due to higher strengths and faster resorption rates of these cements. Magnesium 
phosphate cement or ceramic compositions explored to date include MgHPO4•3H2O, 
MgKPO4•6H2O, Mg3(PO4)2•8H20, MgNH4PO4•6H2O, and Ca3Mg3(PO4)4 [29, 32, 36, 60, 74, 
86]. 
The use of amorphous calcium phosphates (ACPs) in bone scaffolds and cements is 
known, however there is not the same level of understanding regarding the potential of 
amorphous magnesium phosphates for biomedical applications. ACPs are often regarded as 
highly useful as scaffolds or scaffold precursors because of the highly reactive and soluble nature 
of the ACP  [9]. ACP is a critical part of the natural bone formation process, a transient phase 
which is a precursor to HA [192-194].  These ACPs have been used in bone cements to increase 
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the cement reactivity or bioresorbability. ACPs have also been shown to increase 
osteoconductivity of implant coatings as well as increase the mechanical properties of 
composites [192]. Magnesium has been widely shown to stabilize calcium phosphate in the ACP 
stage over conversion to HA [182, 195]. However, the analogy between ACP and amorphous 
magnesium phosphate is not clear as the synthesis of amorphous magnesium phosphate has only 
recently been reported [33]. In the previous study (Chapter 2), a comparison of the 
cytocompatibility of dense substrates of amorphous magnesium phosphate and crystalline tri-
magnesium phosphate showed increased proliferation and differentiation of murine pre-
osteoblast cells on the amorphous TMP substrates over the crystalline CTMP counterpart 
substrates [196]. It is however unclear whether the use of amorphous tri-magnesium phosphates 
is feasible to generate a functional bone cement product, or more importantly, how this cement 
may compare to cement made with a crystalline tri-magnesium phosphate. In this study 
therefore, the functionality of these amorphous and crystalline tri-magnesium phosphate 
powders, as well as the semi-crystalline tri-magnesium phosphates powders, and their propensity 
for cement formation in cement forming reactions with a concentrated, neutral pH ammonium 
phosphate solution particularly, for use in bone cement applications is explored and 
systematically assessed.  
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3.2 MATERIALS AND METHODS 
3.2.1 Synthesis of Magnesium Phosphate Powders 
Magnesium phosphate powders were synthesized via an aqueous precipitation reaction between 
0.3 M MgCl2 and 0.2 M Na3PO4, in deionized water, as described in Equation 2-1.  The 
synthesized powders were then thermally treated to 400 °C, 600 °C or 800 °C for 6 hours at each 
temperature in a box furnace in air to form amorphous, semi-crystalline or fully crystalline 
dehydrated TMP, respectively. Powders were lightly ground and sieved to below 500 µm to 
remove large agglomerated clusters. 
3.2.2 Magnesium Phosphate Powder Characterization 
The as-synthesized and thermally treated magnesium phosphate powder samples were 
characterized utilizing a number of techniques: thermogravimetric analysis and differential 
scanning calorimetry (TGA and DSC), x-ray diffraction (XRD), Fourier transform infrared 
spectroscopy (FTIR), specific surface area (SSA) and scanning electron microscopy (SEM).  The 
detailed specifics regarding controls and parameters used for these characterization methods can 
be found elucidated in Chapter 2.    
3.2.3 Cement Formation 
Series of cements were compared by combining the amorphous, semi-crystalline and crystalline 
Mg3(PO4)2  powders with a pH 7.0, 3 M solution of ammonium phosphate. The solution was 
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made by combining monobasic ammonium phosphate (NH4H2PO4) and dibasic ammonium 
phosphate ((NH4)2HPO4) salts in deionized water at a ratio to obtain pH 7.0.  The ratio of 
monobasic to dibasic ammonium phosphate to yield neutral pH 3 M solution is approximately 
2:7 monobasic:dibasic, which would yield X and Y of approximately 16 and 11, respectively. 
Assuming an ideal complete reaction, this would yield a final product of approximately, 60 % 
MgNH4PO4 and 40 % MgHPO4, as described below. 
The powders were mixed with the ammonium phosphate solution at a variety of powder-
to-liquid ratios (P:L), and thus the effect of the powder state on the cement reactivity was 
assessed. The cementing reaction should proceed per the reaction below for crystalline, semi-
crystalline and amorphous Mg3(PO4)2 according to Equation 3-1. 
Equation 3-1 
Mg3(PO4)2  + (NH4)x(H)yPO4 = x•MgNH4PO4+y•MgHPO4
where x and y are based on the mole balance of the monobasic and dibasic ammonium phosphate 
salts in solution. In addition, with the given P:L ratios, a molar ratio of magnesium phosphate to 
ammonium phosphate greater than one is always maintained. This is because for the acid-base 
reacting cements such as these, an excess of magnesium phosphate ensures that the reaction 
proceeds further in the forward direction towards completion, which should yield greater 
strength and reduce the leaching of remaining soluble salts into the media.  The P:L ranges tested 
in this study is shown in Table 1. The cement nomenclature used is dictated by the thermal 
treatment temperature of the powder, namely 400°C, 600°C or 800°C cement. Additional details, 
such as powder-to-liquid ratio is expressly stated.  
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3.2.4 Cement Characterization 
Cements were made with powders heat treated at 400°C, 600°C and 800°C after a soak time of 
6h at each temperature, using a variety of powder-to-liquid ratios, as indicated in Table 3-1. The 
setting times of the cement pastes were determined with the Gilmore needle test discussed earlier 
in Chapter 1 following the ASTM standard C266-13 at room temperature. Amorphous, semi-
crystalline and crystalline tri-magnesium phosphate powders were mixed with the specified 
volume of solution and stirred for 60 seconds before filling into 10 mm circular molds. The 
handling characteristics will be qualitatively assessed based on consistency and injectability. The 
set cements were stored overnight at 37 °C before subsequent testing. The compressive strength 
of cement cylinders, nominally 6 mm x 12 mm, was analyzed using a 2 kN load cell (Instron, 
Norwood, MA) and a cross head speed of 1.0 mm/min, with 3 samples per condition.  XRD and 
SEM analysis were used to assess the cements following completion of the reaction, utilizing the 
same procedures and equipment specified above. Pellets of the reacted cement were soaked in 
phosphate buffered saline (PBS) for 48 hours at 37 °C. At this point the pH and strength of each 
formulation was recorded. XRD and SEM analyses were again completed on the cements 
following PBS incubation to determine if any, changes occurring due to the extended saline 
incubation. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Magnesium Phosphate Powder Characterization 
Thermogravimetric analysis and the differential scanning calorimetry results of the as-
synthesized TMP powder can be seen in Figure 3-1, showing the vast majority of weight loss 
occurring at temperatures lower than 200 °C, shown in TGA. The exothermic peak observed at 
temperatures less than 700 °C in the DSC scan, without any noticeable corresponding weight 
change, is attributed to the bulk crystallization of the material. These results confirmed the 
selection of temperatures of 400 °C, 600 °C and 800 °C used for obtaining the dehydrated 
amorphous, semi-crystalline and fully crystalline TMP for subsequent cementing reactions.  
Figure 3-1 TGA and DSC of the synthesized Mg3(PO4)2 powders. 
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X-ray diffraction of the synthesized and heat treated powders, shown in Figure 3-2, 
indicates that the synthesized powder is amorphous when generated, and retains the amorphous 
structure following thermal treatment at 400 °C. At 600 °C, crystalline peaks appear but a 
definitive amorphous hump is still retained, and finally at 800 °C, as expected following the 
thermal analysis results, complete conversion to fully crystalline Mg3(PO4)2 (ICCD Card 00-033-
0876) is observed.   
Figure 3-2 XRD of the synthesized Mg3(PO4)2 powders. 
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Fourier transform infrared spectroscopy, seen in Figure 3-3, corroborates the TGA/DSC 
and XRD results. FTIR shows increased crystallinity with thermal treatment indicated by the 
more defined peak separations, from the as-synthesized material through the 800 °C thermal 
treatment, in the 1200 to 900 cm-1 and 700 to 450 cm-1 ranges which correspond to PO43- 
adsorption bands [166]. Additionally, the 600 °C and 800 °C thermally treated powders show an 
absence of a broad hump in the 3500 to 2700 cm-1 range and the band at 1650 cm-1 which are 
indicative of adsorbed water and OH stretching bonds, respectively [166].   
Figure 3-3 FTIR spectra of the synthesized Mg3(PO4)2 powders. 
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Specific surface area measurements, shown in Figure 3-4, of the powders indicate that the 
as-synthesized material displays a high surface area of ~170 m2/g, with subsequent thermal 
treatment significantly reducing the surface area. The initial surface area indicates that the 
particles are likely in the nanometer size range. However, the SEM images shown in Figure 3-5, 
demonstrates that the powders comprise much larger particles. Previous work from our 
laboratory indicate that these particles are in fact, agglomerates of much smaller, nanometer-
sized particles, resulting in the large macroscopic particle clusters contributing to the surface area 
measured values [196].   
Figure 3-4 BET measured surface area of the Mg3(PO4)2 powders. 
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Figure 3-5 Scanning electron microscopy images of synthesized and thermally treated Mg3(PO4)2  
powders. 
3.3.2 Cement Formation 
A variety of P:L ratios for each heat treated powder was tested, with the goal of achieving a 
viscous paste consistency with set times of 10 and 15 minutes.  Table 3-1 contains the P:L ratios 
and the cement setting properties of the 400 °C, 600 °C, and 800 °C heat treated powders. The 
400 °C and 600 °C powders were perceived to be highly reactive, requiring large amounts of 
solution to wet the powder and create a paste. There was no P:L ratio tested for 400 °C and 600 
°C powder which was perceived to be within the ideal parameters for a cement, namely forming 
a moldable paste with setting times of 10 and 15 minutes, as demonstrated in Figure 3-6. The 
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800 °C heat treated powder on the other hand, created a more viable cement, with P:L ratios of 
1:1 creating a low viscosity paste with the most ideal set times (8:53 min and 14:47 min).   
Figure 3-6 Cement settings times as a function of powder crystallinity and powder-to-liquid ratios. 
90 
Table 3-1 Cement handling properties and pH in saline solution. 
Powder P:L Ratio Handling 
pH in 
PBS 
400°C 
1:1 Reacts too quickly, cannot be stirred and molded to form a cement pellet N/A 
1:2 Reacts very quickly, forms a dry, crumbled mixture which could be molded, but does not form a paste. 6.02 
2:5 Reacts quickly, but contains excess liquid to form a chunky paste that does not set. 5.99 
1:3 Reacts more slowly, forms a liquid paste that does not set. 5.96 
600°C 
1:1 Reacts too quickly, cannot be stirred and molded to form a cement pellet 6.87 
1:2 Reacts very quickly, forms a dry, crumbled mixture which could be molded, but does not form a paste. 6.35 
2:5 Reacts very quickly, forms a dry, crumbled mixture which could be molded, but does not form a paste. 6.27 
1:3 Reacts quickly, but contains excess liquid to form a chunky paste which does not set. 6.15 
800°C 
1:1 Forms a nice putty, with desirable set times. 7.47 
2:1 Mixture is dry, forms a crumbled material, but packable into a mold and sets too quickly. 7.58 
3:2 Mixture is dry, forms a dry putty, packable into a mold and sets too quickly.  7.77 
2:3 Forms a very thin putty, set time is too slow. 6.57 
The high reactivity of the amorphous and semi-crystalline powders and the perceived 
increase from very short to long set times in these cements with increasing liquid content, is 
likely due to the complex interplay of the physicochemical properties of the powders and the 
resulting cements. TMP powders mixed with the reacting solution undergo a dissolution-
precipitation type reaction to generate the cemented product, wherein the TMP is partially 
dissolved into the solution, and then re-precipitates the product phase(s). Hurle et al. have 
recently shown that, for calcium phosphate cements, the amount of amorphous calcium 
phosphate plays a strong role in increasing the reactivity of the cement [197]. The authors 
deduced that the high reactivity with amorphous calcium phosphate is due to high, instantaneous 
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dissolution of the amorphous phase into solution, resulting in supersaturated concentrations of 
ions in solution and earlier precipitation of calcium-deficient hydroxyapatite. Additionally, the 
authors determined that the cement crystallite size was reduced when cements were made with 
amorphous calcium phosphate, due to the high super-saturation conditions. Super-saturation 
increase the nucleation probability and number of crystal nucleation sites, ultimately resulting in 
more, smaller crystals [197].   It is possible that for the amorphous and semi-crystalline TMP 
cements considered herein for this study, similar conditions and reactivity can be expected, with 
the amorphous TMP content quickly dissolving, causing super-saturation of the dissolved ion in 
the reacting solution, leading to rapid precipitation of the crystals, giving the cements the less 
than 15 second setting times. With higher liquid volumes as expected, the second setting time 
increases to greater than 1 hour while the first set time remains less than 2 minutes.  This is likely 
due to the sheer volume of excess phosphate liquid used that cannot be completely consumed in 
the ensuing cement reaction since the formation of the crystals and the crystal growth alone 
combined with the exothermic nature of the reaction cannot on its own lead to complete solid 
phase formation. Evaporation of the excess cementing liquid is required to bring the crystals into 
contact and giving the cement mechanical resilience.  
3.3.3 Cement pH and Stability In Vitro 
The pH of the cements generated with 400 °C and 600 °C heat treated TMP were lower 
than the cements from 800 °C TMP, also seen in Table 3-1. Additionally, the mechanical 
resilience of the cements from 400 °C and 600 °C heat treated TMP in PBS was quite low, 
demonstrated in Figure 3-7. These cements were observed to be soft or easily friable after 
incubation in the saline solution, showing mechanical strengths of less than 5 MPa for all the P:L 
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ratios, with strengths less than 2 MPa following PBS incubation. All the cement samples 
demonstrated a loss of mechanical resilience with PBS exposure. In contrast to this however, the 
800 °C TMP cements demonstrated much higher strengths, above 20 MPa, with P:L ratios of at 
least 1:1. These cements showed marginal decrease in strength following PBS incubation, and 
moreover, remained significantly stronger than the native, as-reacted 400 °C and 600 °C TMP 
cements.  
Figure 3-7 Uniaxial compression strength of cements. 
In Figures 3-8 and 3-9 are seen the XRD results of the select 400 °C, 600 °C, and 800 °C 
heat treated TMP cements corresponding to P:L ratios of 1:2, 1:2 and 1:1 respectively, as 
generated (Figure 3-8) and after PBS soaking (Figure 3-9). The diffraction patterns of each 
cement after the final cement setting time shows the formation of, instead of the predicted 
MgNH4PO4 and MgHPO4, an intermediate phase, Mg3(NH4)2H4(PO4)4•8H2O (hannayite, ICCD 
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98-000-6099). The intensity of the peaks differs slightly between the starting TMP powders. In 
addition to this, the 800 °C precursor shows remaining Mg3(PO4)2 while the 400 °C and, to a 
lesser extent the 600 °C heat treated TMP, show an underlying amorphous hump indicating 
remaining amorphous phase, most likely the unreacted amorphous TMP. Following incubation in 
PBS, all the cements transformed into the anticipated MgNH4PO4•6H2O (ICCD 98-002-2086) 
and MgHPO4•3H2O (ICCD 00-035-0780), without any visible remaining crystalline or 
amorphous TMP, as shown in Figure 3-9. This likely indicates that the cements, after setting, are 
not fully reacted, and the exposure to PBS allows for further reaction of the unreacted amorphous 
TMP phase as well as the accompanying transformation of the less stable hannayite phase to 
form the desired MgNH4PO4 phase.  
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Figure 3-8 XRD spectra of 400 °C (P:L 1:2), 600 °C (P:L 1:2), and 800 °C cements (P:L 1:1), after 
completion of the cement reaction. 
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Figure 3-9 XRD spectra of 400 °C (P:L 1:2), 600 °C (P:L 1:2), and 800 °C cements (P:L 1:1) following 
48hour PBS incubation. 
In Figures 3-10 and 3-11 are shown the FTIR results of the select 400 °C, 600 °C, and 
800 °C heat treated TMP precursor cements, corresponding to P:L ratios of 1:2, 1:2 and 1:1 
respectively, as generated (Figure 3-10) and after PBS immersion (Figure 3-11). Similar to the 
powder FTIR spectra, the cement FTIR spectra show peaks surrounding the PO4 vibration 
frequencies (1200 to 900 cm-1 and 700 to 450 cm-1) and OH/HOH vibration regions, as well as 
NH4 vibration bands. As seen in previous studies, the poorly defined bands under the broad 
adsorbed water hump correspond to OH stretching vibrations (3250 cm-1) and NH4 stretching 
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vibration (2900 cm-1) [166, 198]. The bands between 1600 cm-1 and 1400 cm-1 are also 
corresponding to NH4 vibrations, while the additional bands 650-750 cm-1 are attributed to H 
bonding of water [198]. Unlike the XRD, the FTIR analysis shows no significant change in the 
cements after incubation in PBS. This is likely due to the fact that FTIR assesses vibrational 
frequencies, and the P-O, H-O, and N-H bonds’ vibrational frequencies which are inherently 
present in the structure and do not change significantly within the crystallographic and molecular 
structure.   
Figure 3-10 FTIR spectra of 400 °C (P:L 1:2), 600 °C (P:L 1:2), and 800 °C cements (P:L 1:1) after 
reaction completion. 
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Figure 3-11 FTIR spectra of 400 °C (P:L 1:2), 600 °C (P:L 1:2), and 800 °C cements (P:L 1:1) following 
48 hour PBS incubation. 
Figure 3-12 displays the SEM images of the cements after setting and following PBS 
incubation. Both native (external) surface and fracture surface images are shown. It can be seen 
that that the internal and external surfaces of the 400 °C and 600 °C heat treated TMP precursor 
cements were perceived to be quite different following setting. The native, external surfaces of 
these cements appear featureless, with almost wave-like topology containing embedded 
crystallites at 1500x magnification particularly, for the 400 °C derived TMP cement, while the 
internal fracture surface displays more block shaped cuboidal shaped crystals. It is likely that this 
featureless surface of the cements is contributed by the amorphous content with precipitated 
extremely small crystallites embedded, as previously discussed, with no presence of any 
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noticeable crystalline facets emerging due to the rapid nature of the reaction.  The fracture 
surface of the 400 °C and 600 °C TMP cements are similar to the 800 °C TMP cement, although 
the crystalline TMP appears to have resulted in a wider distribution of crystallite sizes in the 
cement structure. Unlike the amorphous and semi-crystalline TMP cements, the crystalline TMP 
resulted in cement with an external surface which is very similar to the internal fracture surface, 
showing block and elongated crystal growth, indicating a slower dissolution-precipitation 
reaction and more controlled crystal growth, as supported by the likely observed reaction rates. 
Following the incubation in PBS, the external morphology of the 400 °C and 600 °C heat treated 
TMP cements changed drastically, with the formation of a smaller cuboidal to spherical particles. 
These same shaped particles are seen in the fracture surface images as well. The 800 °C TMP 
cement appears to have undergone some formation of additional smaller particles at the expense 
of larger crystallites similar to Ostwald’s ripening, but the change is however, not as drastic. The 
significant changes seen in the 400 °C and 600 °C heat treated TMP cements likely plays a role 
in the observed changes in the observed mechanical strength as well as the changes in XRD.  
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Figure 3-12 SEM images of 400 °C (P:L 1:2), 600 °C (P:L 1:2), and 800 °C cements (P:L 1:1). The top 
group of images shows the fracture surface of cements, after reaction completion and after PBS incubation, 
while the bottom group of images shows the native (outside) surface of the same cements, after reaction 
completion and after PBS incubation. (Scale bar: 10 µm) 
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3.3.4 Cement Instability 
In all of these tests, it is not possible to separate the effect of powder crystallinity and the effects 
of powder surface area on the cement viability. However, in this study an attempt is made to 
correlate the physicochemical properties of the powders with the ensuing cementing reaction 
reactivity and the cement functionality. XRD results show similar final product formation for all 
the cement products while SEM and SSA results of reacted cements indicate differences in the 
cement crystallite size with the different starting precursor powders. Thus far, the mechanical 
stability of the cements appears to depend on the rate of initial cementing reaction and the 
cement bond formation, which in turn, appears to be controlled by the physicochemical 
properties of the tri-magnesium phosphate powder. Although there are advantages and desirable 
properties achievable in the amorphous precursor materials, viable cement could not be created 
within the tested parameters of this study. Recently Bhaduri et al. utilized microwave-assisted 
aqueous synthesis of amorphous tri-magnesium phosphate, as well as microwave synthesis of 
magnesium hydroxide cements to alter the exothermicity of the cements [39, 199].  These 
synthesis techniques may be a potential solution to combat the high reactivity of amorphous tri-
magnesium phosphate powders. Additional methods to reduce the reactivity of the amorphous 
TMP in cementing reactions include reduction in specific surface area through thermal treatment 
as well as the formation of densified agglomerates, through pressing of dense pellets and 
subsequent pulverization of these pellets, as well as the utilization of reaction retardants. 
Although not reported here, the first and third alternatives have been recently attempted in our 
laboratory although yielding similar results with no significant improvements in the mechanical 
resilience of the cements. The densification and pulverization method as well as a microwave 
synthesis method are still to be explored. However, moving forward from the results presented 
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here, future studies under these parameters will focus on the fully crystalline, low surface area 
tri-magnesium phosphate cement due to the simplicity and the observed overall efficiency of the 
approach. 
3.4 CONCLUSION 
Crystalline, semi-crystalline and amorphous tri-magnesium phosphate powders were tested with 
a neutral 3 M ammonium phosphate solution in order to assess the cementing reactions of the 
various powders. Under the available parameters, the fully crystalline, low surface area 800 °C 
derived tri-magnesium phosphate powder resulted in cements which demonstrated much better 
workability, more neutral pH and higher strengths than the amorphous or semi-crystalline TMP 
derived cements.  Further studies will thus focus on optimizing the cementing reaction, 
microstructure, and studying the cytocompatibility of this particular cement formulation which 
will be reported in the subsequent chapters to follow. 
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4.0  SPECIFIC AIM 3: ASSESSMENT OF THE EFFECT OF REACTING SOLUTION 
ON THE CEMENTING REACTION WITH TRIMAGNESIUM PHOSPHATE  
4.1 INTRODUCTION 
As discussed in Chapters 1 and 3, there is strong motivation to utilize magnesium phosphate 
cements for bone void filling and repair. While a large number of studies have focused on the use 
of ammonium phosphate salts reacting with TMP or MgO to yield the cement product, other 
reactants may also be explored. Monopotassium hydrogen phosphate (KH2PO4) has been used as 
the reacting salt for the OsteocreteTM formulation and phosphoric acid is also occasionally 
employed [79, 83, 105, 146]. Mestres et al have utilized monosodium hydrogen phosphate in 
antibacterial cement formulations [28, 29, 38]. Similarly, the use of phosphate solutions 
particularly, dilute sodium phosphate solutions are frequently employed in calcium phosphate 
cement generation [35].  
While magnesium and phosphorous are recognized as necessary to healthy bone 
development and maintenance, the role or implications of other ions such as sodium, potassium 
and ammonium are less understood. Although high levels of sodium intake are implicated in low 
bone density and osteoporosis, both sodium and potassium have physician recommended dosage 
intakes which can be found stored in low levels in mature bone [200]. Furthermore, it is 
recommended that an individual consume 1500mg of sodium, 4700mg of potassium and 420 mg 
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of magnesium on a daily basis, indicating systemic toxicity resulting from cement 
implants would be unlikely [201].  Localized toxicity at the site of the implant may still be a 
concern. Dietary potassium has been found to modulate the interaction of interstitial fluid 
surrounding bone mineral [202]. Some researchers have observed that an increase in dietary 
ammonium sulfate improved bone phosphate content in calves while others observed decreased 
bone density when diets were supplemented with ammonium chloride. However, in either of 
these cases the bone metabolic balance is tied to acid/base balance within the body and is 
not directly tied to the presence of ammonium ion [203, 204]. Ammonium ion is routinely 
cleared from the body through the urea cycle  [205]. Thus the utilization of any of these 
ions within a cementing reaction is not anticipated to cause significant negative effects on 
the biocompatibility of the cement product.  
The goal of this chapter is thus to assess the effect of various cement reacting solutions 
comprising potassium phosphate, sodium phosphate and ammonium phosphate with the starting 
solid reacting precursor of crystalline trimagnesium phosphate on the cement forming reactions. 
Although several authors have utilized one or more of these salts and the use of solutions is not 
common, direct comparisons of all three types of salts have not been evaluated. While in Chapter 
3 the ammonium phosphate solution resulted in an encouraging cement product, cements 
resulting from potassium or sodium phosphate solutions may be more desirable as sodium and 
potassium ions are necessary for numerous biological processes while ammonium ions are 
merely a waste product to be cleared by the body. As in Chapter 3, neutral pH solutions of 
these salts will be created through a balanced use of monoatomic and diatomic salts. By 
maintaining a neutral pH of the reacting solution and in the final cement product, the opportunity 
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exists to utilize the solutions directly for drug or biologic delivery as well as attempt the 
incorporation of cells for multifunctional scaffold delivery in future studies.  
4.2 MATERIALS AND METHODS 
4.2.1 Cement Preparation 
Crystalline Mg3(PO4)2  was synthesized according to the protocol described in Chapter 2. The 
powder was thermally treated to 800 °C for 6 hours to ensure a specific surface area (SSA) of 
approximately 1.0 m2/g, as described in Chapter 3.  
The TMP powder was mixed with pH 7.0 solutions of ammonium phosphate, sodium 
phosphate or potassium phosphate, at a 3 M concentration. Three different solution embodiments 
were tested. The solutions were based on potassium, sodium and ammonium phosphate salts. 
The ratio of mono-atomic ammonium, sodium or potassium to diatomic ammonium, sodium or 
potassium soluble phosphate salts is determined such that the solution is at pH 7.0, as described 
for the ammonium solution in Chapter 3.  
 In the simplest form, the theoretical reactions employed for the cementing reactions are 
identical to Equation 3-1 with the sodium and potassium phosphate analogs:  
Equation 4-1 
Mg3(PO4)2  + (Na)x(H)yPO4 = x•MgNaPO4+y•MgHPO4 
Equation 4-2 
Mg3(PO4)2  + (K)x(H)yPO4 = x•MgKPO4+y•MgHPO4 
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where X and Y are based on the mole balance of the monobasic and dibasic ammonium 
phosphate salts in solution discussed in Chapter 3. For example, the ratio of monobasic to dibasic 
ammonium phosphate to yield neutral pH 3M solution is approximately 2:7 to 3:10 (range of 
0.286-0.3) monobasic/dibasic, which would yield X and Y of approximately 23 and 16, 
respectively. Assuming perfect reaction, this would give final product of nearly 59 % 
MgNH4PO4 and 41 % MgHPO4. For potassium phosphate, the salt ratio is 9:10, or 51 % 
MgKPO4 and 49 % MgHPO4, and for sodium phosphate the salt ratio is 2:5 monobasic to dibasic 
for 3M solutions, or 57 % MgNaPO4 and 43 % MgHPO4. These appropriate salt ratios were 
determined experimentally. The 3M sodium phosphate salt solution is super-saturated at room 
temperature, and was stored at 37 °C prior to testing to ensure accurate concentrations during 
cement formation. For simplicity, these solutions are referred to as NH4H (ammonium), NaH 
(sodium), and KH (potassium) solution during subsequent discussion and in all the figures.  
Cements were synthesized as in Chapter 3 as mentioned above.  The powders were mixed 
with the phosphate solution at a variety of powder-to-liquid ratios (P:L), and thus the effect of 
the powder state on the cement reactivity was assessed. As in Chapter 3, with each of the tested 
P:L ratios, a molar ratio of magnesium phosphate to phosphate solution greater than one is 
always maintained to force the forward reaction towards completion and consumption of TMP. 
Additional details such as the powder-to-liquid ratio is expressly stated.  
4.2.2 Cement Characterization 
The setting times of the cement pastes were determined with the Gilmore needle test following 
the ASTM standard C266-13 at room temperature, as previously described. Crystalline tri-
magnesium phosphate powders were mixed with the specified volumes of potassium, sodium 
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and ammonium solution and stirred for 60 seconds before filling into 10 mm circular molds. The 
handling characteristics will be qualitatively assessed based on consistency and injectability. The 
set cements were stored overnight at 37°C before subsequent testing. True density, apparent 
density and porosity as well as XRD analysis were used to assess the cements following 
completion of the reaction, utilizing the same procedures and equipment specified above. Pellets 
of the reacted cement were soaked in 2 ml of phosphate buffered saline (PBS) for 48 hours at 
37°C and the pH was systematically recorded. Density and XRD analyses were again completed 
on the cements following PBS incubation to determine if any changes occurred due to the saline 
incubation.  
The % porosity of cements following PBS incubation was determined according to Equation 4-3.  
Equation 4-3 
% porosity = 1 –ρA/ρT
The true density (ρT) was measured using helium pycnometry (AccuPyc II 1340, Micrometrics) 
and the apparent density (ρA) was determined through Equation 4-4. 
Equation 4-4 
ρA = weight/(πr
2h) 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Initial Cement Characterization 
Crystalline Mg3(PO4)2  was created according the protocol described above and subsequently 
mixed with 3.0 M reacting solutions of ammonium, potassium or sodium phosphate at Ph 7.0. A 
variety of powder-to-liquid (P:L)ratios were evaluated to determine the optimal solution content 
for each cement formulation. In Figure 4-1 is displayed the first and second setting times of the 
cements with varying powder-to-liquid ratios tested. Corresponding to this in Table 4-1 are the 
descriptive assessment of the putty handling characteristics during cement creation and strength 
after setting and drying are complete. It was observed, as in Chapter 3 that varying the P:L ratios 
of ammonium phosphate solution results in significant control over the setting time of the 
magnesium ammonium cement. The setting times of the 3M 1:1 ammonium solution are quite 
similar to those measured for the same embodiment, though with higher variation, indicating 
good reliability with the cement generation.  
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Figure 4-1 Setting times of cements varying with setting solution and powder-to-liquid ratios. 
However, the same control over setting time is not observed with the sodium and 
potassium phosphate solutions. The setting times are exaggerated, displaying no ‘set’ time at all 
or set times that are far greater than one hour at room temperature. Similar results were observed 
when testing at 37 °C (data not shown).  Following overnight incubation at 37 °C, cements were 
removed from the molds and the durability of the cement product was determined. For most 
cements made with the ammonium phosphate solutions, a durable product resulted.  
In comparison, the majority of the cements made with sodium and potassium containing 
cement reacting solutions were perceived to be not strong, often cracking or crumbling apart 
during this process. Reducing the solution concentration to 1 M slowed the 2nd set time of the 
cement made with the ammonium phosphate solutions only slightly compared to the P:L of 1:1 
for 3M concentration, but did not appear to affect the setting time of the cements made with 
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sodium or potassium phosphate solutions. The lower concentration however, resulted in slightly 
less durable products after drying.  
Table 4-1 Handling of cement putties and durability after drying 
Solution P:L Handling Durability 
1M NH4H 1:1 Good putty viscosity Durable, did not crumble when handled 
3M NH4H 
1:1 Good putty viscosity Durable 
1:1.5 Liquid, low viscosity Durable, did not crumble when handled 
1.5:1 Viscosity high, not flowable, must be pressed into mold Durable, did not crumble when handled 
2:1 Too dry, does not form putty Crumbles when handled 
1M NaH 1:1 Liquid, low viscosity Breaks easily when handled 
3M NaH 
1:1 Viscosity is good, putty-like. Mostly holds together, edges may crumble 
1:1.5 Liquid, very low viscosity Breaks easily when handled 
1.5:1 Viscosity high, not flowable, must be pressed into mold Breaks easily when handled 
2:1 Too dry, does not form putty Crumbles when handled 
1M KH 1:1 Liquid, very low viscosity Breaks easily when handled 
3M KH 
1:1 Viscosity like a putty Mostly holds together 
1:1.5 Liquid, very low viscosity Breaks easily when handled 
1.5:1 Viscosity high, not flowable, must be pressed into mold Breaks easily when handled 
2:1 Too dry, does not form putty Crumbles when handled 
Resulting cement pellets or pieces were incubated in PBS for up to 48 hours at 37 °C. 
The pH was recorded at 24 hours and the PBS was replaced following which the pH was 
measured again at 48 hours, the results of which can be seen in Figure 4-2. For the ammonium 
phosphate derived cements at a concentration of 3M, the pH after 24 hours was slightly acidic 
(6.6-7.0) but neutralized (7.4-7.6) following replenishing of PBS and additional incubation time 
of 48h. High liquid content, at P:L of 1:1.5, resulted in more acidic cements (6.6-6.7) while 
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lower liquid content, at P:L ratios of 1.5:1 and 2:1, resulted in more neutral cements (6.9-7.0). As 
seen in the previous chapter, use of higher liquid contents results in more struvite formation than 
newberyite, likely leaving unreacted hydrogen ions which serve to lower the media pH initially. 
Reducing the solution concentration to 1 M resulted in a more basic pH (7.6) at both 24 and 48 
hours of incubation. Conversely, the pH of all sodium and potassium derived cement products 
was slightly basic, generally 7.5-7.7, at both 24 and 48 hour PBS incubation for the 1 M 1:1 
cements as well as the 3 M cements at every P:L ratio tested. The sodium phosphate derived 
cements were very slightly more basic at 24 hours than at 48 hours while the potassium 
phosphate solution based cements were slightly more basic at 48 hours than 24 hours.  Following 
incubation in PBS, the more durable sodium and potassium phosphate derived cements were 
however, observed to break into pieces.  
Figure 4-2 pH of cements following 24 and 48 hours incubated in PBS at 37 °C. 
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As the cements created with 3 M solutions at a 1:1 powder-to-liquid ratio resulted in a 
moderately durable product for all three solutions, these samples were further tested to examine 
the materials properties of the resulting cement products.  In Figure 4-3 is displayed the true 
density (a), apparent density (b) measurements and calculated porosity (c) of these cement 
embodiments. The true density measurements are of n=1 and the true density and porosity 
measurements are of n=2. The true density measurements indicate that the ammonium phosphate 
derived cement has a similar true density in the as generated form and after 48 hours incubation 
in PBS with a value of 2.1 g/cm3, while the sodium and potassium derived cements undergo a 
marked decrease in true density following PBS incubation with density values reducing from 2.6 
to 2.0 g/cm3 for the sodium phosphate containing cement and 2.5 to 2.2 g/cm3 for the potassium 
phosphate derived cement.  
Apparent density of the as generated cements was much higher for the ammonium 
phosphate derived cements (1.55 g/cm3) than potassium phosphate containing cements (1.40 
g/cm3),  which were higher still than the sodium phosphate containing cements (1.05 g/cm3).  
Following incubation in PBS the apparent density of the ammonium and potassium phosphate 
containing cements decreases (1.40 g/cm3 and 1.10 g/cm3) but that of sodium phosphate 
containing cements remains the same (1.05 g/cm3).   
Porosity calculations indicate the ammonium phosphate derived cements have much 
lower porosity than the sodium or potassium phosphate solution derived cements, both as 
generated and after PBS incubation. The ammonium and potassium phosphate derived cements 
had marginal increases in porosity following PBS incubation, 30 to 38% and 43 to 50% 
respectively, while the sodium phosphate derived cement had a large decrease in porosity from 
60 to 46%.  
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Figure 4-3 True density, apparent density and porosity measurements of cements as generated and 
after 48 hours incubated PBS at 37 °C. 
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X-ray diffraction measurements and phase identification of all the cements in both, as 
generated and after PBS incubation can be seen in Figure 4-4. As seen in Chapter 3, the 
ammonium phosphate derived cement is initially comprised of the anticipated MgNH4PO4•6H2O 
(c) and MgHPO4•3H2O (d) as well as unreacted Mg3(PO4)2 (a) and the same temporary phase (b) 
Mg3(NH4)2H4(PO4)4•8H2O, and following incubation, the MgNH4PO4•6H2O (c) phase is the 
dominant one along with MgHPO4•3H2O (d) and a small amount of Mg3(PO4)2 (a). The as 
generated sodium phosphate made cement displaces mostly Mg3(PO4)2 with a small amount of 
(e) MgNa3H(PO4)2 (ICCD Card 00-035-0811) and (f) Na1.05Mg3.96(PO4)3 (ICCD 00-054-0072). 
Following PBS incubation the diffraction pattern is quite similar, with the addition of 
MgHPO4•3H2O (d) and a slight reduction in maximum peak high of (e) and (f). Similarly, 
potassium phosphate derived cements show a majority of unreacted Mg3(PO4)2 (a). The as 
generated potassium phosphate containing cement also has small amounts of MgHPO4•3H2O (d), 
(g) KMgPO4·6H2O (ICCD 00-035-0812), (h) Mg3(PO4)2·8H2O (ICCD 00-033-0878) and (k) 
KH2PO4 (ICCD 00-031-1030). Following PBS incubation the soluble KH2PO4 and the hydrated 
trimagnesium phosphate (h) are completely removed following dissolution. In addition to the 
unreacted trimagnesium phosphate (a) in the final structure are K2Mg(PO3)4 (I, ICCD 00-024-
0877) (i) and the anticipated phases  KMgPO4·6H2O (g) and MgHPO4•3H2O (d).  
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Figure 4-4 XRD spectra of cements as generated and after 48 hours of incubation in PBS at 37 °C 
Phases are (a) Mg3(PO4)2, (b) Mg3(NH4)2H4(PO4)4•8H2O, (c) MgNH4PO4•6H2O (d) MgHPO4•3H2O (e) 
MgNa3H(PO4)2, (f) Na1.05Mg3.96(PO4)3, (g) KMgPO4·6H2O, (h) Mg3(PO4)2·8H2O, (i) K2Mg(PO3)4, and (k) 
KH2PO4. 
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The density and x-ray diffraction data discussed above can provide some inferences as to 
why the setting times were not well controlled and consequently, the cement products were 
mechanically inferior for the sodium and potassium phosphate derived cements. When compared 
to the ammonium phosphate cementing reaction, the reaction for the sodium and potassium 
phosphate cements does not proceed nearly as far towards completion, indicated by the 
extremely high levels of unreacted TMP remaining in the cement products indicated by the XRD 
data. A change in morality or the liquid content also does not appear to significantly alter this 
fact. In actuality, at high liquid contents these cements tend to react to an even smaller degree 
resulting in a cement that readily falls apart. As a result, the rigid product formed can be 
attributed as much to the effect of drying as it is to any cementing reaction. Cements with lower 
liquid content, ammonium phosphate included, contain too little water to form a moldable 
product. It was not possible, for the sodium and potassium phosphate based cements to find a 
liquid ratio which resulted in a clinically relevant setting time in part because, under the 
conditions tested, the product is not ‘setting’ through the completion of the necessary 
dissolution/precipitation/crystal growth mechanism characteristic of cementing reactions. The 
high true density, low apparent density and high porosity observed for the sodium and potassium 
phosphate based cements can then be attributed to the same lack of incomplete cementing 
reaction. The higher true density results from the higher true densities of unreacted salts when 
compared to hydrated phosphate phases present in the ammonium phosphate product. Lower 
apparent density and higher porosity result from the drying and accompanying loss of water from 
the putty, instead of incorporation of the water into the structure. This leaves poorly reacted 
cement product and poorly adhered unreacted TMP powder and salt crystals remaining in the 
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structure. The systems nevertheless warrant more attention which can be the subject of future 
research. 
4.3.2 Alternative Strategies   
A variety of additional methods beyond altering the P:L can be used in order to accelerate the 
cementing reaction, including increasing the reacting salt concentration, changing the pH and 
adding an accelerant. In order to determine if the neutral pH of the solution reduced the reaction 
rate, similar 3 M solutions were created with only monoatomic ammonium or diatomic 
ammonium salts. The cement setting times with this series of 6 solutions at two different P:L can 
be found in Figure 4-5. For the ammonium phosphate solutions, the diatomic ammonium salt 
solution slowed the cementing reaction from 25 min 1st setting time (ST) at P:L of 1:1 versus 9 
min at P:L of 2:1. The monoatomic ammonium salt solution decreased the reaction time to 4 
min. The opposite was seen with the sodium solutions. The diatomic sodium phosphate solution 
reduced the first setting time to 8 min at P:L of 1:1 while the monoatomic sodium phosphate 
solution increased the 1st ST at 1:1 to beyond 60 min. The use of monoatomic or diatomic 
potassium salt did not serve to reduce the 1st ST below 60 min. In all cases increasing the P:L to 
2:1 reduced the setting time as in Figure 4-1. Cements were allowed to dry at 37 °C before 
removing them from the molds. Although the diatomic sodium phosphate solution reduced the 
setting time to within a reasonable range, the resulting pellet was not found to be durable similar 
to the successful ammonium phosphate solution embodiments comprising P:L of 2:1 and 1:1 
when removed from the mold.  
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Figure 4-5 Cement setting times of 3M monoatomic or diatomic hydrogen salt solutions at two different 
P:L ratios of 1:1 and 2:1. 
The inclusion of some form of amorphous calcium phosphate is frequently used to 
accelerate the reaction of CPCs and reduce the setting time [197]. As discussed in Chapter 3, 
amorphous phases are typically expected to react more quickly than crystalline analogs. For this 
reason, the testing methodology from Chapter 3 was revisited, utilizing amorphous TMP reacting 
with 3M pH 7.0 sodium and potassium solutions. Although this strategy did not yield durable 
cements with the ammonium phosphate solution, the slower reaction rate of the sodium and 
potassium cements reopens the possibility with these solutions.  Similar to Chapter 3, powder-to-
liquid ratios less than 1:1 were required to create a liquid putty due to the high surface area of the 
amorphous powder. While the putty slowly dried and satisfied the mechanical resilience for the 
1st ST, these formulations did not result in the 2nd ST meeting the mechanical requirement for a 
hard and set product after 60 minutes. The formulation also failed to provide an acceptable 
cement product even after extended incubation in PBS at 37 °C for 48 hours.  
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A final strategy to increase the reaction rate of the cement, or induce other precipitation-
controlled reactions, is to use a ‘seed’ phase. In this strategy, a portion of the product phase is 
included in the initial formulation as a ‘seed’ for the reacting material to grow a new product 
phase on the starting initial precursor. This strategy overcomes nucleation kinetic barrier, the 
greatest energy barrier to crystal growth in solution, and is frequently employed in a wide variety 
of industrial practices, including with struvite synthesis [206-208]. 
To create seed crystals, 1 gram of crystalline TMP was immersed in 10 mL of each of the 
three 3 M, pH 7.0 reacting solutions comprising of the desired mixture of diatomic and 
monoatomic ammonium sodium and potassium phosphate as described earlier. The extreme 
excess of the reacting salt should drive the chemical reaction towards completion. The highest 
possible salt concentration is desired for the same reason, however the sodium solution is super-
saturated at room temperature at the 3 M concentration, thus higher concentrations could not be 
explored. Mixtures were incubated at 37 °C for 48 hours, stirring occasionally. At this point, the 
excess solution was decanted and the resulting powder was rinsed with DI water, then acetone 
and dried at 70 °C overnight. The powders were then analyzed through XRD to confirm the 
presence of the anticipated product phases: MgNH4PO4, MgHPO4, MgKPO4 and MgNaPO4 or 
hydrated analogs of these phases. The XRD spectra of the seed powders as well as the spectra of 
matched phases can be found in Figure 4-6. Results indicate that the ammonium (NH4H) solution 
reacted completely to form struvite over the more soluble newberyite. In stark contrast to this, 
the spectra of the sodium (NaH) and potassium (KH) seed powders are nearly identical to the 
unreacted TMP powder, indicating that even with extreme excess of the reacting solution, the 
proposed cementing reaction is not proceeding under the given conditions.  
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Figure 4-6 X-ray diffraction patters of generated seed crystals from ammonium, potassium and sodium 
solutions and matching phase spectra, Mg3(PO4)2 and MgNH4PO4•6H2O. 
Testing results of the numerous cement embodiments explored with sodium and 
potassium phosphate solutions clearly indicate that, while hypothetically possible, the driving 
force for these reactions is extremely weak. Numerous other researchers have successfully 
explored magnesium phosphate cement formulations with potassium and sodium phosphate 
reacting salts. Mestres et al have repeatedly shown a magnesium sodium phosphate cement 
formulation to be fast setting, strong and antibacterial while BSI Inc. has patented and is taking 
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into clinic the OsteocreteTM magnesium potassium phosphate cement formulation [28, 29, 38, 66, 
67, 73]. The difference however between the cement formulations with these researchers and the 
cement studied here is with the magnesium source: both Mestres and the OsteocreteTM 
formulation use MgO while this study is based on the use of Mg3(PO4)2 that is likely more stable 
requiring further activation. No studies could be found successfully using TMP and sodium or 
potassium phosphate salts or solutions. It is likely that the activation energy for the reactions 
proposed in Equations 4-1 and 4-2 is too high to ensure completion of the reaction with 
regularity.  
4.4 CONCLUSIONS 
Solutions of sodium phosphate, potassium phosphate and ammonium phosphate mixtures of the 
monoatomic and diatomic phosphate forms were created at a 3 M concentration and neutral pH 
and the cementing reaction of these solutions was tested with crystalline tri-magnesium 
phosphate powder. Under the tested parameters, the ammonium phosphate solution, as 
previously demonstrated, created a hard cement construct under clinically appropriate setting 
times. The sodium and potassium phosphate solutions on the other hand, did not obtain clinically 
appropriate setting times under any tested solution volumes or P:L ratios. X-ray diffraction 
results indicate only low levels of cement product phases in the set cements, with a bulk of the 
unreacted tri-magnesium phosphate remaining. Due to this lack of reaction completion, cement 
constructs made with sodium and potassium phosphate solutions were not mechanically durable. 
Alternative strategies, including altering the solution concentration, solution pH and reacting salt, 
and utilization of amorphous tri-magnesium phosphate all of which unfortunately, did not result 
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in increasing the reaction rate or completion of the reaction. Further studies were thus focused on 
optimizing cement formulations from the ammonium phosphate solution embodiment.  
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5.0  SPECIFIC AIM 4: EVALUATION OF THE EFFECT OF MANNITOL 
POROGEN ADDITION ON A MAGNESIUM AMMONIUM PHOSPHATE CEMENT 
FORMULATION 
5.1 INTRODUCTION 
Porosity is widely regarded as a necessary parameter for the generation of functionally integrated 
scaffolds for tissue engineering, including hard tissue implants. Pore structure should be 
integrated in order to permit cellular infiltration and migration as well as provide mass transport 
for cellular nutrition. Methods typically utilized to generate porosity include the addition of salt 
or sugar crystals, the use of degradable fibers, utilization of 3D printing or the use of gases to 
generate pores [109, 111, 209-215].  The pores generated should be inter-connected with 
macropore sizes in the 100-600µm range [111, 216]. In particular, in ceramic systems, the 
porous structure negatively impacts the strength of the scaffold, and thus it is necessary to 
optimize the porosity while also maximizing the strength of the scaffold.  With CPCs, 
researchers have explored the addition of water soluble mannitol sugar as a porogen. The 
addition of mannitol is known to increase the cement macroporosity and dissolution rates while 
also resulting in significant loss of mechanical strength [210, 211, 213, 217-220]. Importantly, 
the addition of the soluble mannitol does not affect the cytocompatibility of the cement scaffolds. 
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Due to the hierarchical structure of HA mineral and collagen, natural bone displays high 
strengths, on average of 130-190MPa for cortical bone and 3.6-9.3 MPa for cancellous bone 
[97]. While highly dense (< 20 % porosity) HA cements may achieve strengths of up to 150MPa 
under laboratory conditions, commercially available HA cements generally display strengths 
below 30MPa at 40 % or more porosity [93, 221]. Brushite cements on the other hand, rarely 
display strengths above 20 MPa, and these cements display these characteristics without the 
incorporation of macropores [93]. Comparatively, MgP cements have routinely demonstrated 
strengths between 40-85MPa [36, 37, 56, 57]. Under these conditions, it is conceivable to 
develop MPCs with strengths comparable or greater than brushite cements while also introducing 
porosity to provide for cellular infiltration and scaffold resorption.  The goal of this study is thus 
to evaluate the role of mannitol on the workability, mechanical durability and cytocompatibility 
of the magnesium ammonium phosphate cement system developed through the work already 
discussed in Chapters 3 and 4. 
5.2 MATERIALS AND METHODS 
5.2.1 Cement Preparation 
Trimagnesium phosphate (TMP, Mg3(PO4)2) powder was synthesized through an aqueous 
precipitation reaction as detailed in Chapter 2. The resulting powder was thermally treated to 
800°C for 6 hours in air to form anhydrous crystalline TMP powder with a surface area less than 
1 m2/g, as detailed in Chapter 3. The powder was then lightly ground and sieved to below 500 
µm to remove large agglomerates.  
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Cements were created by combining the synthesized TMP powder with 0, 10, 20, 30, 40 
or 50 weight % mannitol sugar crystals (Sigma-Aldrich) then mixing the powder with the 3 M 
pH 7.0 ammonium phosphate reacting solution comprising a mixture of diammonium phosphate 
and ammonium dihydrogen phosphate solutions to create the cement via the reaction described 
in detail in Chapter 3.   Cement powders were created by then mixing with the ammonium 
phosphate solution at a variety of powder-to-liquid ratios (P:L) wherein the powder is the 
combined TMP and mannitol. Cements were stirred for sixty seconds then filled into cylindrical 
molds, 6 mm diameter, 15 mm height for mechanical testing and 10 mm diameter, 2 mm height 
for cell culture. Samples were correspondingly stored overnight at 37 °C prior to testing. 
5.2.2 Cement Characterization 
Cement setting times were measured at room temperature utilizing the Gilmore needle test, as 
described in Chapter 3. Cement phases were identified using x-ray diffraction (XRD) as outlined 
in Chapters 2, 3 and 4. Fourier transform infrared spectroscopy (FTIR) was used to identify 
differences in molecular chemical linkages between the different cement systems. Cements were 
observed under scanning electron microscope (SEM). XRD, FTIR and SEM testing were 
performed as described in Chapter 2.   
5.2.3  Mechanical Properties of Cements 
Wet compressive strengths of the cements were analyzed with a 2 kN load cell at a cross head 
speed of 1.0 mm per minute (Instron, Norwood MA).  Cement cylinders were incubated in 
phosphate buffered saline (PBS) at 37 °C prior to compression testing to determine the change in 
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strength due to aqueous conditions as well as the effect of mannitol dissolution. PBS incubation 
time points considered were 0, 1, 3, 5, 7 and 14 days, with 5 samples at each time point. 
Brunauer-Emmett-Teller method specific surface area (SSA) of cements was measured from N2 
adsorption-desorption isotherms on a Micrometrics ASAP 2020 instrument. The true density and 
% porosity of cements following PBS incubation was determined following Equations 4-3 and 4-
4 outlined in Chapter 4.  
5.2.4 In Vitro Dissolution Characteristics 
Cement pellets were incubated in PBS, at a concentration of 10ml of PBS per 1.0 gram of 
cement, at 37 °C. The PBS was changed every 24 hours. At each time point (1, 3, 5, 7, 14 days) 
the pH of the PBS was measured and the wet weight of each sample was recorded. In order to 
determine ion concentrations, the collected PBS solution was diluted in 0.03 M Tris buffer 
solution and analyzed by inductively coupled plasma optical emission spectroscopy (ICP-OES, 
iCAP duo 6500, Thermo Fisher). Cement samples incubated in PBS were dried overnight at 37 
°C then characterized using XRD, FTIR, SSA, density and SEM analyses to compare with the 
as-generated cement samples to determine if any changes occurred due to the saline incubation. 
5.2.5 Cytocompatibility 
Murine MC3T3−E1 preosteoblast cells were utilized for cell culture studies. The substrates were 
sterilized as previously described, soaked in culture media for 24 h, then seeded with MC3T3 
cells at a density of 40,000 cells/well. The media was changed every other day throughout the 
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testing period. Live/Dead staining and MTT cellular activity assay were completed as described 
in Chapter 2.  Cell number quantification was completed using the CyQuant cell proliferation 
assay according to the manufacturer’s instructions. Briefly, at each time point, the media was 
fully removed from samples and the samples were placed in -70 °C for at least 24 hours. When 
ready to test, the samples were thawed to room temperature then incubated in 400 µl of CyQuant 
cell lysis buffer and the dye solution for 5 minutes away from light. Following this, 200 µl of 
each solution was pipetted into a 96 well plate and the fluorescence was read at an excitation 
wavelength of 480 nm and emission wavelength of 520 nm. Hydroxyapatite and brushite CPCs 
were created to compare with the MPC cements. Common formulations of each cement were 
employed. Apatite cements were created utilizing α-TCP (HIMED, USA) and a 2.5%  Na2HPO4 
(Sigma Aldrich) solution at a powder to liquid (P:L) ratio of 2.5:1. Brushite cements were 
created using β-TCP (HIMED, USA) and monocalcium phosphate monohydrate (Ca(H2PO4)2 
Sigma Aldrich) at a 1:1 mole ratio employing a 0.5 M citric acid solution at a powder to liquid 
(P:L) ratio of 3:1.    
5.2.6 Statistics 
Statistical calculations were performed using IBM SPSS Statistics 23 statistical analysis 
program.  For appropriate quantitative assessments, including ionic content via ICP-OES, MTT 
viability assay and mechanical strengths, the mean and standard deviation was assessed for a 
sample size of four per sample. Statistically significant differences were assessed through one-
way ANOVA with Tukey’s post hoc testing where the significance was set at p < 0.05. 
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5.3 RESULTS 
5.3.1 Cement Setting Times 
In order to develop a series of cements with clinically appropriate setting times, powder mixtures 
with 0-50 wt% mannitol were mixed with a variety of powder-to-liquid ratios. Since the addition 
of the poor forming mannitol can change the setting times, Figure 5-1 shows the first and second 
setting times for each combination in the series. At each mannitol content, the P:L ratio with the 
first and second setting times of approximately 8-10 min and 15-20 minutes at room temperature 
were chosen for further assessment. Powder-to-liquid ratios chosen for further exploration are 
denoted with stars in Figure 5-1. The optimized P:L ratios were: 1:1 for 0%, 1.5:1 for 10% and 
20%, 1.75:1 for 30% and 40% and 2:1 for 50%.   Here, the chosen P:L ratios were not always 
statistically different than others for the first or second set time, hence the P:L averages closest to 
the stated goals were chosen.  
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Figure 5-1 First and second setting times of mannitol-containing magnesium phosphate cements (n=4). 
5.3.2 Cement Characterization 
The cement embodiments chosen above were incubated in PBS, and initial properties as well as 
changes due to aqueous incubation were analyzed.  Figure 5-2 displays the x-ray diffraction 
patterns collected from the as-prepared cements and after 14 days in PBS. Phases present in the 
as-reacted cement were correspondingly unreacted precursor TMP (Mg3(PO4)2, +), hannayite 
(Mg3(NH4)2H4(PO4)4•8H2O, $), and mannitol (>). Following 14 days of incubation in PBS, 
struvite (MgNH4PO4•6H2O, *) and newberyite (MgHPO4•3H2O, #) were the predominant 
phases, along with a small amount of unreacted TMP but no hannayite or mannitol was observed 
to be present.  
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Figure 5-2  X-ray Diffraction patterns of mannitol-containing magnesium phosphate cements at (a) 0 
days in PBS (as generated) and (b) 14 days in PBS. Phases present are denoted: struvite (*), newberyite (#), 
unreacted trimangesium phosphate (+), mannitol (>), and hannayite ($). 
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FTIR spectra analysis of the select mannitol containing cements as generated and 
following 14 days of incubation in PBS, as well as the spectra of pure mannitol for comparison, 
can be seen in Figure 5-3. The spectra of all the cements shows bands associated with the 
ammonium and phosphate bonds, including 1200-900 cm-1 and 700-450 cm-1 ranges which 
correspond to the PO4 vibrational frequencies  as well as peaks in the bands between 1600-1400 
cm-1 which are attributed to NH4 vibrations, as discussed in Chapter 2. Similarly, the broad hump 
from 3500-2000 cm-1 is due to adsorbed water, and NH4 stretching vibrations observed at 2900 
cm-1 and in the 1600-1400 cm-1 band range. Additionally, at Day 0, peaks associated with 
mannitol sugar can be seen in the mannitol-containing cements (50% shown in Figure 5-3). 
These peaks are associated with  O-Hand C-H stretching vibrations in the range between 3700 
and 2500 cm−1 as well as C-H vibrations between 1400and 1200 cm−1 [222]. The removal of 
mannitol from the cement structure is confirmed through FTIR as the bands associated with 
mannitol are no longer present after PBS incubation. While significant changes in crystal 
structure were observed through XRD, FTIR analysis shows no corresponding changes in the 
cement character after PBS incubation. This is attributed to the FTIR analysis primarily detecting 
changes in molecular linkages of infra-red active molecular bonds regardless of amorphous or 
crystalline state in comparison to the various characteristic crystallographic diffraction planes 
determined by XRD analysis for a particular crystalline phase as opposed to no significant 
diffraction observed for amorphous systems. FTIR assesses vibrational frequencies present in 
chemical moieties. The vibrational frequencies present in the cement do not change significantly 
within the specific crystallographic structure.   
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Figure 5-3 FTIR spectra of select mannitol containing cements as generated and after 14 days of 
incubation in PBS. 
Figure 5-4 shows the pH values (a) and weight change (b) of mannitol containing 
cements through 14 days of incubation in PBS. After one day in PBS, pH values varied between 
~7.0 and 7.5, with most cement embodiments becoming slightly more acidic than the PBS 
control with no statistical difference observed between cement samples or PBS. At 3 days in 
PBS, pH values of cements increased from 7.5-7.7, with pH increasing as the mannitol content 
increased. At further time points, the pH values of each cement embodiment displayed a slight 
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gradual decline, remaining slightly more basic than PBS. For time points 3 days and beyond, all 
the cements exhibited statistically higher pH than PBS. In general, the pH of 0% and 10% 
mannitol was statistically lower than 40% and 50% mannitol cements, with 20% and 30% not 
being statistically different than the others. Change in weight of mannitol containing cements, 
observed in Figure 5-4b, indicates that over the time period studied the main change in weight 
occurs within the first 24 hours in PBS. Weight change followed a linear relationship between 
weight loss and mannitol content, with 0% mannitol cements gaining on average 6% weight at 
Day 1 while 50% mannitol cements lost on average 2% of the starting weight.  Weight change 
statistics followed a similar trend, with low mannitol content cements expectedly displaying 
statistically less weight loss than the high mannitol content cements.  
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Figure 5-4  pH measurements (a) and weight change (b) of mannitol containing cements through 14 
days of incubation in PBS (n=4). 
In Figure 5-5 are displayed the daily ion concentrations of magnesium and phosphorous resulting 
from the cement dissolution. Results from ICP analysis indicate significantly elevated levels of 
magnesium and phosphorous in solution when compared with the PBS, which contains a 
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baseline of phosphorus but no magnesium. High variability is observed in the initial incubation 
time (Day 1) after which the cement dissolution appears to decline and stabilize. In both the 
magnesium and phosphorus ion concentration measurements the levels measured were 
significantly higher than PBS controls. Magnesium ion levels (at 3 days and beyond) were 
measured between 0.8 and 1.1 mMol concentrations, slightly reducing over time to range 
between 0.6 and 0.8 mMol at 14 days. Phosporous ion levels (at 3 days and beyond) were 
measured at 2.5-2.8 mMol. No statically significantly differences were observed between cement 
samples, although trends of increasing magnesium concentration with increasing mannitol 
content are seen.  
Figure 5-5 Daily magnesium (a) and phosphorus (b) ion concentration measure by ICP-OES through 14 
days of incubation in PBS at 37°C (n=4). 
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5.3.3 Cement Strength and Porosity 
Figure 5-6 shows the change in mechanical strength of mannitol cements as generated 
and with up to 14 days incubation in PBS. After generation, prior to PBS incubation, the cement 
compressive strengths of all cement embodiments ranged from 15-25 MPa with no statistical 
difference observed. Following PBS incubation, a loss of strength corresponded directly with an 
increase in mannitol content in the starting formulation as expected. After one day in PBS, the 
cement strength averages ranged from 19 MPa at 0% to 5 MPa at 30% to 1MPa at 50% mannitol 
content. This strength level remained constant for each cement embodiment through 7 days of 
testing. At 14 days in PBS, the mechanical strength slightly increased in many cement 
embodiments. (Not statistically significant.)  At all time points, there is high variability of 
strength measurements, particularly with the 0% mannitol cements and as in the above 
measurements, statistically significant differences between incremental changes in mannitol 
content are generally not observed but statistically significant differences exist between further 
separated measurements following PBS incubation. For example, 0% mannitol is not statistically 
stronger than 10% mannitol at any PBS incubation time point but both are always statistically 
stronger than 40% and 50% mannitol containing cements at those identical time points.  
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Figure 5-6 Compressive strength of magnesium ammonium cements, with up to 50 weight % mannitol 
porogen addition, through 14 days of incubation in PBS (n=4). 
In Figure 5-7 can be observed the true density (a), apparent density (b), SSA (c), and 
%porosity (d) of cements observed through 14 days in PBS. With the as generated cements, the 
true density followed a linear trend decreasing from 2.35 to 1.90 g/cm3, each with increasing 
mannitol content significantly lowering the measurement values. At day one there is still a 
similar trend of reduction in true density, from 2.35 to 2.25 g/cm3, but to less of an extent, with 
40% and 50% mannitol showing lower values than the other embodiments.  At further time 
points, the true density of all cements was the same. For comparison, the true density of mannitol 
is 1.49 g/cm3.  
The apparent density of the as generated cements and cements after 1 day in PBS 
averaged between 1.3-1.6 g/cm3 with the 0% mannitol cement slightly higher in density than the 
mannitol containing cements. Following further PBS incubation, the apparent density of the 0% 
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mannitol cement slightly decreases to 1.4 g/cm3 while the densities of the mannitol containing 
cements drop much more drastically, to an average of 1.2 g/cm3 at 5 days and near 1.0 g/cm3 at 
14 days in PBS.  There is no consistent trend or statistically significant differences in apparent 
density observed between the various mannitol containing cements.  
The BET measured surface area of the 0% mannitol cement was 125 m2/g in the as 
generated cement while the mannitol containing cements displayed a specific surface area 
between 93 for the 10% cement declining to 80 for the 50% cement. While there was a trend of 
reduced surface area with increased mannitol content, the samples were not statistically different 
from each other. Following incubation in PBS, the specific surface area of all cements drastically 
increased. The 0% cement increased to greater than 150 m2/g while the mannitol containing 
cements increased to between 135-175 m2/g. The 0% mannitol cement notwithstanding, the 
cements displayed a general trend of increased surface area with increasing mannitol content. 
However, as with the above measurements, the incremental increase in porogen content did not 
result in a statistically significant change but a large difference in mannitol content was generally 
statistically different, specifically the SSA of 10% mannitol was always lower than the SSA of 
50% mannitol. For comparison, the average surface area of mannitol was 0.29 m2/g.  
Finally, for porosity measurements, the as generated cements averaged porosity between 
35-40%, with the 10% and 30% samples statically being higher than the 20% and 40% samples, 
respectively. Following PBS incubation, the porosity of the 0% cement remained steady between 
30-35% while the porosity of the mannitol-containing cements rose significantly, increasing at 
each time point, to an average value between 55-60% at 14 days. Interestingly, there was no 
consistent trend of increased porosity observed with increasing mannitol content as would be 
expected for each time point of PBS incubation.  
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Figure 5-7 Measurements of true density (a), apparent density (b), surface area (c) and porosity (d) of 
mannitol containing cements through 14 days of incubation in PBS at 37 °C (n=4). 
In Figure 5-8 can be seen representative mercury intrusion porosimetry results for the 
mannitol cements. In order to gain an understanding of the pore size distribution, samples of the 
cement were tested in the as generated and after 3 days of incubation in PBS to allow for 
mannitol dissolution. Figures 5-8a and 5-8b depict the differential intrusion at 0 and 3 days, 
respectively, while plots 5-8c and 5-8d depict the cumulative intrusion at the same time points. 
Mercury intrusion results show that the pore size distribution of the cements at day 0 (a) was 
quite similar, with a small amount of macropores around 100 µm and a significant portion of 
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micropores between 2.0-0.2 µm. A slight increase in micropore volume and size is seen with 
increasing mannitol content, from 0.11 mL/g peaking at 0.9 µm for the 0% to 0.19 mL/g peaking 
at 1.1 µm for the 50% mannitol cement. Cumulative intrusion at day 0 (c) indicates that the 
increased micropore volume results in a slight increase in cumulative intrusion as well, from 0.09 
mL/g at 0% to 0.13 mL/g at 50%. Differential intrusion after 3 days of incubation indicated an 
increase in mid level (10 µm) pores as well as micropores (less than 1 µm), particularly for the 
50% mannitol sample. Cumulative intrusion indicates a moderate increase in intrusion volume 
for the 0, 10, and 30% mannitol samples (up to 0.2 mL/g) but a large increase in intrusion 
volume for the 50% mannitol sample is observed as would be expected. It is important to note 
that mercury intrusion porosimetry measurements are of one individual sample and used to 
observe only general trends in pore structure but are not stastically measured.  
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Figure 5-8 Mercury intrusion porosimetry measurements of mannitol supplemented cements. In (a) and 
(b) are the log differential intrusion volumes at 0 and 3 days of PBS incubation, respectively. In (c) and (d) 
are the cumulative intrusion volumes at 0 and 3 days of PBS incubation, respectively (n=1, representative 
only)  
In Figures 5-9 and 5-10 are displayed the SEM images of cement pressed and fracture 
surfaces, respectively, at 0 and 14 days incubation in PBS with a scale bar of 50 µm. In Figure 5- 
9 the pressed (external) surface of the as generated cements shows a generally smooth surface 
with consistent cement morphology grain size. The presence of mannitol is particularly 
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noticeable in the 40% and 50% samples, seen as smooth, elongated, darker gray grains in the 
images. After 14 days in PBS the surface of the cement is less smooth, with the cement pellets 
covered in new crystal growth. These crystals are larger and of a more oblong morphology than 
the grains seen on the surface of the as generated cement. The morphology of mannitol crystals 
is not seen in any samples, and obvious macroporosity resulting from the removal of the 
mannitol is not observed.  
In Figure 5-10, the internal fracture surface of the cements as generated is similar to the 
external surface, showing a consistent grain size and morphology of the cements with significant 
presence of long, smooth mannitol crystals  in higher content cements. Crystals appear to of the 
size ranging from 10-200 µm, however the mercury porosimetry indicates additional particles 
below 10 µm. After 14 days of PBS incubation the internal cement microstructure shows 
significant portions of macropores 50-100 µm in size as well as noticeable porosity below 10 µm 
in size. Cement grain structure is more similar to that of the as-generated cement, showing the 
growth of some fine crystals but not the growth of large oblong crystals as seen on the surface of 
the cement. The surface crystal growth is then likely due to reprecipitation on the surface from 
the cements sitting in a stagnant (non-continuous flow) salt media for an extended period of time. 
In Figure 5-11 can be seen the internal surface of the cements at higher magnification 
after 1 day in PBS, with a scale bar of 10 µm. These images indicate the cement microstructure 
is very similar to that of the 800 °C crystalline TMP- ammonium phosphate solution cement 
studied in Chapter 3. The higher magnification images show the same block and elongated 
crystal type in all cements, regardless of the original mannitol content. 
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Figure 5-9 SEM images of the exposed cement surface as generated (Day 0) and after 14 days of PBS 
incubation (Scale bar is 50 µm). 
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Figure 5-10 SEM images of the fracture (internal) cement surface as generated (Day 0) and after 14 days 
of PBS incubation (Scale bar is 50 µm). 
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Figure 5-11 SEM images of internal cement surface after 1 day in PBS at 1500x magnification (Scale bar 
is 10 µm). 
5.3.4 Cytocompatibility 
In Figure 5-12 are displayed the Live/Dead staining of MC3T3 cells at 0 and 7 days of 
culture on cement pellets. Images at days 1 and 7 indicate that the addition of mannitol does not 
visibly improve nor harm the cytocompatibility of the cement. All cements, including 
hydroxyapatite and brushite controls, demonstrated lower cell viability and cell numbers than the 
tissue culture plastic control. Day 7 results indicate that the cell proliferation from day 7 was 
low, and brushite cements appear to have an increased level of dead cells.  
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Figure 5-12 Live/Dead staining of MC3T3s on cements at 1 and 7 days of culture (Scale bar is 200 µm). 
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Figure 5-13 contains the MTT cellular activity (a) and cell number quantification (b) 
results tested with MC3T3 pre-osteoblast cells. Globally there were not significant trends 
between cement samples for MTT or cell number. At day 3, MTT indicated high activity for 0% 
mannitol samples and brushite samples than others. At day 7, the tissue culture control had 
higher MTT cell activity. Activity levels for cement constructs did not appear to change with 
time.  
Cell number results indicate drastically more cells on the tissue culture control samples 
than on any of the cement constructs. Cell numbers on cement constructs increased slightly from 
day 1 to day 3, and cell number on the apatite cement increased significantly at day 7.  It is 
important to note that MTT and cell number measurements were conducted on the cement 
construct alone. Tissue culture measurements were normalized to the cement construct surface 
area, from 1.9 cm2 on the well plate to 0.785 cm2 for the cement sample. The number of cells 
seeded on pellet surface (normalized from 40,000 cells/well) was about 16,000 cells per pellet. 
Thus the total cell number on cements was significantly lower than the original seeding density.  
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Figure 5-13 MTT (a) and cell number (b) data for MC3T3s grown on cements at 1, 3 and 7 days culture 
(n=4, p<0.05 indicated with *). 
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5.4 DISCUSSION 
For the development of the next generation of synthetic bone graft substitutes a wide variety of 
properties are desired, including ease of use, mechanical strength, degradability and 
osteoconductivity. Porosity is near the top of this list because it is known to improve the implant 
integration with the host tissue and allows for nutrient flow and cellular ingrowth. Experience 
has shown that dense constructs may not integrate well with the patient’s native bone, even 
resulting in long term implant infection and likely rejection. Mannitol has frequently been 
employed as a porogen in calcium phosphate cements because it dissolves quickly and does not 
cause biocompatibility issues nor disrupts the cementing reaction [111, 217, 218]. 
The addition of mannitol to the magnesium ammonium phosphate cement (MPC) 
resulted in longer setting times at a given powder-to-liquid ratio (Figure 5-1) which is to be 
expected as the sugar crystal does not participate in the cementing reaction. For this reason, a 
variety of P:L were tested to optimize the setting time of each cement formulation, with the 
optimized P:L to be used for the remainder of the study.  XRD (Figure 5-2) and FTIR (Figure 5-
3) test analyses shows the cementing reaction proceeded the same way as observed in Chapters 2
and 3, with the mannitol not affecting the phase formation of the as generated cement nor the 
phase evolution following the PBS incubation. This is supported as well by the SEM results in 
Figures 5-9, 5-10 and especially 5-11, which show the presence of mannitol and resulting 
porosity but no change in cement crystal microstructure with the mannitol addition. Results 
indicate that the mannitol is fully dissolved at the 14 day time point, evidenced by the lack of 
mannitol peaks in the XRD or FTIR plots.  This is also supported by the changes in weight, 
surface area and true density shown in Figure 5-7, which show a significant change between the 
as generated cement and cements after 1 day in PBS, but little or no change beyond this point.  
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Major changes in weight (Figure 5-4b) occurred only after initial PBS exposure, with the 
0% mannitol sample gaining 6% of its initial weight, trending downwards to 2% weight loss with 
the 50% mannitol sample. While these weight changes are not at the 10-50% change of the 
original mannitol inclusion, this level of weight change would not be expected. The 
measurements were taken as wet weight, where the samples are not dried after PBS incubation, 
so liquid is present as filled in many of the pores as well as the crystals of the cement holding 
associated water molecules. Additionally, the mannitol content was a weight percentage of the 
dry powder, to which a significant volume of solution was added and consumed.  
Elevated magnesium and phosphate ion levels (Figure 5-5), slightly elevated pH 
measurements (Figure 5-4a) and reduced apparent density and increase porosity at longer PBS 
incubation time points (Figure 5-7) indicate that the cement scaffolds are continuing to dissolve 
over the time frame studied, even if that dissolution is not distinctly observable in the wet weight 
measurements.  It is interesting to note that the apparent density and porosity level of the 0% 
mannitol cement remained unchanged while the mannitol containing cements changed. It is 
possible that, even the small amount of mannitol addition, resulted in enough additional 
interconnected porosity to change the dissolution/precipitation kinetics within the micropores of 
the mannitol-containing cement structures.  This could result in more dissolution within the 
micropores of mannitol cements while the 0% cement dissolution could only occur in more 
poorly connected pores and from the surface of the sample, which would not change the porosity 
level.  
Although the compressive strength of cements (Figure 5-6) after PBS incubation 
drastically decreased with increasing mannitol content, the increasing porosity observed at longer 
incubation times did not further decrease the cement strength.  Failure of ceramic materials is 
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catastrophic, not a process of deformation as observed in polymers and metallic materials, and 
the strength is controlled or dictated by the largest defect in the material [223]. As every pore in 
a cement is structurally a defect, it holds to bare then that the failure of the cement is controlled 
by the largest defects present in the material.  The native cement, with 0% mannitol, naturally 
contains pores in a variety of sizes, including occasional macropores introduced during mixing. 
Although the surface images do not appear macroporous, SEM images of the internal cement 
structures  in Figure 5-10 confirm significant  porosity, including some 50 µm+ sized pores and 
channels. Mercury porosimetry (Figure 5-8) results indicate however that the introduction of 
mannitol did not drastically increase the amount of macropores as anticipated.  The addition of 
mannitol introduces more porosity to the structure until the material has more defects than the 
cement construct. The addition of more sub-micron sized porosity through mannitol dissolution 
would not result in significant further reduction in strength because the strength is controlled by 
the larger pores, which were already present. However, the introduction of more microporosity 
may result in more interconnected porosity yielding a larger over-all defect with increasing 
mannitol content. The trends in strength and porosity observations are further complicated by the 
fact that cement structures are composed of unique grains and crystals held together through 
some bonding and mechanical interference, as demonstrated in Figure 5-11 as well as in Chapter 
3, and not dense as typically observed in sintered ceramic constructs.  
Cytocompatibilty results from live/dead staining (Figure 5-12) and MTT and cell number 
assays (Figure 5-13) indicate that the addition of mannitol does not appear to improve or harm 
the MC3T3 osteoblast cell viability.  Cell viability on all cement constructs is lower than on the 
tissue culture plastic, which is not unexpected as the cements are a dynamic system, with 
continuous dissolution of the various phases and the sugar crystals and changing the media pH 
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combined with ion concentrations changing constantly. It is encouraging that the magnesium 
ammonium cement embodiments are comparable to hydroxyapatite and brushite CPCs which are 
considered the industry standard in bone cements. However, mannitol was added to the 
magnesium phosphate cement with the intent to improve fluid flow and cellular infiltration into 
the constructs. The fluid flow objective was met, evidenced by the increasing porosity and 
magnesium and phosphorous ion levels.  Cell number and activity levels however, did not seem 
to increase with increasing mannitol content. Indeed, although the overall porosity increased, the 
mannitol did not introduce significant additional macroporosity to the cement structure, indicated 
through mercury porosimetry results (Figure 5-8). While some macroporosity may have 
increased, the level does not appear to be enough to create interconnected macropores, 
preventing thorough cellular infiltration of the construct. There is also the potential that pH and 
ion levels within the cement porosity were more extreme than the levels measured in the media 
and this too reduced the driving force for inducing cellular infiltration.  As some cells can be 
seen within the near-surface pores in the live/dead images (appearing round and out of focus), 
the lack of cellular infiltration is likely a combination of these two factors. The true effects of the 
addition of mannitol can only be observed in-vivo when the pre-molded constructs are implanted 
into a relevant animal model which is a likely direction to be continued in the near future to 
ascertain the true efficacy of the MPC derived by the ammonium phosphate solution approach. 
5.5 CONCLUSION 
Magnesium ammonium phosphate cements were successfully created with up to 50 weight % 
mannitol pore formers. Optimized powder-to-liquid ratios were chosen to yield clinically 
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appropriate handling characteristics and setting times of 10-15 minutes. All embodiments 
maintained a balanced pH and moderate cytocompatibility. Addition of even 10 weight % 
mannitol resulted in significantly increased porosity of the cement. The porosity of mannitol 
containing cements increased with increasing aqueous incubation, and the majority of this 
porosity was below 10 um, which prevented significant cellular infiltration. The addition of 
mannitol significantly reduced the compressive strength of the cement after aqueous solution 
incubation, with increasing mannitol content decreasing the strength. Given these results, it is 
recommended that a low level of mannitol addition (10-20%) positively improves porosity, while 
only moderately affecting the strength of the cement. The true efficacy of the system will 
however, be assessed only following in-vivo studies in suitable and relevant animal models. 
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6.0  SPECIFIC AIM 5: EFFECT OF FIBER REINFORCEMENT OF A MAGNESIUM 
AMMONIUM PHOSPHATE CEMENT WITH WETSPUN POLYCAPROLACTONE 
FIBERS 
6.1 INTRODUCTION 
While calcium phosphate cements have been the obvious choice as a repair scaffold because the 
chemical composition of these cements mimics that of native bone mineral, magnesium 
phosphate cement (MPC) formulations are an alternative to calcium phosphate forming cements 
[10].  MPCs have frequently been reported to display greater control over clinically appropriate 
setting times, greater compressive strength, and more rapid resorption and bone growth than their 
calcium phosphate counterparts [28-34]. Compressive strength for these cements often range up 
to 85 MPa [36-38, 56-59].  Ginebra et al recently explored MPCs for dental applications, 
showing pushout strengths greater than 20 MPa, intrinsic antibacterial capabilities and no foreign 
body response, inflammation or necrosis [28, 36].   Magnesium plays a vital role in bone 
calcification and density, metabolism of bone mineral and increasing bone cell adhesion and 
stability [19, 34, 42].   
Although calcium and magnesium phosphate cements have become highly engineered 
medical devices, their use is ultimately limited to void filling and non-load-bearing applications 
due to the intrinsically brittle nature of the ceramic. While the compressive strength of these 
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cements are often greater than cortical bone and close to trabecular bone, the flexural strength 
leaves much to be desired [128]. Typical flexural strengths of calcium phosphate cements range 
from 5-15 MPa, compared to the 200 MPa flexural strength of cortical bone [26, 224, 225]. To 
improve the flexural strength and reduce the brittleness, reinforcement strategies may include 
compaction of the wet body, introducing bimodal particle size distributions, creating a dual-
setting cement system and introducing fibrous reinforcement [226]. The concept of 
reinforcement through fibrous inclusions is widely utilized in the commercial cement industry to 
improve the fracture toughness and reduce catastrophic brittle failure of concrete [227]. The 
same principle, only at a smaller scale, is under exploration for ceramic bone cements. Use of 
polymer fibers may improve the toughness, decrease brittle fracture and improve the ability of 
the cement systems to withstand drilling stresses [228]. Reinforcement of calcium phosphate 
bone cements has been examined with poly(lactide-co-glycolide), chitosan, carbon nanotubes 
and bioglass as the fibrous inclusions [118, 119, 161, 226, 229-233]. The inclusion of 
biodegradable fibers can also serve as a mechanism to create porosity following in vivo 
implantation, which improves the implant’s cellular influx and new bone growth [128].  
In addition to creating porosity for cellular infiltration, the utilization of a biodegradable 
polymer such as polycaprolactone (PCL) provides the potential to deliver drugs or biologics 
during the degradation process. Osteomyelitis is a significant complication of orthopedic 
surgery, often resulting in secondary surgery to remove the infected implant [234]. Sustained, 
long-term delivery of antibiotics from the implant reduces or eliminates these concerns [235]. 
Antiobiotic loaded calcium phosphate cements have been explored in a variety of modalities, 
including mixing the antibiotic into the powder or liquid phase, and the addition of drug-loaded 
degradable microspheres or fibers [132, 134, 236-238]. Finally, the use of a biodegradable 
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polymer such as polycaprolactone (PCL) or poly(lactide-co-glycolide) (PLGA) may allow the 
degradation profile to be tailored to achieve optimal porosity evolution, allowing for exploring 
drug release, inducing cellular infiltration and ultimately causing bone ingrowth [239-242].  
Wet spinning is one of the several synthesis techniques which can be used to create fibers 
for these applications [243-247]. Wet spinning involves dissolving the polymer of choice in a 
good solvent for the polymer then injecting this solution into a non-solvent coagulating bath, 
which leaches out the solvent leaving behind a pure, solidified polymer fiber [246, 248]. Similar 
to electrospinning, numerous factors affect the final morphology and materials properties of 
resulting fibers, including solvent and coagulant choices and draw ratio [243, 245, 246].  
To date, fiber reinforcement of magnesium phosphate bone cements (MPBC) has not 
been explored. In this study, fibers of polycaprolactone (PCL) were generated through a wet-
spinning mechanism. These fibers were then characterized and subsequently added to a 
magnesium phosphate cement (MPC) embodiment and the effect of these fibers on the cement 
properties was further explored.  
6.2 MATERIALS AND METHODS 
6.2.1 Fiber Generation and Characterization 
Polycaprolactone (PCL, 70,000-90,000 MW, Sigma Aldrich) was dissolved in a 1:1 ratio of 
acetone and tetrahydrofuran at a concentration of 2.0 g/mL. The polymer solution was incubated 
at 37 °C and stirred for 24 hours prior to wet spinning.  Wet-spinning was performed by injecting 
the PCL solution through a 16 gauge blunt-tip needle into a double coagulation bath of 98% 
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ethanol at a rate of 5 mL/hour. Ethanol is a poor solvent for PCL, thus serves as a coagulation 
bath, extracting the acetone and tetrahydrofuran and leaving the polymer fiber behind. Dual 
coagulation baths were used because this resulted in better solvent extraction and fiber drying. 
The linear collection rate of the PCL fibers was set to 250 cm/min to generate approximately 100 
micron diameter fibers. A schematic of the wet-spinning set-up can be found in Figure 6-1.  The 
fibers were dried in a desiccator for at least 24 hours, then cut into 1.5 mm long pieces using a 
scalpel and stored in a desiccator until use.  Generated fibers were imaged through digital optical 
microscopy (Keyence VHX-600K) to measure the diameter and length of fiber pieces. The 
mechanical strength of the fibers was tested through tensile testing of individual fibers (MTS 
Insight 1SL) at a rate of 25 mm/min to rupture.  
Figure 6-1 Schematic of the wet spinning set up. 
6.2.2 Cement Generation 
The cement formulation consisted of Mg3(PO4)2 (TMP, Sigma Aldrich) combined with the as-
prepared PCL fibers and a pH 7.0 ammonium phosphate solution.  The commercially obtained 
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TMP powder was thermally treated for 6 hours at 1000 °C under air in order to decrease the 
powder surface area below 1.0m2/g thus reducing the powder reactivity.  The 3.0 M, pH 7.0 
ammonium phosphate solution was made by combining appropriate amounts of monoatomic and 
diatomic ammonium phosphate salts at a ratio of 2:7 monoatomic:diatomic salt in deionized 
water. The thermally-treated TMP powder was gently mixed with the PCL fibers, at 0 %, 5 %, 
7.5 %, 10 %, and 15 % fiber content by weight to create the cement powder.  The cement powder 
was then mixed with the ammonium phosphate solution at 0.83 mL solution per 1 gram of TMP 
powder, maintaining a consistent powder-to-liquid ratio of 1:0.83 independent of the fiber 
content.  Putties were mixed for 60 seconds, then lightly pressed into molds, and dried at 37 °C 
overnight prior to further testing as outlined in Chapter 5 for the mannitol containing cements.  
6.2.3 Cement Characterization and In Vitro Dissolution 
First and second setting times of cement pastes were determined using the Gilmore needle test at 
room temperature following the ASTM standard C266-13 at room temperature and handling 
characteristics were qualitatively assessed based on consistency and handling ease as for the 
mannitol containing cements discussed in Chapter 5 and for non-mannitol containing cements in 
Chapter 3. Cement phases were identified through x-ray diffraction. Fourier transform infrared 
(FTIR) spectroscopy was used to identify or analyze any differences in molecular linkages 
between cements. Cements were also observed under scanning electron microscope as  
introduced in Chapter 2. Specific surface area (SSA) was measured as well as true density and 
apparent density, which were used to calculate percent porosity as outlined in the earlier 
chapters. The percent porosity is then calculated from the envelope and true densities following 
Equations 4-3 and 4-4 as previously described in Chapter 4. 
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Cement strengths were analyzed in compression and 3 point bending modalities. For 
compression testing, cement cylinders, nominally 6mm diameter by 13 mm height, were utilized 
and for 3 point bend testing, rectangular cement constructs 4.5 mm by 4.5 mm by 16 mm long 
were utilized. Compression testing was completed following modified ASTM D 695 and ASTM 
C39 methods employing a 2 kN load cell at a crosshead speed of 1.0 mm per minute (Instron, 
Norwood MA).  Bend testing was completed following modified ASTM C1609 method, 
employing a 500 N load cell, with a span between contact points of 13.5 mm and a crosshead 
speed of 0.05 mm per minute to 0.15 mm displacement then 0.10 mm per minute to 0.30 mm 
displacement.  For both sets of mechanical testing, cements were incubated in phosphate 
buffered saline (PBS) at 37 °C prior to testing to determine the change in strength due to aqueous 
incubation. PBS incubation time points were 0, 1, 5, 15 and 30 days with 4 samples considered 
for each time point for each test. Strength measurements were calculated following Equation 6-1: 
Equation 6-1 
f=PL/bd2
 Where f is the strength in Mpa, P is the load in N, L is the span length (13.5 mm), b is the 
sample width and d is the sample height, both in mm. Peak strength was calculated using 
Equation 6-1 with the maximum strength obtained before initial failure of the sample. L/50 
residual strength was calculated following Equation 6-1 using the load at a displacement of L/50, 
or 0.27 mm.  Fracture toughness was determined by integrating the stress-strain plot to determine 
the area under the curve at the peak strength displacement and at L/50 displacement. The area 
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under the curve, recorded as toughness, is in Joules (J).  Samples of the post-fracture cements 
were then imaged under SEM in order observe the fracture-surface morphology.  
Cement pellets were incubated in PBS at 37 °C at a concentration of 10 mL of PBS per 1 
gram of cement. The PBS was changed every 24 hours, and the pH and sample weight was 
measured at east time point (1, 3, 5, 7, 15, 30 days) during the study.  Samples incubated in PBS 
were dried overnight at 37 °C and characterized through XRD, FTIR, SSA, density and SEM, 
under the conditions outlined above, in order to assess changes in the cement from the as-
generated stage due to the aqueous solution incubation. 
6.2.4 Cell viability 
MC3T3 cells were grown on cement substrates, following THF incubation to remove the fibers, 
to demonstrate cell viability and short-term ingrowth into pores. Fiber removal was confirmed 
through visual inspection. Cells were cultured and seeded as previously described in Chapter 5 
for the mannitol containing cements. After 24 hours, live/dead staining was completed after 
which samples were fixed, dehydrated and sputter coated for SEM observation using the 
procedure described in Chapter 2.  
160 
6.3 RESULTS 
6.3.1 Fiber Characterization 
The use of a dual ethanol coagulation bath wet spinning system to create PCL fibers reliably 
generated opaque fibers of approximately 100 µm diameter under the conditions stated above. 
The arithmetic mean was 101.3 ± 15.5 µm while the geometric mean was 100.1 ± 1.7 µm. The 
cut fibers averaged a length of approximately 1.45 µm, with the arithmetic mean 1.45 ± 238 mm 
and the geometric mean 1.426 ± 0.012 mm. A total of 150 fibers were measured for each 
diameter and length calculations. An example image of the fibers can be seen in Figure 6-2.  
Figure 6-2 Macroscopic (a) and optical microscopy (b) image of the PCL fibers derived by wet-
spinning. 
Table 6-1 shows the mechanical properties of the individual fibers tested in tension to 
failure (average of 14) and an example of the representative stress-strain curve can be seen in 
Figure 6-3. The fibers were able to undergo a large amount of plastic elongation prior to rupture 
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as expected, on average more than 600%. Engineering and True stress and strain are reported due 
to the large amount of deformation the fibers experience before failure.  This level of 
deformation is expected to improve the flexibility and toughness of the cement while reducing 
the ultimate strength of the cement.   
Table 6-1 Mechanical properties of fibers at failure. 
Max Load (N) EngineeringStress (MPa) 
True Stress 
(MPa) 
Engineering  
Strain True Strain Elongation (%) 
0.21± 0.045 19.3 ± 4.9 119.0 ± 45.0 5.21 ± 2.47 1.91 ± 0.33 637 ± 119 
Figure 6-3 Example Fiber Stress-Strain Curve. 
6.3.2 Cement Characterization 
Cements were generated with up to 15 weight % PCL fiber and resulted in setting times (ST) of 
6:30-9:00 minutes 1st ST and 12:30-15:00 minutes 2nd ST, as depicted in Figure 6-4. A general 
trend of reduced set time with increasing fiber content was observed. No statistically significant 
differences exist between the 1st ST of the samples. However, significant differences exist 
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between the 2nd STs of the cements, specifically 0% and 7.5% fiber content are significantly 
larger than 5%, 10% and 15% fiber containing cements. Up to 10 % fiber resulted in a putty 
which was moldable but not flow-able at the given liquid content.  At 15 % fiber, the cement 
consistency during mixing was sponge-like and difficult to handle. After final setting however, 
all embodiments resulted in cement bodies which were durable to the touch and easy to handle. 
Figure 6-4 First and second setting times of fiber containing cements 
The cements were incubated in PBS at 37 °C, and initial properties as well as changes 
due to aqueous incubation were analyzed.  In Figure 6-5 are shown the XRD patterns obtained 
from the as prepared cements and after 30 days immersion in PBS. Phases present in the initial 
cement resulting after reaction and setting were unreacted precursor TMP (Mg3(PO4)2, ICCD 00-
033-0876, +), struvite (MgNH4PO4•6H2O, ICCD 98-002-2086, *) and newberyite 
(MgHPO4•3H2O, ICCD 00-035-0780, #) in addition a small amount of hannayite 
(Mg3(NH4)2H4(PO4)4•8H2O, ICCD 98-000-6099, $). Following 30 days of incubation in PBS, 
struvite and newberyite were the dominant phases, with a significant amount of unreacted TMP 
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remaining but with no hannayite similar to the trend observed in mannitol containing cements 
discussed in Chapter 5. 
Figure 6-5 X-ray diffraction spectra of cements at (a) 0 days and  (b) 30 days of incubation in PBS. 
Phases present are denoted: struvite (*), newberyite (#), unreacted trimangesium phosphate (+), and 
hannayite ($). 
Figure 6-6 shows the FTIR spectra of cements at 0 (a) and 30 (b) days of incubation in 
PBS at 37 °C, as well as the FTIR spectra of the PCL fiber for comparison. PCL fiber is 
occasionally detected in the cement spectra, such as the 10 % fiber sample at 0 days, particularly 
notable around the 1750 cm-1 wavenumber.  However, given the composite nature of the cement, 
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the fiber is not observed in all samples. Beyond the bands indicative of PCL, no differences are 
seen between sample types or time point measurements. Typical bands corresponding to PO4, 
water, OH and NH4 vibrations are also seen in all samples as is the case for the cements 
discussed in Chapter 5. As these bands are identical to previous analysis, a more detailed 
discussion of specific FTIR band wavelengths of the magnesium ammonium cement formulation 
can found in Section 3.3.3 with corresponding Figures 3-10 & 3-11.  
Figure 6-6 FTIR spectra of cements at 0 days (a) and 30 days (b)  incubation in PBS at 37 °C. 
In Figure 6-7 is displayed the pH and weight change measured through 30 days in PBS. 
Measurements of PBS (6-7a) throughout cement incubation indicates that there is an initial mild 
drop in pH to 7.0-7.25, likely due to any unreacted solution dissolving, followed by an increase 
in pH to approximately 7.50-7.75 for all the samples. This measurement plateaus after 3 days, 
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with only slight variations seen through 30 days of incubation in PBS. Figure 6-7b shows the 
change in weight of samples through the same 30 day period. These measurements, collected on 
the wet samples at each time point, indicate an initial increase in cement weight of 6-7%, a value 
which remains constant throughout the times points observed. There is no significant difference 
between conditions at any time point, or between time points for each condition.   
Figure 6-7 pH (a) and weight change (b) of cements through 30 days of incubation in PBS. 
In Figure 6-8 are the density trends of the magnesium phosphate fiber reinforced cements 
(MPFRC) cements incubated in PBS through 30 days at 37 °C. These measurements are of n=1 
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and are used only as an indication of the expected trends. True density measurements (a) show a 
decrease with increasing fiber content, from 2.5 g/cm3 at 0% fiber to 2.0 g/cm3 at 15% fiber, 
which is to be expected as the polymer true density is lower than the cement true density. 
Following THF immersion inducing dissolution of the PCL, true density of all samples is nearly 
the same (2.4 g/cm3), indicating the complete removal of the PCL from the cement structure. 
There is a mild trend of decreasing true density with PBS incubation, which may be caused by 
water incorporation and cement product hydration as well as through new crystal growth within 
the porous structure of the cement.  
Envelope density (b), or apparent density, shows a similar trend of lower density with 
increasing fiber content, from 1.62 g/cm3 at 0% fiber to 1.45 g/cm3 at 15% fiber. The apparent 
density following THF incubation is quite similar to the initial apparent density after cement 
generation for each sample, indicating that the apparent density is heavily influenced by the 
innate porosity of the cement.  Here there is a mild trend of increasing apparent density with 
increasing PBS incubation time, which may similarly be a result of cement hydration or new 
crystal growth during incubation. 
Porosity measurements (c) indicate some decreasing porosity of the as-generated cement 
with increasing fiber content, from 38% at 0% fiber to 29% with 15% fiber. As the wet-spun 
fiber are by nature mostly dense constructs and the cement is innately porous, this trend is 
anticipated; the higher over-all cement content yields a higher initial porosity value. Porosity 
levels decrease slightly with increased PBS incubation, corresponding well to the decreased true 
density and increased apparent density seen in (a) and (b).  Less expected, porosity 
measurements following THF incubation indicate all samples contained 50-55% porosity, which 
is a large increase event especially for the 0% fiber cements. This may be attributed in part 
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dehydration of the cement scaffold from the solvent incubation resulting in loss of water and 
adsorbed solvents.  
Figure 6-8 Density trends of cements through PBS incubation and with the PCL fibers removed 
(labeled THF) showing the true density (a), envelope density (b) and porosity (c). 
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In Figure 6-9 is plotted representative log differential (instantaneous) and cumulative 
mercury intrusion porosimetry of cement samples as generated and following THF incubation to 
remove the fibers. Mercury intrusion is utilized to assess pore size distribution of the cement. 
Results of instantaneous intrusion of the as generated cement (a) indicate all samples contain 
some level of macroporosity (around 100 µm in size) as well as a significant amount of 
microporosity (3 µm and below). Following THF immersion (b) to remove PCL fibers, the level 
of macroporosity increases with increasing fiber content. These macropores range from 50-100 
µm in size matching the fiber diameter in general. Cumulative mercury intrusion indicates slight 
differences in porosity in the as generated cements (c) while the THF incubated samples (d) 
indicate the increased macroporsity of fiber containing cements.  
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Figure 6-9 Mercury intrusion porosimetry depicting the log differential (or instantaneous) intrusion 
volume of cements as generated (a) and with PCL fibers removed (b) and cumulative intrusion volume of 
cements as generated (c) and with PCL fibers removed (d). 
In Figure 6-10 are representative force-displacement curves obtained following the 3 
point bending modality of cements with varying amounts of fiber content. These representative 
images demonstrate increasing residual strength following peak fracture with increasing fiber 
content in the cement, indicated by arrows in each image. These plots point to the fact that, 
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through with the inclusion of up to 15 weight % wet-spun PCL fibers, the cement failure remains 
within the pseudo-strain hardening modality.  
Figure 6-10 Representative force-displacement curves in 3-point bending of fiber reinforced cements. 
In Figure 6-11 are 3 point bend strength of the cement samples at (a) the peak strength 
and (b) L/50 residual strength through 30 days of incubation in PBS. L/50 is indicative of a 
measurement at a fracture displacement distance of the sample length/50 as an indication of 
‘residual’ strength or toughness following initial peak strength measurements.  At Days 0, 1 and 
5 there are no statistical differences in the peak strength values (a) of the cements, however there 
is a very high level of variability in several of the sample sets. At Day 15 and 30 the 0% fiber 
samples are significantly stronger than all of the fiber containing cements and the 5% fiber 
cements are significantly stronger than the 15% cements. A trend of decreasing strength with 
increasing fiber content at longer incubation times is thus observed. Additionally, while this 
study lacks the statistical power to confirm, there appears to be an increase in cement strength at 
longer PBS incubation time points, particularly with the 0% fiber cement samples. The residual 
strength measurements (b) indicate increasing residual strength with increasing fiber content. At 
all the time points, all fiber-containing cements demonstrated non-zero residual strengths, in 
comparison to the complete failure and resulting zero residual strength of the 0% fiber cement. 
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Within each time point, lower fiber content results in statistically lower residual strength broadly, 
but may not be statistically different than one step change in fiber content. For example, 5% fiber 
samples are never significantly lower than 7.5% samples, but are nearly always significantly 
lower than 10% (Day 30 notwithstanding) and always significantly lower than 15% samples. 
Cements with 15% fiber demonstrated high residual strengths than all other samples at 0, 1, 15 
and 30 days of PBS incubation, but were not significantly higher than 10% fiber cements at Day 
15.  
Figure 6-11 3 point bend strength of cement samples at (a) the peak strength and (b) L/50 residual 
strength through 30 days of incubation in PBS. 
Toughness under 3 point bending of cement samples is shown in Figure 6-12 at (a) the 
peak strength point and (b) L/50 residual point through 30 days of incubation in PBS. Through 
all the tested time points, there is no significant difference in measured peak toughness of 
samples at any given time point. The initial peak toughness did increase in the 30 day 
measurement over the earlier time points, from an average of nearly 2 J to 3 J in all samples. 
Residual toughness is a measure of the total energy absorbed during testing through a facture 
displacement of L/50. Here again the influence of fiber content can be seen, with all fiber-
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containing samples demonstrating significantly high toughness than the 0% fiber cement at every 
time point studied. Similar to 6-11b above, the increasing fiber content increases the toughness 
measurement globally, but one step in increased fiber content generally does not lead to a 
statistically significant increase in toughness. Cements containing 5% fiber demonstrated 
statistically lower toughness values than 10 and 15% fiber cements at day 0 and lower strengths 
than 15% fiber cements at each other time point.  Cements containing 15% fiber demonstrated 
statistically higher residual toughness than 5 and 7.5% and 10% fiber cements at days 0, 1, 15 
and 30.  
Figure 6-12  Toughness under 3-point bending of cement samples at (a) the peak strength point and (b) 
L/50 residual point through 30 days of incubation in PBS. 
For comparison purposes, compressive strength of cements at the same PBS incubation 
time points were measured, the results of which can be found in Figure 6-13.  Here there is a 
high level of variability in each sample set, and there is nearly no statistically significant 
differences among the compressive strengths measured. Only the 15% fiber cements demonstrate 
statistically a gradual (not statistically significant) decrease and then increase in strength 
throughout the 30 days of PBS incubation.   
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Figure 6-13 Compressive strength of fiber reinforced cements through 30 days of incubation in PBS. 
Figure 6-14 and 6-15 contain SEM images of the external surface (6-14) and internal 
fracture surface (6-15) of cements at 0, 1 and 30 days of incubation in PBS. The scale bar here is 
100 µm.  Figure 6-14 indicates a smooth pressed surface with PCL fibers emerging from the 
surface of those cements which contain them. Following only one day in PBS the cement surface 
morphology demonstrates the evolution of new crystal growth on the surface. These crystals are 
of a hexagonal morphology. At 30 days in PBS, this crystal growth is more wide spread, as 
crystals appear to have grown over the surface of the polymeric fibers as well, a distinct 
difference from the smooth fiber morphology observed in the day 0 images. The additional 
crystals grown at extended PBS incubation are smaller in size and of a more rounded 
morphology. Figure 6-15 depicts the fracture surface morphology of the cements which were 
tested beyond L/50 displacement in mechanical testing discussed above, with the scale bar at 50 
µm, showing a more zoomed in picture of the internal surface. These images show a fine crystal 
size within the as-generated cement and a smooth interface between the cement and polymer 
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fiber. Following PBS incubation similar hexagonal crystals are observed in many of the cement 
images.  
 
 
Figure 6-14 SEM images of the external (pressed) surface of fiber containing cements as generated and 
at 1 and 30 days of incubation in PBS at 37 °C (100µm scale bar). 
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Figure 6-15 SEM images of the internal (fracture) surface of fiber containing cements as generated and 
at 1 and 30 days of incubation in PBS at 37 °C (50um scale bar). 
Figures 6-16 and 6-17 show representative live/dead staining and SEM images 
(respectively) of MC3T3 osteoblast cells growing within the macroporous structure created after 
the PCL fibers had been removed through THF incubation. Live/dead images show consistent 
cell viability, independent of pore former content, as well as cell growth within the pores, seen as 
spherical shaped cells significantly out of focus. SEM images indicate the cells are well attached 
within the pore structure, not merely deposited or floating within the pores.  
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Figure 6-16 Live/dead staining of MC3T3 cells on magnesium ammonium cement scaffolds after fiber 
leaching (Scale bar is 100 µm). 
Figure 6-17 SEM images of MC3T3 cells on magnesium ammonium cement scaffolds after fiber leaching 
(Scale bar is 50 µm). 
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6.4 DISCUSSION 
The use of fiber reinforcement in cement and concrete materials has its roots in common 
industrial practices, particularly the use of steel rebar to toughen concrete for building 
construction. The use of fiber reinforcement for calcium phosphate bone cements (CPCs) has 
been the subject of both academic and industrial investigation, exploring natural and synthetic 
polymers as well as ceramics [128, 249]. Fiber reinforced cement (FRC) is a general term which 
can refer to the use of short fibers, long fibers, short bundles of fibers, yarns of twisted fibers and 
woven structures and these fiber constructs can be randomly oriented or intentionally directional 
in their orientation [249]. In this study, individual 100 µm diameter fibers of polycaprolactone 
cut to a short length (1.5 mm) are utilized in a random orientation. In published studies, short 
lengths individual fibers or yarns are most commonly used, with fiber diameter ranging from 30 
nm to 350 µm and length ranging from 30 nm to 200 mm. These properties, in addition to 
several others shown in Figure 6-18a play a significant role in mechanical behavior of FRCs and 
ultimately control the failure modality of the cement, from brittle to quasi-brittle (tension 
softening) to ductile (strain hardening), the stress stain curves and failure depictions of which are 
shown in Figure 6-18b [249].  
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Figure 6-18 Material parameters affecting mechanical behavior of FRCs (a) and representative stress-
strain curves of FRCs failing through brittle, tension softening or strain hardening modalities, taken from 
Krueger et al. [249].   
Wet spinning was used to create the PCL fibers used in this study. As previously 
described, wet spinning is a relatively simple, inexpensive, small scale process to create 
polymeric fibers of diameters larger than electrospinning [245, 246].  It also lends the capability 
to incorporate drugs and biologics, particularly heat-sensitive drugs, into the fiber construct [243-
245]. Wet spinning does have its disadvantages, including lower tensile strength than melt-
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extruded fibers of the same diameter and the use of significant volume of solvents in the 
coagulation bath.  
In order to create the polymer fibers, a “good” solvent formulation and “poor” solvent 
were chosen for PCL with the aid of the thorough work of Luo et al evaluating the effect of 
solvent-polymer solubility and dielectric constant on the electrospinning of PCL [248]. 
Numerous parameters required optimization, include solvent ratios (acetone:THF), volume 
content of polymer, flow rate and needle gauge size, collection speed and coagulation bath 
configuration. Altering a variety of these parameters including solution concentration, polymer 
molecular weight, solvent and coagulant bath chemicals and collection rate yielded a wide 
variety of fiber diameters and morphologies. For the sake of brevity of the thesis, the details of 
the various optimization parameters studied and tested are not presented here, but several authors 
have evaluated the role of these and other parameters on the resulting wet-spun fiber product 
[243-245, 247].   
The fibers created with the described set up were smooth and opaque (Figure 6-2), with a 
reliable diameter of 100 µm, optimized to allow for cellular infiltration after fiber degradation.  
Fibers experienced very little elastic deformation before undergoing massive plastic deformation 
(Table 6-1 and Figure 6-3), greater than 600%, under tensile testing to failure.   Deformation 
induced a visual change from being opaque to transparent in the visual examination of the optical 
transparency of the fibers, noticeable on the cut ends of the fiber in Figure 6-2b.  Fibers were 
added at 5, 7.5, 10 and 15 weight % to the TMP. Studied concentrations in the literature range 
from 0.2-30 weight % fiber addition however fiber content greater than 3 volume % typically 
result in poor workability and injectability of the cement [128, 249]. The length of the fibers was 
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chosen based on Krueger et al to meet the critical length requirement based on the desired 100 
µm diameter.  
The addition of PCL fibers to the magnesium ammonium cement matrix slightly reduced 
the cement setting time  (Figure 6-3). No statistically significant differences exist between the 1st 
ST of the samples, however significant differences exist between 2nd STs of the cements, 
specifically 0% and 7.5% are significantly larger than 10% and 15% similar to what has been 
reported by others. It did not however affect the cementing reaction, demonstrated through XRD 
(Figure 6-5) and FTIR (Figure 6-6).  Similarly, the addition of the fibers did not significantly 
affect the pH or weight change of the cement constructs through 30 days in PBS.   The addition 
of polymeric fibers reduces the true density of the bulk cement (Figure 6-8a) and following fiber 
leaching, leaves behind a large increase  in porosity as expected (Figure 6-8c). The removal of 
fibers results in substantially more macropores (> 50 um), increasing with increasing fiber 
content. Live/dead staining (Figure 6-16) and SEM imaging (Figure 6-17) of MC3T3 cells grown 
on cement constructs with the fibers removed indicate that, unlike mannitol porogen cements 
studied in Chapter 5, the 100 µm PCL fibers leave behind well formed macropores which can 
facilitate cellular in-growth. Cells are seen as spherical and out of focus in live/dead staining, 
indicating that they are within the fiber channels, and SEM imaging confirms that the cells 
within the channels are well adhered to the cement, not floating.  As discussed in Chapter 5 
however, proper fluid flow and interconnected porosity are required for optimal cement 
integration and remain concerns with these cements as well.  
The inclusion of fibers in cements is intended to reduce or eliminate the catastrophic 
brittle failure which these materials undergo. Including fibers improves the toughness of the 
material through a complex set of mechanical interactions between the fibers and cement matrix. 
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Depending on the design, mechanical failure can transition from brittle failure to tension 
softening (quasi brittle) failure to strain hardening behavior [249]. Quasi-brittle failure 
demonstrates a maximum fracture strength through the matrix material followed by reduced 
residual ductility and strength through the fiber pullout, fracture or plastic deformation. In 
contrast, strain hardening behavior demonstrates initial matrix failure but greater yet maximum 
fracture strength through the energy dissipation of the fibers, resulting in hardening through 
additional strain. Energy adsorption through the fiber-matrix interactions can result from several 
mechanisms including interface debonding, fiber pullout and fiber deformation.  The tensile 
strength and elastic modulus of fiber play an important role in the reinforcement. A high tensile 
strength and elastic modulus facilitate stress transfer to the fiber from the matrix as a whole at 
large failure strain levels giving the cement high extensibility [128]. Compared to melt-extruded 
fibers, the wet spun fibers created here demonstrate low tensile strength and long, low modulus 
plastic deformation but high strain to failure.  
Evaluating the effect of fiber reinforcement on cement mechanical properties requires 
evaluating not only compressive testing but flexural testing. Compressive testing cannot be used 
to evaluate changes in toughness and is not sensitive to the effects of fiber addition [249]. This is 
confirmed with compression testing of the MPC-FRCs (Figure 6-13) which showed no 
significant change as a function of fiber content.  Instead, failure in bending is required to 
properly evaluate the effect of fiber reinforcement on the cement matrix. Figure 6-10 clearly 
demonstrates classic quasi brittle failure modality of the MPC-FRC composites, with increasing 
fiber content not affecting the peak strength of the as generated cement, but reducing the peak 
strength with increasing incubation time in PBS (Figure 6-11). The failure interface seen in 
Figure 6-14 image of 7.5% fiber cement at day 1 looks remarkably similar to the quasi-brittle 
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failure depiction in Figure 6-18b. Residual strength measurements (6-11b) and toughness 
measurements (6-12b) at L/50 displacement in bending furthermore clearly show the 
improvement in mechanical properties of the cement with fiber incorporation.  
While the inclusion of fibers improved mechanical toughness, further improvements to 
the designed system can still be implemented. Mechanical testing of the fibers indicates immense 
plastic deformation, but at the expense of the elastic modulus of the fiber. Low modulus fibers 
may impart toughness through moderate load transfer from the cement matrix, however this is 
only done effectively at high volume content of fibers, such as the 10 and 15 weight % fiber 
cements in this study. Improving the elastic modulus is known to significantly improve the load 
transfer, increasing the residual strength of the cement [249]. Improving the elastic modulus is 
frequently done through drawing of the spun fibers, but would result in reduced fiber diameter. 
Visual evaluation of the cement as generated and after PBS incubation through SEM imaging 
confirms significant deformation of fibers, particularly Figure 6-14 image of Day 1 7.5 % and 
Figure 6-15 images of Day 30, 5% and 7.5% cements. In addition to this, numerous images show 
the ends of fiber or smooth round holes left behind where fibers have been pulled out. These 
images indicate that there is poor interface bonding between the fiber and cement. Improving the 
interfacial bonding would result in significantly more energy adsorption during deformation. 
This may be done by increasing the surface roughness of the fibers as well as altering the surface 
chemistry [249]. An improvement in these two parameters could allow for reducing the volume 
fraction of fiber content while improving the cement failure modality to strain hardening instead 
of tension softening, while also improving the workability of the cement in clinical settings. 
These are some avenues that could be explored in the near future as the system is further 
developed. 
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6.5 CONCLUSION 
Wet spinning of high molecular weight polycaprolactone solution through a dual ethanol 
coagulation bath system results in reliably produced, 100 µm diameter PCL fibers. These fibers 
were introduced into a magnesium ammonium phosphate cement system to test the handling and 
mechanical resilience of the resulting cement. Increasing fiber content increased residual strength 
and toughness of the cements while not affecting the initial peak strength of the cements. Due to 
the low modulus of the wet-spun fibers, cements failed in a tension-softening modality, and high 
volumes of fiber was required to retain the majority of the initial strength value. The high-fiber 
content cements performed well through the entire aqueous incubation period studied but were 
difficult to handle when forming do to the fiber content. Additional processing of the wet-spun 
fibers to increase the tensile strength and module is recommended, which would improve the 
bending failure of the cements while allowing for reduced fiber content to improve handling 
characteristics. Cytocompatibility studies showed cellular infiltration into pores formed from 
fiber removal. This confirms that the design of polycaprolactone wet-spun fiber-reinforced 
magnesium ammonium phosphate cement with degradable fibers imparts improved mechanical 
performance of the cement construct while allowing for cellular infiltration through fiber 
degradation.  
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7.0  CONCLUSIONS AND FUTURE WORK 
Calcium phosphate cements (CPCs) have received considerable attention as bone void fillers. 
However, for the past decade, magnesium phosphate based ceramic implants and cements have 
been gradually gaining interest as a faster-degrading alternative to CPCs with a unique 
combination of observed properties including high strength, controlled setting time and pH 
including intrinsic anti-bacterial and adhesive properties. The work reported here expands upon 
the currently limited knowledge of magnesium phosphates particularly, exploring the effect of 
amorphous or crystalline of trimagnesium phosphate (TMP) powder as a bulk scaffold. 
Additionally, the work investigated the use of TMP as a starting cement precursor, evaluating the 
potential of a variety of reacting salts applied in neutral pH solution as well as exploring the 
effect of the addition of a fast-dissolve porogen and slowly degrading biocompatible and 
biodegradable polymer fiber.  
This work has shown that, in bulk scaffold form, the amorphous TMP demonstrated 
unique mineralization potential leading to improved osteoclast cytocompatibility when compared 
to the more inert crystalline trimagnesium phosphate pellet scaffold. The high mineralization 
potential of the amorphous scaffolds are attributed to the high surface area as well as the 
amorphous nature of the synthesized TMP generated through aqueous precipitation and the high 
dissolution of this amorphous material as well as the rapid growth of calcium-rich crystals and 
influence of serum present in the culture media.  While the amorphous scaffold improved 
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osteoblast cytocompatibility, both amorphous and crystalline scaffolds suspended the formation 
of mature osteoclasts from monocytes. The growth of calcium-rich rosette crystals on the 
amorphous trimagnesium phosphate pellet however, did not seem to affect the osteoclast culture. 
When explored as the precursor ceramic in a cementing reaction with a 3.0 M, neutral pH 
ammonium phosphate solution, amorphous and semi-crystalline embodiments of the synthesized 
trimagnesium phosphate resulted in poor cements, with uncontrolled set time, poor putty 
consistency and low mechanical strengths, due to the highly reactive nature of the amorphous 
and semi-crystalline trimagnesium phosphate powder. This reactivity was however, 
insurmountable utilizing traditional reaction retardant methods. In comparison, the crystalline 
trimagnesium phosphate resulted in a malleable putties with clinically relevant setting times and 
resulting products that were strong as well as exhibiting good handling characteristics.  
The crystalline trimagnesium phosphate was also used to explore the cementing reactions 
with salt solutions of sodium phosphate, potassium phosphate or ammonium phosphate, all at a 
concentration of 3.0 M and pH of 7.0 as before. The sodium and potassium salts formed 
workable putties, but resulted in exceedingly long setting times and mechanically poor cements. 
This was attributed to a low chemical driving force for the reaction to proceed to completion. 
The effect was also not overcome with variations in powder-to-liquid ratio, changes in reaction 
temperature, the use of amorphous trimagnesium phosphate in lieu of the crystalline counterpart, 
or the use of sodium and potassium solutions of different pH. In comparison, the ammonium 
phosphate solution reaction proceeded rapidly enough propelling the reaction forward towards 
completion to a larger extent, resulting in mechanically strong cements.  
This optimized magnesium ammonium phosphate cement formulation was next used to 
explore the effect of added porosity through the inclusion of quickly dissolving mannitol sugar 
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crystals as a porogen. Using the same synthesized crystalline trimagnesium phosphate powder 
and 3.0 M, pH 7.0 ammonium phosphate solution, mannitol content up to half of the total 
powder weight was added, and ammonium phosphate solution volume was optimized based on 
mannitol content. The inclusion of mannitol did not however, affect the crystallinity, pH or 
cytocompatibility of the resulting cement. Increasing mannitol resulted in progressively 
decreased compressive strengths. The addition of mannitol indeed expectedly resulted in 
increased microporosity and total porosity greater than 60% of the cement volume.  
In order to explore the effect of fiber reinforcement on magnesium phosphate cement, 
highly deformable fibers of polycaprolactone (PCL) were created through a wet-spinning 
method, resulting in fibers 100 µm in diameter and 1.5 mm in length. Using commercially 
available crystalline trimagnesium phosphate as the cement precursor and the same 3.0 M, pH 
7.0 ammonium phosphate reacting solution, cements with up to 15 weight % fiber content were 
created. Increasing fiber content resulted in increasing residual strength and cement toughness 
determined by 3-point bending failure tests. Low fiber containing cements displayed better 
workability than high fiber containing cements. Removal of fibers through dissolution resulted in 
large increases in macroporosity and visible cellular infiltration into the porous channels created 
by the fibers.  
Based on the work conducted so far and the promising results obtained, it would be 
reasonable to continue the work into the future. An obvious missing link that would be relevant 
to explore would be investigating clinically crucial properties including cement injectability and 
cohesion in blood and aqueous environments. Unique properties of some magnesium cements, 
including bone-bone and bone-tendon adhesion and inherent antibacterial activity should be 
evaluated with the various formulations explored in this work. The use of the neutral pH solution 
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was designed in order to allow for the incorporation of drugs, biologics or cells for delivery in 
vivo, which has not yet been explored with this or other magnesium phosphate cements. 
Similarly, with additional optimization and processing design, the wet-spun fibers could impart 
even more mechanical resilience while also serving as an excellent platform as a delivery agent 
for controlled release of drugs or biologics during degradation. Moving expeditiously towards 
exploring these systems in relevant animal model studies will be particularly useful to fully 
understand the complex relationship between porosity, dissolution and bone tissue growth with 
these novel magnesium phosphate systems. The knowledge gained throughout the work reported 
here combined with the potential future work will likely expand the fundamental understanding 
of magnesium cements even more for bone repair applications. These advances in turn, can lead 
the way for exploring even further the wide possibilities within the realm of magnesium cement 
systems. Possibilities include comparisons between magnesium oxide and trimagnesium 
phosphate based formulations as well as formulations including other magnesium ceramics such 
as magnesium hydroxide. Additional studies will include expanding the system to include other 
ions and compounds such as calcium, strontium, silicates and carbonates into the magnesium 
bone cements. The field is therefore filled with expanding possibilities with tremendous potential 
for advancing the knowledge base of resorbable inorganic cement systems. 
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APPENDIX A 
EXPLORATION OF CALCIUM AND STRONTIUM SUBSTITUTION INTO 
TRIMAGNESIUM PHOSPHATE THROUGH AQUEOUS PRECIPITATION 
A.1 INTRODUCTION 
The study of magnesium phosphates for bone cements is a relatively new field of study 
compared to traditional calcium phosphates. Calcium phosphate bone cements have been 
exploited to a large extent because the composition closely mimics mineralized bone matrix, 
although the mechanical strength and resorption rate of these cements are not ideal.  In addition 
to calcium, many other ions such as magnesium, silicon, zinc, potassium and copper play 
important roles in bone regeneration, from regulating the metabolic processes and osteoblastic 
differentiation genes to promoting angiogenesis and increasing bone cell adhesion [167, 250] .  
With regards to bone formation and dissolution, magnesium has been shown to play a major role 
in calcification and bone density, mineral metabolism, hydroxyapatite crystal formation and 
increased bone cell adhesion and stability [19, 34, 41, 43]. Phosphate is not only a main 
component of bone growth, but has also been shown to stimulate expression of matrix gla protein 
which is involved in bone formation [167]. Strontium consumption on the other hand has been 
shown to increase bone density in low doses and is frequently given as a supplement to patients 
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with osteoporosis in Europe, albeit excessive doses have been shown to result in defective 
mineralization in bone and rickets disease [125]. Strontium has been shown to support osteoblast 
differentiation through enhancing Wnt/β- catenin signaling while inhibiting the formation of 
osteoclasts [251, 252].   
Substitutions between magnesium, calcium and strontium in phosphate apatite type 
ceramics have been widely explored because all three are divalent cations with positive 
biological functions reported in bone [253-263]. Magnesium substitution into β-TCP scaffolds is 
known to increase the temperature at which the β-TCP to α-TCP phase transformation occurs, 
enabling improved sintering and densification [120, 134]. Magnesium substitution also stabilizes 
β-TCP scaffolds allowing significantly more control over particle size and crystallinity. 
Magnesium substitution, especially at high levels, has been shown frequently to improve 
cytocompatibility of calcium phosphate materials. Strontium substitution into calcium 
phosphates on the other hand, has been shown to increase the material solubility [264]. While the 
substitution of calcium and strontium into magnesium phosphate through aqueous synthesis has 
not been explored, Zhou et al recently explored microwave-assisted synthesis with magnesium 
and calcium substituted into strontium phosphate, showing that the magnesium-strontium 
phosphate improved cytocompatibility compared to strontium-calcium phosphate and pure 
strontium phosphate while also increasing the solubility [265]. The objective of this study is to 
essentially investigate the effects of calcium and strontium substitution on the crystal structure 
and phase evolution of tri-magnesium phosphate powders under simple aqueous synthesis 
conditions that was explored in detail in Chapter 2.  
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A.2 MATERIALS AND METHODS 
A.2.1 Materials synthesis 
Calcium and strontium substituted trimagnesium phosphate powders were synthesized through a 
modification of the aqueous precipitation synthesis method introduced and described in Chapter 
2. Strontium chloride (SrCl2) or calcium chloride (CaCl2) were added to the magnesium chloride
solution during synthesis, to achieve hypothetical nominal substitutions amounts following 
Equation A-1 which follows Equation 2-1 modified with x as the substituted ion level. Amount 
of substitutions considered and evaluated were 0, 5, 10, 25 and 50 mole % of magnesium 
content.  
Equation A-1 
2PO43- + 3(xY2+ + (1-x)Mg2+) →(YxMg1-x)3(PO4)2 ;  
Y = Sr, Ca and the phosphate solution was Na3PO4 similar to what is described in Chapter 2 
Sodium phosphate solution remained the same as in Chapter 2. Phosphate solution was 
pipetted into the magnesium/calcium/strontium salt solution, resulting in a white precipitate 
which was then centrifuged, washed and dried according to the protocol established in Chapter 2. 
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A.2.2 Materials Characterization 
To assess the efficacy of calcium or strontium substitution into the TMP crystal structure, 
powders were thermally treated to a variety of temperatures: no treatment, 500 °C, 600 °C, 700 
°C and 800 °C for 6 hours and subjected to XRD and FTIR analysis as described in the earlier 
chapters.  TGA/DSC analysis was completed on the synthesized powders to determine the level 
of hydration and onset temperature of bulk crystallization as in Chapter 3. The synthesized 
powders were dissolved in 8% nitric acid solution and then evaluated for their elemental contents 
using ICP-OES as previously described, measuring the magnesium, calcium, strontium and 
phosphorous levels for each sample. The powders were coated in palladium and observed under 
SEM to evaluate morphological changes due to doping.  
A.2.3 Cytocompatibility 
The synthesized powders were thermally treated to 200 °C and 800 °C for 6 hours to obtain 
amorphous, partially dehydrated powder and fully crystalline powders as in Chapter 2. Pellets 
were created using a Carver press as described, with powders thermally treated, pressed and then 
the pellets were thermally treated again to the same temperature (200 °C or 800 °C) to help bond 
the powder in the pellet.  Pellets were sterilized using UV radiation. MC3T3 osteoblasts were 
seeded on pellets at a cell density of 40,000 cells/well and cultured as previously described in 
Chapter 2. After 48 hours, cells were subjected to live/dead staining.  
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A.3 RESULTS AND DISCUSSION 
Figure A-1 shows the x-ray diffraction patterns collected on calcium and strontium doped 
trimagnesium phosphate following synthesis to examine the structural state of the as-prepared 
doped materials. These results indicate that all powders were initially amorphous similar to the 
unsubstituted TMP previously studied.  
 
 
Figure A-1 X-ray diffraction patterns of the as synthesized calcium and strontium doped tri-magesnium 
phosphate powder indicating that all the as-prepared powders were amorphous. 
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Figures A-2 and A-3 display the XRD patterns of calcium and strontium doped TMP, 
respectively, after thermal treatment to 800 oC for 6 hours in air to crystallize the powders.  
Phases are identified as: (a)  Mg3(PO4)2 (farringtonite, ICCD 98-001-7103), (b) 
Na1.05Mg3.96(PO4)3 (sodium magnesium phosphate, ICCD 00-054-0072), (c) Ca4Mg5(PO4)6 
(stanfieldite, ICCD 00-011-0231), (d) Ca3(PO4)2 (tricalcium phosphate, ICCD 00-003-0713), (e) 
Mg21Ca4Na4(PO4)18 (magnesium calcium sodium phosphate, 01-073-0020), (f) SrMg2(PO4)2 
(magnesium strontium phosphate, ICCD 00-014-0206),  (g)  NaMg(PO4) (sodium magnesium 
phosphate, ICCD 00-032-1123), (h) Sr9Mg(PO3OH)(PO4)6 (ICCD 00-048-1855), (i) Sr(PO3)3 
(ICCD 01-076-4588), (k) Sr2P2O7•½H2O (ICCD 00-012-0369) and (x) for as of yet unidentified 
peaks.  XRD of attempted calcium or strontium substitution indicates that ionic substation into 
the TMP crystal structure was generally not achieved through the aqueous precipitation method 
utilized.  A doped crystal structure would demonstrate peak broadening and shifting of the 2θ 
peak positions, which can then be analyzed through Reitveld refinement to determine the amount 
of substitution [266].  Diffraction patterns of 800 °C calcium substituted TMP show multiphasic 
materials at even 5 mole % addition. TMP 5% Ca showed the presence of Na1.05Mg3.96(PO4)3 (b) 
as well as a small amount of Mg21Ca4Na4(PO4)18 (e) mixed in with the  Mg3(PO4)2 (a) phase. 
Increasing substitution to TMP 10% Ca showed the removal of Na1.05Mg3.96(PO4)3 (b) and a large 
increase in Mg21Ca4Na4(PO4)18 (e)  as well as a reduction in Mg3(PO4)2  (a). Increasing the 
calcium level to 25% further reduced Mg3(PO4)2 (a), maintaining a high level of 
Mg21Ca4Na4(PO4)18 (e)  and showed the development of  Ca4Mg5(PO4)6 (c). Finally at 50% 
calcium/ 50% magnesium, Mg3(PO4)2 (a) is a minor phase, along with Ca4Mg5(PO4)6 (c). A 
significant portion of Mg21Ca4Na4(PO4)18 (e)  is present, with the most intense peaks 
corresponding to the development of Ca3(PO4)2 (d).  
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Figure A-2 X-ray diffraction results of calcium doping into tri-magnesium phosphate through aqueous 
co-precipitation and thermal treatment to 800 °C for 6 hours in air, phases are (a) Mg3(PO4)2, (b) 
Na1.05Mg3.96(PO4)3 , (c) Ca4Mg5(PO4)6, (d) Ca3(PO4)2, and (e) Mg21Ca4Na4(PO4)18 .
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A similar trend is seen in the strontium substituted phosphate as seen for the phosphate 
with the corresponding calcium substitution, with all strontium-containing powders developing 
into multiphase materials. TMP with even 5% Sr similar to Ca showed multi-phases mainly 
Mg3(PO4)2 (a) with a small amount of SrMg2(PO4)2 (f) and NaMg(PO4) (g). Increasing the 
strontium amount to 10% resulted in increasing levels of SrMg2(PO4)2 (f), the evolution of 
Sr(PO3)3 (i) and a low level of NaMg(PO4) (g). Increasing further to 25% Sr, the level of 
SrMg2(PO4)2 (f) and Sr(PO3)3 (i) increase while the amount of Mg3(PO4)2 (a) and NaMg(PO4) (g) 
continue to decrease. An additional phase, Sr9Mg(PO3OH)(PO4)6 (h) evolves. At 50% Sr, (h) 
Sr9Mg(PO3OH)(PO4)6 becomes a major phase, with low levels of Sr(PO3)3 (i) and a small 
amount of (k) Sr2P2O7•½H2O. In addition to this, XRD spectra of 10, 25 and 50% Sr powders 
exhibit major peaks which currently remain unidentified, marked with an x at approximately 23°, 
33° and 47° 2θ, respectively further serving as an indicator of the phase instability of the system 
at 800oC. Several other minor peaks are not explicitly identified in Figure A-3 and are likely 
attributed to small amounts of (a), (g) or minor peaks of (h), (i) and (k), however the spectra is 
heavily complex with overlapping peaks and these minor peaks cannot be readily identified 
requiring deconvolution that was not conducted for this study.  
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Figure A-3 X-ray diffraction results of strontium doping into tri-magnesium phosphate through 
aqueous co-precipitation and thermal treatment to 800 °C for 6 hours in air. Phases are identified as (a) 
Farringtonite  (f) Magnesium strontium phosphate,  (g)   Sodium magnesium phosphate, (h) 00-048-1855, (i) 
01-076-4588, (k) 00-012-0369 and (x) for as of yet unidentified peaks. 
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Figure A-4 shows the SEM images of calcium and strontium substituted powders as well 
as the unsubstituted powder in the as-synthesized and following thermal treatment to 800 °C for 
6 hours in air. SEM images indicate that there is no significant change in the bulk particle 
morphology following thermal treatment for the unsubstituted phosphate. However, there is 
significant change in particle morphology with calcium or strontium addition. Increasing 
substitution amounts results in the particle shape morphing from the flat, hexagonal plates of 
pure TMP into agglomerates of somewhat spherical irregular, globular particles. Low strontium 
and calcium levels (5 and 10%) show retention of some hexagonal particle morphology, while 
higher strontium and calcium levels (25 and 50%) do not show these particles. This trend is 
consistent with the XRD results, indicating significant portions of TMP remaining at low 
substitution levels but those levels reducing with increasing ion substitution.  
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Figure A-4 SEM images of calcium and strontium doped TMP powders as synthesized and after 
thermal treatment to 800 °C for 6h in air. Scale bar 50 microns. 
TGA/DSC of the amorphous powder was conducted to ascertain phase transition and 
crystallization temperatures in an attempt to isolate whether the materials are initially doped 
within the amorphous structure since the powders were perceived to be amorphous when 
synthesized and multiphase following thermal treatment to 800 °C. Several dynamic situation 
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could arise such as the materials may be doped but tend to crystallize into single-phase doped 
material and/or phase separate at high temperature thermal treatment, or the material may phase 
separate as part of the crystallization process. Table A-1 shows the results of mass loss and 
temperature of the crystallization peak measured through TGA/DSC. In Figure A-5 are 
representative plots of (a) undoped TMP, (b) TMP 50% Ca and (c) TMP 50% Sr showing the 
mass loss profile and heat flow profiles of these powders. Results in Figure A-5 and Table A-1 
show that the hydration level of calcium substitution TMP was similar to that of undoped TMP 
(27%), ranging from 25% for 5% Ca to 21% for 50% Ca. Strontium substituted powders showed 
slightly lower hydration levels at higher strontium content, dropping from 27% at 5% Sr to 15% 
at 50% Sr. The crystallization or phase evolution peak temperature decreased with increasing 
substitution for both calcium and strontium, dropping from 688 °C at 5% Ca to 645 °C at 50% 
Ca and 687 °C at 5% Sr to 657 °C at 50% Sr. While there were gradual shifts in the hydration 
level and crystallization or phase evolution temperature, the DSC plots show similar patterns of 
hydration loss below 200 °C and crystallization around 675 °C. Calcium and strontium 
substituted plots do not show any additional inflection point which may be indicative of a two-
step crystallization followed by a phase separation process.  
Table A-1 TGA/DSC mass loss and crystallization change peak temperature measurements of calcium 
and strontium doped TMP precipitates. 
 TGA/DTA 
Results Control 
5% 
Ca 
10% 
Ca 
25% 
Ca 
50% 
Ca 
5% 
Sr 
10% 
Sr 
25% 
Sr 
50% 
Sr 
Total mass % lost 27.14 24.98 25.02 32.51 21.28 26.75 23.48 20.08 14.45 
Temp. of second 
peak (°C) 676.6 687.9 670.1 657.7 645.5 687 687.7 652.9 657.1 
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Figure A-5 TGA/DSC plots of un-doped TMP (a), 50% calcium doped TMP (b) and 50% strontium 
doped TMP (c). 
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XRD results of calcium and strontium substituted TMP powders thermally treated to 500 
°C, 600 °C and 700 °C can be seen in Figures A-6, A-7 and A-8, respectively. Spectra indicate 
progressively increased crystallization for both ions. Powders treated to 500 °C remained 
amorphous similar to the as synthesized powder (Figure A-6). Powders treated to 600 °C 
however, showed partial crystallization (Figure A-7). Increasing the level of calcium or 
strontium appears to slow the crystallization of the powder, evidenced by the less defined peaks 
seen in both calcium (a) and strontium (b) at higher doping levels. The addition of strontium in 
particular stabilized the amorphous phase for a longer period. This seems contradictory to the 
DCS results which indicated a reduction in crystallization temperature, however the reduction 
was minor and the DSC plot of the 50% strontium substituted TMP shows this crystallization 
‘peak’ to be less well defined than seen often seen with TMP. The less definition in the peak may 
indicate a more gradual change that does not yield a significant energy peak in DSC. 
Furthermore, DSC is more indicative of dynamic changes while the heat treatment is conducted 
for a period of 6h allowing enough time for diffusion processes to occur.  
XRD results of the powders treated to lower thermal temperatures also confirm that the 
powders transition into multiphase materials upon crystallization and at no point form truly 
doped, single-phase materials, even at low (5%) substitution levels. Figure A-7 demonstrates the 
first instance of crystallization (600 oC thermal treatment) and the substituted materials show 
additional peaks not present in the baseline TMP spectra. These peaks match well with the 
phases identified in Figure A-2 and A-3, however the identification is more difficult with the 
presence of amorphous content at lower temperatures.    
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Figure A-6 XRD of calcium and strontium doped TMP thermally treated to 500 °C for 6 hours. 
Figure A-7 XRD of calcium and strontium doped TMP thermally treated to 600 °C for 6 hours. 
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Figure A-8 XRD of calcium and strontium doped TMP thermally treated to 700 °C for 6 hours. 
Similar trends of water loss and crystallization are seen through FTIR of the doped 
materials. Figure A-9 shows the spectra of calcium doped TMP as synthesized (a), and thermally 
treated to 500 °C (b), 600 °C (c) and 800 °C (d) while Figure A-10 shows the same for strontium 
doped TMP. As discussed in the FTIR of pure TMP in Chapter 2, FTIR spectra here show that 
all synthesized powders (A-9a and A-10a) are amorphous, indicated by the non-descript 
phosphate peaks at 1000 and 500 cm-1, and are heavily hydrated, evidenced by the large hump 
between 2500-3500 cm -1 and the peak around 1600 cm -1. Thermal treatment to 500 °C results in 
removal of the water hump and peak (A-9b and A-10b), while the phosphate peaks remain broad. 
Thermal treatment to 600 °C indicates (A-9c and A-10c) the beginnings of crystallization shown 
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by the peak separation of the phosphate peaks, as discussed in Chapter 2. Similar to results from 
XRD, FTIR indicates reduced crystallization with increasing dopant content, evidenced by less 
peak separation of the phosphate peaks. This conclusion however is convoluted by the 
multiphase nature of the materials. Thermal treatment to 800 °C (A-9d and A-10d) indicates 
differences in the phosphate peak number and position, particularly evident in the 50% strontium 
sample (A-10d). The multiple peaks and lack of peak distinction (A-9d, Ca 50%) can be 
attributed to the multitude of phosphate compounds present, each with its own specific bond 
configurations and vibrational patterns.  
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Figure A-9 FTIR spectra of calcium doped TMP as synthesized and thermally treated to 500, 600 and 
800 °C for 6 hours each in air. 
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Figure A-10 FTIR spectra of strontium doped TMP as synthesized and thermally treated to 500, 600 and 
800 °C for 6h in air.
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ICP was utilized to determine ion content from which ion molecular ratios were 
calculated, the results of which can be seen in Table A-2. The calcium to substituent element 
ratios were close to the intended substitution levels for both calcium and strontium substitution. 
This indicates that although the resulting powders were multiphasic, calcium, strontium and 
magnesium ions were not disproportionately removed in solution during synthesis. Theoretically 
the molar concentration of Mg in TMP is 60%, experimentally this value was measured at 55% 
in pure TMP. This value should be the total cation concentration across all the samples. 
However, measurements showed an increase in molar cation concentration with increasing 
substitute ion concentration. This increase was more marked in the strontium substituted 
samples. This is consistent with the phases seen in XRD in that there were frequently phases 
present which included more than three cations per every two phosphate groups.  
Table A-2 Molecular ion ratios of magensium, calcium, strontium and phosphorous measured through 
ICP-OES. 
Ca/Ca+Mg Sr/Sr+Mg Ca+Mg+Sr/ (P+Mg+Ca/Sr) 
TMP AS 0.550 
 TMP 5pCa AS 0.041 0.559 
TMP 10pCa AS 0.087 0.563 
TMP 25pCa AS 0.234 0.565 
 TMP 50pCa AS 0.442 0.604 
TMP 5pSr AS 0.054 0.571 
TMP 10pSr AS 0.088 0.599 
TMP 25pSr AS 0.251 0.658 
TMP 50pSr AS 0.456 0.719 
Finally, live/dead staining results shown in Figure A-11 indicate increased calcium and 
strontium substitution on 800°C thermally treated samples promoted improved cell viability as 
compared to the TMP baseline material, achieving viability levels close to β-TCP controls.  
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Figure A-11 Live/dead staining of MC3T3 cells grown on calcium and strontium substituted TMP pellets 
thermally treated to 800 °C for 6 hours in air. Scale bar is 200 µm. 
A.4 CONCLUSION 
This study investigated the feasibility and effects of calcium and strontium substitution on the 
time-temperature-transformation of trimagnesium phosphate powder through modifications to 
the aqueous precipitation reaction introduced in Chapter 2. The phases present in and the crystal 
structure of the doped samples were determined using XRD, FTIR, and SEM. Additionally ICP 
was used to determine the composition of the samples. The findings indicate that true 
substitution of the substitute ion into the TMP structure did not occur to a large extent. Instead 
209 
the introduction of substitute ions resulted in phase separation even at low substitution 
concentrations of 5 mole%. An increase in the substitute ion concentration increased the stability 
of the amorphous phase, as evidenced by the increasing presence of this phase in samples with a 
higher substitute ion concentration. Morphologically, there is a shift in powder form from a plate 
like structure to a more spherical shape with increasing doping concentrations. Cytocompatibility 
was improved with substitute ion addition, especially through the addition of strontium to the 
chemical structure. As these substituted materials were to be used in place of pure tri-magnesium 
phosphate for a cementing reaction, alternative synthesis methods, such as refluxing or thermal 
treatment, will be explored in the future or even the use of the amorphous Ca and Sr substituted 
TMP as the starting cement precursors will also likely be explored.  
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APPENDIX B 
BIODEGRADABLE POLY(LACTIDE-CO-GLYCOLIDE) COATINGS ON 
MAGNESIUM ALLOYS FOR ORTHOPEDIC APPLICATIONS 
In addition to the work done surrounding fundamental analysis and practical improvements to 
magnesium-based cementitious materials, research was conducted to study the effect of 
polymeric coatings on metallic magnesium biomaterial substrates, which will be the subject of 
Appendices B and C. In Appendix B polymeric film coatings were applied by dip coating on two 
magnesium alloy systems, AZ31 and Mg4Y, in an attempt to slow the degradation of these 
alloys under in vitro conditions. Poly(lactic-co-glycolic acid) polymer in solution was explored 
at various concentrations, yielding coatings of varying thicknesses on the alloy substrates. 
Electrochemical corrosion studies indicate that the coatings initially provide some corrosion 
protection. Degradation studies showed reduced degradation over three days, but beyond this 
time point do not maintain a reduction in corrosion rate. Scanning electron microscopy indicates 
inhomogeneous coating durability, with gas pocket formation in the polymer coating, resulting in 
eventual detachment from the alloy surface. In vitro studies of cell viability utilizing mouse 
osteoblast cells showed improved biocompatibility of polymer coated substrates over the bare 
AZ31 and Mg4Y substrates. Results demonstrate that while challenges remain for long term 
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degradation control, the developed polymeric coatings nevertheless provide short term corrosion 
protection and improved biocompatibility of magnesium alloys for possible use in orthopedic 
applications. Results of these studies are described herein. 
B.1 INTRODUCTION 
Historically, within the orthopedic market, fixation and repair have been limited to implantation 
of inert alloys, such as titanium and stainless steel, to immobilize and heal damaged bone [267-
269].  Magnesium and magnesium-based alloys pose a bright prospect for use in orthopedic and 
craniofacial repair applications since these alloys not only display physical properties strikingly 
similar to natural bone but also exhibit the unique ability to degrade in vivo [267, 270-272]. As a 
result, these alloys are potentially promising candidates for orthopedic fixation plates and screw 
device. Such implants that degrade on demand in vivo following completion of their primary 
function to providing support to the underlying fractured bone or healing of the non-union  are 
indeed desirable because this type of implant reduces the chance of long term complications 
associated with permanent implants, including foreign body response, delayed type 
hypersensitivity, and secondary removal surgery [267, 273]. Consequently, research into the 
potential of magnesium-based alloys for implants that degrade in this manner has increased 
exponentially in the past five years. The current barrier to clinical implementation for 
magnesium alloys is the aggressive degradation rate, accompanying hydrogen gas evolution, and 
limited bioactivity [273, 274]. This hydrogen gas evolution results in undesirable gas pocket 
formation near the site of implantation. The corrosion of magnesium in vivo results in hydrogen 
gas evolution per the general reaction in Equation B-1:  
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Equation B-1 
Mg + 2H2O  Mg 2+ + 2(OH)- + H2
It can be seen from Equation B-1 that the dissolution of one atom of magnesium 
generates one molecule of hydrogen gas [275]. It is also generally accepted that magnesium and 
the hydroxide ions will react to form Mg(OH)2 passivation layer on the surface of the implant. 
However, this layer is not highly stable and that magnesium alloys are susceptible to pitting 
corrosion [268]. 
Strategies to limit degradation rate in vivo include exploring unique alloying elements, 
processing strategies and applying surface coatings. Alloying and improvements in processing 
methodologies may obtain slower degradation rates, but are not likely to drastically improve 
surface bioactivity of the implant, which can ultimately affect osseo-integration and new bone 
growth [274, 276]. The utilization of surface coating is thus of great interest, as coatings have the 
potential to both slow degradation and increase the biocompatibility of implants. Specifically of 
interest are calcium-phosphate based coatings due to their structural similarity to the mineralized 
component of natural bone, and degradable polymeric coatings [272, 277-281]. Coatings of 
degradable polymers can not only act as a corrosion barrier, but can be used to deliver drugs, 
genes and growth factors at the body-implant interface [282]. Among the many natural and 
synthetic polymers explored poly (lactide-co-glycolide) (PLGA) has numerous justifications for 
use as a coating owing to their high biocompatibility, clearance through FDA for numerous 
devices, well explored drug delivery capabilities and ability to tailor in vivo degradation rates 
with metabolically digestible degradation products [283-286]. The integration of PLGA on the 
surface of magnesium alloys could therefore potentially serve to inhibit corrosion and 
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additionally act as a scaffold to elude antibiotic agents, such as cefoxitin sodium, or growth 
factors, such as BMP-2 [287, 288]. Previously, Li et al explored a high molecular weight 90:10 
PLGA on a magnesium 6 wt% zinc alloy, and showed some corrosion protection of the alloy, as 
demonstrated by polarization curves and electrochemical impedance spectroscopy [289]. 
Surprisingly, the authors determined that a thinner coating would provide more protection 
against corrosion than a thicker coating. The authors speculated that the thinner coating is 
sufficient to passivate the alloy surface and that a thicker coating would contains more defects 
than the thinner coating while providing no additional passivation, thus leading to an inferior 
corrosion protection profile for the thicker coating. Xu et al and Lu et al have recently reported 
the incorporation of PLGA, films or spheres, into composite coatings for drug-release purposes 
[290, 291].  
In this study, a mid-range molecular weight 50:50 PLGA is coated on to two magnesium 
alloy systems, AZ31 (96 % Mg, 3 % Al and 1 % Zn by weight) and Mg4Y (96 % Mg and 4 % Y, 
by weight). It should be noted that this is the first report of PLGA coatings on AZ31 or Mg-Y 
alloy systems to the best of our knowledge. The present study was conducted in order to evaluate 
the potential of PLGA coatings to slow the corrosion and increase the biocompatibility of the 
AZ31 and Mg4Y alloys. The successful implementation of PLGA for this purpose could lead to 
the use of PLGA as a one-step, multifunctional coatings for magnesium-based alloys for use in 
orthopedic applications requiring biocompatibility and time dependent corrosion protection.  
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B.2 MATERIALS AND METHODS 
B.2.1 Materials and Sample Preparation 
Hot rolled AZ31 alloy was acquired from Alfa Aesar (Ward Hill, MA, USA) and was used as 
received. Mg4Y was acquired from GKSS Research Institute (Geesthacht, Germany) in ingot 
form, graciously provided by Dr. Norbert Hort, and further homogenized by heat treating to 525 
°C in ultra-high purity Argon (UHP-Ar)under inert atmosphere for 8 h. Samples were cut into 
squares 1.25 x 1.25 x 0.08 cm in size and cleaned by etching in 3 % nitric acid solution. The 
samples were then rinsed with acetone, polished to 1200 grit (5 μm) SiC polishing paper, and 
sonicated for 30 minutes in acetone. Cleaned and polished samples were stored in acetone until 
application of the polymer coatings. Poly(D,L-lactide-co-glycolide), Mw 30,000-60,000, (Sigma-
Aldrich) was dissolved in dichloromethane at 10 and 20 % weight/volume, from here on referred 
to as AZ31-PLGA 10 %, AZ31-PLGA 20 %, Mg4Y-PLGA 10 % and Mg4Y-PLGA 20 %, 
respectively, depending on the alloy and polymer concentration utilized. The polished substrates 
were subsequently dipped into the respective polymer solution at room temperature, allowed to 
reside for 1 minute, withdrawn at a speed of 200 μm/s using a dip coater (Desktop Dip Coater, 
Model No EQ-HWTL-01-A, MTI Corporation, USA), and then finally allowed to dry at room 
temperature. This dip coating process was repeated in triplicate on each sample for each test 
completed.  
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B.2.2 Characterization of Coatings 
The coating thickness of the films was calculated by measuring the weight gain from dip coating 
in polymer solutions and the sample dimensions. Thickness measurements were taken in 
triplicate and averaged. The presence of the coatings was further confirmed by attenuated total 
reflectance Fourier transform infrared spectroscopy (ATR-FTIR, Nicolet 6700 
spectrophotometer, Thermo Electron Corporation) using a diamond ATR Smart orbit. Spectra 
were obtained at 1.0 cm-1 resolution averaging 32 scans in the 400 – 2500 cm-1 frequency range. 
B.2.3 In vitro Degradation and Corrosion 
Electrochemical corrosion characterization studies of the coated alloy samples were performed 
using CH604A (CH Instruments Inc) electrochemical work station. Following sample 
preparation as described in the previous section, one side of each sample was connected to a wire 
with silver epoxy and then electrically insulated, so that only one side is exposed for conducting 
the electrochemical tests. The length and width measurements were taken for corrosion current 
calculations. Ag/AgCl and a platinum wire were employed as the reference and counter 
electrodes, respectively. Testing was carried out utilizing a 3-neck jacketed flask (ACE 
Glassware) filled with 125 mL Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10 % 
fetal bovine serum (FBS, Atlanta Biologicals, Lawerenceville, GA) and 1 % 
penicillin/streptomycin antibiotics (P/S, Gibco, Grand Island,NY), equilibrated to 37 °C. All the 
specimens were allowed to equilibrate to reach a stable open circuit potential (OCP), before 
initiating the polarization tests at a scan rate of 1.0 mV/s. The corrosion current was determined 
using the Tafel extrapolation of the polarization curve and normalized by the exposed surface 
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area to yield a measurement of corrosion current density. The software program Origin with a 
Tafel packet was used to perform the Tafel extrapolation and plot the data.  
Corrosion profile up to 21 days was assessed by analyzing the magnesium ion 
concentration in media extracted after sample incubation. The coated substrates were sterilized 
by UV light exposure for 1 h per side. Each substrate was then soaked in 2 mL of DMEM 
containing 10 % FBS and 1 % P/S under standard growth conditions of 37 ºC, 5 % CO2 and 95 
% relative humidity for 21 days. The media was changed and collected every 24 h to monitor the 
degradation rate under in vitro conditions. The collected media was diluted in 0.03 M Tris buffer 
solution and analyzed using inductively coupled plasma optical emission spectroscopy (ICP-
OES, iCAP duo 6500 Thermo Fisher). Magnesium ion concentrations in solution were compared 
to media and uncoated substrate controls. The coatings were characterized post-corrosion using a 
digital optical microscope (Keyence VHX-600K) and a scanning electron microscope at 10 kV 
(SEM, Philips XL30 FEG ESEM). Samples were sputter coated with palladium (Cressington 
sputter coater 108A) for observation of the surface morphology post corrosion using SEM. 
B.2.4 Cell Culture 
Murine MC3T3 –E1 pre-osteoblast cells obtained from ATCC (Manassas, VA) were utilized for 
cell culture studies. Cells were cultured in minimum essential medium alpha (α-MEM, Gibco, 
Grand Island, NY) containing 10 % fetal bovine serum (FBS, Atlanta Biologicals, 
Lawerenceville, GA) and 1 % penicillin/streptomycin antibiotics (P/S, Gibco, Grand Island, NY) 
at 37 oC, 5 % CO2 and 95 % relative humidity. Substrates were placed in 12 well plates and 
sterilized using UV radiation for 40 minutes on each side. The substrates were then seeded with 
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MC3T3 cells, after third to seventh passage, at a density of 60,000 cells/well, with a total media 
volume of 2 mL/well. Media was changed every other day throughout the testing period. 
B.2.5 Live/Dead Assay and Cytoskeletal Imaging 
Cell viability was assessed using Live/Dead staining (Invitrogen, Live/Dead Staining Kit). The 
assays were performed on day 1 and day 3 substrate cell cultures. The coated alloy substrates 
were rinsed with phosphate buffered saline (PBS, Lonza BioWhittaker Buffers and Buffered 
Salines, 1x, 0.0067 M(PO4) without calcium or magnesium) and then incubated for 30 minutes in 
live/dead stain, calcein AM and ethidium homodimer-1, diluted in PBS. After incubation, the 
samples were again washed with PBS and then imaged using fluorescence microscopy (Olympus 
CKX41, Olympus DP25 Microscope Camera).   
Following fluorescence imaging, cells were fixed using a 2.5 % glutaraldehyde solution 
for 15 minutes. Fixed samples were then subjected to alcohol dehydration and mounted for SEM 
imaging. Samples were coated with palladium in order to observe the cell morphology using 
SEM. 
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B.3 RESULTS AND DISCUSSION 
B.3.1 Coating Characterization 
The thickness of the coatings was calculated by measuring the sample dimensions and the gain in 
weight following dip coating, assuming a fully dense, nonporous coating and the manufacturer-
provided material density of 1.34 g/ml using the Equation B-2 
Equation B-2 
Thickness = 104 * weight gain / [density * surface area] 
where thickness is in µm, weight gain in g, density in g/cm3 and surface area in cm2. Resulting 
thicknesses indicate that there is a large increase in coating thickness with a higher solution 
concentration, Table B-1. There is no statistical difference however between the coating 
thickness on AZ31 or Mg4Y alloy with either polymer concentrations, indicating similar 
interaction occurring between the alloy surface and the polymer solution for both alloys. 
Table B-1 Coating thicknesses on magnesium substrates. 
Sample Type Thickness (µm) 
AZ31-PLGA 10% ~1.6 
AZ31-PLGA 20% ~41.8 
Mg4Y-PLGA 10% ~1.6 
Mg4Y-PLGA 20% ~62.1 
FT-IR was used to confirm the presence of the polymer coatings on the alloy. Figure B-1 
shows the FT-IR spectrum of uncoated Mg alloys, PLGA and PLGA coated samples. The 
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characteristic bonds at numerous wave numbers, such as the carbonyl stretching at 1750 cm-1, C–
O–C stretching at ~1080 cm-1are indicative of the presence of the PLGA polymer [292]. No such 
peaks are expectedly seen on the bare metal substrates devoid of the polymer. Differences 
between the coating thicknesses, as expected, did not appear to influence and cause any changes 
to the obtained spectra. 
Figure B-12 FTIR spectra of Uncoated AZ31 (a), Uncoated Mg4Y (b), pure PLGA (c) and coated 
samples AZ31-PLGA 10 % (d), AZ31-PLGA 20 % (e), Mg4Y-PLGA 10 % (f) and Mg4Y-PLGA 20 
% (g), showing clear presence of PLGA on all coated substrates. 
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B.3.2 In Vitro Degradation 
Polarization curves for the coated and uncoated substrates can be seen in Figure B-2 for AZ31 
substrates (a) and Mg4Y substrates (b). Table B-2 gives a summary of the corrosion potential 
and corrosion current densities as calculated from extrapolation of the Tafel plots. For the AZ31 
alloy, PLGA coatings on the substrates resulted in an Ecorr that is less negative than the uncoated 
alloy, indicating that the coating did provide a barrier for corrosion. Increase in polymer 
thickness further yielded an increase in Ecorr indicating the beneficial influence of the thicker 
polymer coating. The presence of the polymer coatings on AZ31 visibly also lowered the icorr 
values compared to the uncoated AZ31 alloy substrate, although there was no significant 
variation between the two different polymer concentrations and thickness of the polymer 
coatings. The addition of PLGA coatings on Mg4Y alloy substrates also resulted in Ecorr values 
which are less negative than the uncoated substrates as well as reductions in icorr values similar to 
the coatings on AZ31. Similar to the coatings on the AZ31 substrate, there was no perceivable 
difference in the icorr values between the two polymer concentrations and consequent thickness of 
the polymer coatings. Additionally, unlike the coatings on AZ31increasing the thickness of the 
PLGA coating on Mg4Y substrates did not offer much change in the Ecorr or icorr values. It should 
be however noted that the corrosion potential of the uncoated Mg4Y is more negative compared 
to the uncoated commercial AZ31 alloy indicative of a more reactive alloy surface, which is not 
consistent with predictions reported by previous researchers [286].  This is possibly a 
consequence of the difference in the processing conditions of the alloys. AZ31 is a commercial 
product that has been likely processed with better precision and impurity control than the 
laboratory-generated Mg4Y that was not subjected to any further processing modifications 
following casting other than the standard homogenization treatments. Despite these differences 
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between the two alloy substrates to begin with, overall however, the polarization curves of the 
polymer coated AZ31 and Mg4Y substrates do exhibit corrosion protection of the bare AZ31 and 
Mg4Y alloys as demonstrated by less negative Ecorr as well as a reduction in icorr for all the 
coated substrates regardless of the thickness and the polymer concentration.  
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Figure B-2 Polarization curves of substrates AZ31 (a) uncoated (i), PLGA 10 % (ii) and PLGA 20 % 
(iii) coatings and Mg4Y (b) uncoated (i), PLGA10 % (ii) and PLGA 20 % (iii) coatings. 
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Table B-2 Corrosion potential (Ecorr) and current density (icorr) values for coated and uncoated 
substrates. 
Ecorr (V) icorr (A/cm2) 
AZ31-Uncoated -1.54 3.10E-05 
AZ31-PLGA10% -1.469 5.20E-06 
AZ31-PLGA20% -1.415 6.05E-06 
Mg4Y-Uncoated -1.664 4.42E-05 
Mg4Y-PLGA10% -1.485 8.09E-06 
Mg4Y-PLGA20% -1.469 6.85E-06 
Coated and uncoated substrates were further immersed in DMEM with FBS and P/S 
which was changed daily and maintained under in vitro conditions to qualitatively determine the 
effect of polymeric coatings on the stability and degradation rate of the alloys. SEM images of 
the coated substrates of AZ31 and Mg4Y are shown in Figures B-3 and B-4 respectively, at three 
time points namely, 3, 12 and 15 or 21 days. At day 3, microscopic inspection indicates that 
coatings on all substrates are present; however noticeable changes to the substrate surface begin 
to appear particularly with the coatings corresponding to higher polymer concentration and 
higher thickness. Coatings of PLGA 10 % show the onset of corrosion under the surface, as 
indicated by the plate-like morphology typical of magnesium corrosion product which is also 
seen in the AZ31 and Mg4Y uncoated substrates. Comparing the PLGA 10 % coated substrates 
with the uncoated substrates, the coatings appear to slow the corrosion for shorter time points. 
The corrosion however progresses with increase in incubation time. Coatings of PLGA 20 % 
show the formation of gas bubbles, likely of trapped hydrogen gas, forming underneath the 
polymeric surface during 3 days of incubation. As the incubation time progresses, these bubbles 
appear to grow with increasing volume of gas generated reaching the maximum pressure leading 
to collapse of the gas bubbles, consequently leaving the unprotected substrate fully exposed in 
some areas to the liquid environment while the polymer remains intact in other non-specific 
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areas. The same plate-like corrosion product can be seen on the exposed areas of the substrate. 
This effect appears to be especially aggravated on the Mg4Y-PLGA 20 % surface. The Mg4Y 
alloy appears to undergo more aggressive corrosion in the presence of PLGA in contrast to the 
AZ31 alloy. Previous research indicates that opposite effect should be true in the uncoated alloys 
[286]. However, to the authors knowledge, these two alloys, with or without coatings, have not 
been directly compared.  For all polymer coatings, the polymer provides partial protection of the 
alloy surface initially, but the stability of the coating appears to break down with incubation time 
leading to eventual swelling, deformation, and delamination of the polymer from the alloy 
surface.   
Figure B-3 SEM Images of uncoated and PLGA coated AZ31 substrates post incubation in media (Scale 
bar is 500 μm). 
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Figure B-4 SEM Images of uncoated and PLGA coated Mg4Y substrates post incubation in media 
(Scale bar is 500 μm). 
ICP was used to determine ionic concentrations of magnesium in the DMEM collected in 
order to further evaluate the degradation of the AZ31 and Mg4Y substrates when coated with the 
protective PLGA polymer (Figures B-5 a & b). For all samples, including uncoated substrates, 
there is an increase in magnesium ion concentration above pure media baseline. Both AZ31- 
PLGA 10 % and Mg4Y- PLGA 10 % coatings show some reduction in magnesium ion release at 
day 3, and at subsequent time points  AZ31-PLGA 10 % coatings yield magnesium 
concentrations similar to the uncoated substrate for subsequent time points until day 12 beyond 
which the magnesium ion concentration appear to be slightly elevated compared to the uncoated 
AZ31 alloy.  For AZ31-PLGA 20 % and Mg4Y- PLGA 20 %, there is again a reduction in 
magnesium ion release in comparison to the uncoated substrates at day 3. However, at later time 
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points this reduction is not maintained. The PLGA 20 % coatings on both substrates appear 
antagonistic, with the daily ion release rate increasing rapidly until day 9 above that of the 
uncoated substrates with the Mg4Y-PLGA 20 % exhibiting almost two-fold higher dissolution of 
Mg compared to the corresponding coating on AZ31. This is unexpected because as corrosion of 
the metal alloy underneath the PLGA coating proceeds, pH should increase, pushing the surface 
closer to passivation [268]. This would in turn reduce the corrosion because the buildup of the 
more robust magnesium hydroxide layer would lead to some corrosion protection for the alloy 
surface [293].  
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Figure B-5 ICP measurements of daily magnesium ion concentration in extracted incubation media for 
AZ31 coated and uncoated samples (a) and Mg4Y coated and uncoated samples (b). 
It is also important to note that PLGA is considered semi-permeable to water, as the 
water penetration into the bulk of the polymer occurs faster than surface hydrolytic degradation 
of the polymer [294]. It is well known that the hydrolytic degradation within the bulk of the 
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PLGA coating would result in the formation of acidic byproducts. These byproducts could react 
with the magnesium corrosion ions or magnesium hydroxide, forming soluble magnesium 
lactates or magnesium glycolates. The formation of lactates and glycolates will prevent the 
formation and growth of dense and thick corrosion protective magnesium hydroxide layer. It is 
therefore very unlikely that the reaction products of  magnesium lactate and glycolate can form 
dense corrosion protective layers as  these salts are more soluble than magnesium hydroxide 
[295, 296]. The local increase in pH as well as absence of any corrosion protective layer will 
therefore lead to the rapid corrosion of the underlying bare surfaces. The effect is expected to be 
greater with the thicker coating, thus explaining the greater corrosion seen with the PLGA 20 % 
coatings.  
The corrosion results observed by us compare well with the observation of the coating 
tests reported by Chen et al, wherein PCL and PLA coatings on pure magnesium displayed a 
“special interaction” [280]. The authors observed that the individual degradations of the polymer 
coating and the magnesium alloy were each antagonistic of the other and that this reciprocity 
ultimately undermined the corrosion resistance of the material under dynamic degradation tests. 
The hypothesized effect reported by Chen et al correlates well with the ICP results of day 3 
reported here as well as the electrochemical corrosion results, which asses that the corrosion 
protection by the PLGA coating on AZ31 and Mg4Y is only observed at very early time points, 
demonstrating that the PLGA coatings regardless of the concentration only serve to provide a 
physical barrier to corrosion, through day 3, but that protection is not maintained beyond six 
days of incubation, presumably due to the penetration of water into the PLGA bulk coating and 
the subsequent degradation of both the polymer coating and the magnesium alloy substrate. The 
discussed mechanism is also consistent with the SEM observations, which clearly show the 
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formation of large number of hydrogen gas bubbles in AZ31 PLGA 20 % and Mg4Y PLGA 20 
% coatings in contrast with the corresponding AZ31and Mg4Y substrates containing PLGA 20 
% coatings (see Figures B-3 & B-4).  
Figure B-6 shows the digital optical images of the incubated substrates at the same three 
time points as shown in the SEM images. These images also support the previous observations of 
coating protection and durability, including the formation of bubbles beneath the polymer (day 3 
PLGA 20 % on AZ31 and Mg4Y), the separation of the thicker coatings from the alloy surface 
(especially PLGA 20 % on Mg4Y) and the more aggressive corrosion of Mg4Y in comparison to 
AZ31. 
Figure B-6 Digital Optical Images of PLGA coated AZ31 and Mg4Y substrates post incubation in media 
(Scale bar is 2 mm). 
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B.3.3 Cytocompatibility 
SEM images of cells fixed on the surface of the alloys 24 h following seeding can be seen in 
Figure B-7 and the Live/Dead staining of osteoblasts at 1 and 3 days post seeding can be seen in 
Figure B-8. These SEM images show the cell cytoskeletons, indicated by the arrows, flattened 
and extended on the polymeric surface, indicating good adhesion of the osteoblasts validating the 
polymer coated surface being favorable for cell attachment. Staining of cells at one and three 
days (Figure B-8) shows an increase in cell number at day 3 over day 1, indicating no inhibition 
for cell proliferation, especially for the polymer coated AZ31 substrates. It appears therefore that 
the formation of gas bubbles in the polymer plays a direct role in the location and the manner in 
which the cells grow. For example, AZ31-PLGA 20 % at day 3 shows open regions where the 
hydrogen bubbles resulting from corrosion have burst open preventing attachment of the cells. 
Surrounding the gas pocket are areas of high density of cells, but within the spherical gas bubble 
pocket regions no cells have proliferated. Additionally, as seen in Mg4Y-PLGA 10 % at day 3, 
where cells may have proliferated within the spherical gas pocket region following collapse of 
the gas bubbles or underneath the polymeric coating, those cells do not survive. This is likely due 
to the change in local ion concentrations as discussed above. The application of PLGA coatings 
on the surface of AZ31 and Mg4Y alloys despite the time dependent corrosion protection 
demonstrated in Figure B- 3 and B-4, has a clear improvement on the biocompatibility of the 
uncoated alloy surface showing improved cell viability and proliferation over the uncoated 
substrates.   
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Figure B-7 Morphology of MC3T3 osteoblasts at 24 hrs post-seeding, indicating better cell adhesion for 
thicker PLGA coatings (Scale bar is 100 μm). 
232 
Figure B-8 Live/Dead Staining of MC3T3 osteoblasts on coated and uncoated substrates indicating 
improved biocompatibility of coated substrates over uncoated substrates (Scale bar is 100 μm). 
Compiling the various corrosion and cell adhesion, viability and proliferation results, it is 
clear that although the biocompatibility of the PLGA coating is better, the corrosion protective 
nature of PLGA coatings on the surface of magnesium alloys however is inconsistent. While 
numerous factors affect the degradation rate of poly(lactide-co-glycolide) polymers, the crucial 
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issue with utilizing PLGA (and many other degradable polymers) as a temporary tool for 
corrosion protection is the mechanism of PLGA degradation. PLGA is known to undergo bulk 
erosion in vivo, wherein the full body of the material is simultaneously attacked by water, as 
opposed to surface erosion, where only the surface of the material is degraded [294]. In the 
context of protecting metallic surfaces from corrosion, the bulk erosion of the polymeric coating 
leads to rapid exposure of the surface to water and acidic erosion byproducts. Thus, the amount 
of water exposure to the underlying bare metal surfaces is limited but not fully prevented. This 
appears to be exaggerated by the evolution of hydrogen gas upon initiation of corrosion. The gas 
is trapped below the polymeric coating, forming gas pockets which burst and expose larger areas 
of the metallic substrate to aqueous attack. Further studies and optimized coating strategies to 
increase the alloy surface-polymer coating adhesion may yield improved corrosion resistance 
because an increased adhesion would reduce or eliminate gas pocket formation between the 
polymer and alloy. These studies are currently in progress and will be reported subsequently. 
B.4 CONCLUSION 
A 50:50 poly(lactide-co-glycolide) polymer with two different concentrations was coated onto 
the surface of both AZ31 and Mg4Y alloys through a solution dip-coating method. The 
implementation of PLGA yielded homogeneous and reliable coatings on AZ31 and Mg4Y alloy 
substrates offering some level of immediate corrosion protection over a limited time period. 
However, once the aqueous corrosion attack is initiated, the polymer offers little protection over 
subsequent time periods although dramatic improvements in osteoblast adhesion and 
proliferation are observed on the surface of both alloy substrates. Between the two alloys, Mg4Y 
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substrates, both coated and uncoated, appear less resistant to corrosion than AZ31 substrates, 
which is in direct contrast with results from previous studies. Preventing the formation of gas 
pockets below the polymeric coatings, through increased alloy-polymer adhesion, may lead to 
improved corrosion resistance rendering the implementation of these coated Mg alloy substrates 
for possible use in orthopedic fixation plate application while also permitting the utilization of 
PLGA for additional biotechnological applications such as drug delivery.   
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APPENDIX C 
CORROSION PROTECTION AND IMPROVED CYTOCOMPATIBILITY OF 
BIODEGRADABLE POLYMERIC LAYER-BY-LAYER COATINGS ON AZ31 
MAGNESIUM ALLOYS  
Composite coatings of electrostatically assembled layer-by-layer anionic and cationic polymers 
combined with an Mg(OH)2 surface treatment serve to provide a protective coating on AZ31 
magnesium alloy substrates.  This ceramic conversion coating and layer-by-layer polymeric 
coating combinations reduced the initial and long term corrosion progression of the AZ31 alloy. 
X-ray diffraction and Fourier transform infrared spectroscopy confirmed the successful 
application of coatings.  Potentiostatic polarization tests indicate improved initial corrosion 
resistance.  Hydrogen evolution measurements over a two week period and magnesium ion levels 
over a one week period indeed indicate longer range corrosion protection and retention of the 
Mg(OH)2 passivation layer in comparison to uncoated substrates.  Live/Dead staining and DNA 
quantification were thus used as measures of biocompatibility and proliferation while actin 
staining and scanning electron microscopy were used to further observe cellular morphology and 
integration with the coated substrates. The coatings simultaneously provided improved 
cytocompatibility, cellular adhesion and proliferation in comparison to the uncoated alloy surface 
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utilizing both murine pre-osteoblast MC3T3 cells and human mesenchymal stem cells. The 
implementation of such coatings on magnesium alloy implants could serve to improve the 
corrosion resistance and cellular integration of these implants with the native tissue while 
delivering vital drugs or biological elements to the site of implantation. Results of these studies 
are reported herein. 
C.1 INTRODUCTION 
The utilization of stainless steel or titanium biomedical implants is favorable for clinical 
applications requiring load-bearing capacities. Necessary as these products may be in today’s 
medical procedures, these inert implants are far from ideal, lacking beneficial characteristics seen 
in many polymeric and ceramic implants, especially biodegradability [267, 270, 271, 297]. 
Alternatively, for the past decade there has been a renewed interest in replacing these implants 
with magnesium-based alloys, which are degradable in vivo through simple corrosion and 
display mechanical properties similar to native bone [269, 275].  The body innately requires 
magnesium to function and at low levels is able to absorb the hydrogen gas released, however, at 
faster rates the corrosion can result in hydrogen gas pocket formation and implant failure  [268, 
273, 274, 298].   As the interest in degradable magnesium alloys for biomedical applications 
escalates, the uncontrolled degradation remains a major challenge. For clinically relevant 
magnesium devices, the rates of corrosion must be controlled to ensure functionality and to avoid 
the accumulation of the hydrogen gas formed during corrosion. In general, two approaches have 
been adopted to tailor alloy degradation. The first is by modifying the alloy  itself  through 
appropriate alloy design, and the second is via the surface modification, such as the application 
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of coatings [293].   Implementation of suitable  coatings can not only serve to delay  the initial 
degradation of the alloy, but may also improve  biocompatibility  enabling enhanced 
osseointegration  between the coated implant to the surrounding tissue [279, 281, 293, 299, 300]. 
Coatings of metal-based implants typically fall into two general classes:  conversion coatings and 
deposition coatings.  Coatings of these two archetypes, with a variety of  techniques and 
compositions, have been employed by researchers to prevent or slow the corrosion of magnesium 
[293].  In conversion coatings, the coating is formed in situ, through a reaction between the 
substrate and its environment, and is typically inorganic [293].  For magnesium alloys these 
coatings are often oxides, phosphates or fluorides. Although conversion coatings exhibit good 
adhesion to the substrate, there remain concerns with respect to the  mechanical durability and 
biocompatibility of  these coatings [293]. The most highly studied conversion coatings calcium 
phosphate based, especially hydroxyapatite due to its similarity to native mineralized tissues. 
Although the biocompatibility of calcium phosphate coatings is generally higher than other 
conversion coatings, the corrosion protection of conversion coatings are shown to be low 
because these coatings often display cracks or pores which result in unfavorable corrosion levels 
[293]  It is surmised that the most effective conversion coating, plasma electrolytic anodization 
(PEO) coating application. These coatings show the greatest corrosion protection due to the 
physical technique of application not the chemical stability of the coating applied.  For 
deposition coatings, a coating is applied through physical interactions with the metal surface. 
These coatings are typically organic or ceramic, and for magnesium alloys will often require a 
conversion coating pre-treatment to improve the adhesion of the coating to the alloy [293, 301]. 
Inorganic deposition coatings are typically hydroxyapatite-based and tend to show high 
biocompatibility but poor corrosion protection due to the porous nature of the coating [277].  
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Organic deposition coatings have been widely studied with varying conclusions. Typically ‘one-
step’ organic coatings applied without a primary conversion coating do not show good adhesion 
or protection of the surface. Organic coatings in ‘two-steps’ which combine apply a conversion 
coating prior to the deposited coating show better adhesion and corrosion protection [293].  
A more complex coating process, known as layer-by-layer deposition, has the potential to 
improve upon the disadvantages   of other coating techniques. Layer-by-layer assembly of 
polymer layers resulting in polyelectrolyte multilayer (PEM) film was introduced only 20 years 
ago by Decher and Lvov and relies on static interactions positively charged and negatively 
charged polymer chains dissolved in solutions [302-306]. By incubating a substrate in alternating 
solutions of positive and negatively charged polymers, thin well-adhered film layers are formed. 
With this technique, a wide variety of solution parameters, such as concentration, pH, molecular 
weight and additives can be tailored to manipulate the final properties of the coating, including 
stiffness, hydrophobicity, protein adhesion, degradation rate and drug elusion, surface charge and 
cell attachment and interactions [307-310].  Additionally, the coating layer assembly can be 
manipulated to incorporate drugs, biological molecules and nanoparticles into the coatings [307].  
These coatings have been widely explored for biomedical applications [307, 311].  The 
implementation of the layer-by-layer coating technique for biomedical magnesium alloys was 
first attempted recently by Cai et al, exploring the combination of poly(ethylene imine) and 
poly(styrene sulfonate) with 8-hydroxyquinoline on a AZ91 magnesium alloy [299].  Very 
recently Liu et al explored the corrosion resistance of chitosan/poly(styrene sulfonate) 
multilayers on a mirco-arc oxidized magnesium surface [312]. In both cases the researchers 
showed improved corrosion resistance of the coated alloy however the exploration into the 
biocompatibility of these surfaces is minimal or non-existent, respectively.  
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This work demonstrates the implementation of a combination of coating techniques, 
utilizing an Mg(OH)2 passivation layer formed through chemical conversion in situ in 
conjunction with the layer-by-layer (LbL) deposition of a degradable PEM coating, to form a 
protective,  biocompatible coating on a commercially available AZ31 magnesium alloy. The 
anionic polymers explored in this study were polycaprolactone (PCL) and two different 
poly(lactide-go-glycolide) (PLGA) formulations. These  polymers were selected since they have  
been  widely  used both in research and clinically. They are also biocompatible and 
biodegradable with metabolically digestible degradation products, and are currently  utilized in 
FDA-approved medical devices [283, 284].  The cationic polymers explored were 
polyethylenimine (PEI) and polyallylamine hydrochloride (PAH). These polymers have been 
studied for applications such as gene delivery, antibacterial uses and cell encapsulation [310, 
313-315].  The resulting coated substrates were characterized for immediate and long term 
corrosion protection to understand the roles of the resultant PEM on the degradation behavior of 
the underlying AZ31 alloy. Furthermore, the cytocompatibility of the PEM coated substrates was 
tested with murine osteoblasts and human mesenchymal stem cells. 
C.2 MATERIALS AND METHODS 
C.2.1 Materials and Sample Preparation 
Hot rolled AZ31 alloy was acquired from Alfa Aesar (Ward Hill, MA, USA) and was used 
without further thermal or mechanical treatment. Samples were cut into 1.25 x 1.25 x 0.08 cm 
 240 
pieces and cleaned by etching in 3% nitric acid solution in ethanol. Samples were then polished 
to 1200 grit (5 μm) using SiC polishing paper and sonicated for 30 minutes in acetone. 
Following sonication, samples were incubated in a 5M NaOH solution for 2 hours at 60 °C to 
form an Mg(OH)2 surface layer, then dried in air at 60 °C for 1 hour.  Samples were 
subsequently rinsed in deionized water for 5 minutes, then again dried at 60 °C for 30 minutes. 
Layer-by-layer coatings were created via a dip-coating method (Desktop Dip Coater, Model No 
EQ-HWTL-01-A, MTI Corporation, USA), wherein for each coating the substrates were dipped 
into the polymer solution, incubated for 1 minute, withdrawn at 200 μm/s and dried in air. Layers 
were generated with the following sequence, “ABCBCBCBCB”. Solutions A and C contain 
cationic polymers, polyethylenimine (PEI, MW 25,000) at 10 mg/ml in DI water and 
poly(allylamine hydrochloride) (PAH, MW 58,000) at 5 mg/ml in 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid buffer (HEPES buffer), respectively. Solution B consists of a synthetic 
anionic polymer, 50:50 poly(lactide-co-glycolide) (PLGA 50:50, MW 30,000-60,000)  75:25 
poly(lactide-co-glycolide) (PLGA75:25, MW 76,000-115,000) or polycaprolactone (PCL, MW 
70,000-90,000) each at 50 mg/ml in dichloromethane. All five polymers were acquired from 
Sigma-Aldrich. Three different variations of layer-by-layer coatings were generated, depending 
on the anionic polymer used, subsequently termed PLGA50:50, PLGA75:25 or PCL depending 
on the anionic polymer utilized for the ‘B’ layer. 
C.2.2 Characterization of Coatings 
The formation of the Mg(OH)2 layer was confirmed utilizing glancing angle x-ray diffraction 
(GA-XRD, Philips PWI830 Diffractometer) using copper Kα radiation with a 2θ range of 10-80º, 
0.02º step size and an ω angle of 1º offset. The chemical nature of the coatings was confirmed by 
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Attenuated Total Reflectance Fourier Transform Infrared spectroscopy (ATR-FTIR, Nicolet 
6700 spectrophotometer, Thermo Electron Corporation) using a diamond ATR Smart orbit. 
Spectra were obtained at 1.0 cm-1 resolution averaging 64 scans in the 400 – 2500 cm-1 
frequency range. The surface morphology of the coating was studied using scanning electron 
microscopy (SEM, Joel JSM-6610LV) at 10 kV operating voltage. Prior to imaging samples 
were sputter coated with palladium (Cressington sputter coater 108A). 
C.2.3 Electrochemical Corrosion 
Electrochemical corrosion characterization of the coated alloy samples was performed using a 
CH604A (CH Instruments Inc) electrochemical work station. Following sample preparation as 
described previously, length and width were measured and then one side of each sample was 
connected to a wire with silver epoxy and then electrically insulated with polymeric epoxy, such 
that only one side is exposed for electrochemical testing. Ag/AgCl reference electrode (4.0M 
KCl, Accument) and a platinum wire counter electrode were employed. Testing was carried out 
utilizing a 3-neck jacketed flask (ACE Glassware) filled with 125mL Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10 % fetal bovine serum (FBS, Atlanta Biologicals, 
Lawerenceville, GA) and 1 % penicillin/streptomycin antibiotics (P/S, Gibco, Grand Island,NY), 
equilibrated to 37 °C. All the specimens were allowed to equilibrate to reach a stable open circuit 
potential (OCP), before initiating the potentiostatic polarization tests at a scan rate of 1.0 mV/s. 
The corrosion current was determined using the Tafel extrapolation of the polarization curve and 
normalized by the exposed surface area to yield a measurement of corrosion current density. The 
Tafel extrapolation was taken at potential values 50 mV below and above the corrosion potential 
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value to ensure proper extrapolation.   The software program Origin with a Tafel extrapolation 
packet was used to perform the analysis and plot the data. 
C.2.4 In Vitro Degradation 
Corrosion profile up to 7 days was assessed by analyzing the magnesium ion concentration in 
media extracted after sample incubation. The coated substrates were sterilized by UV light 
exposure for 1 hour per side. Each substrate was then soaked in 2 mL of DMEM containing 10 
% FBS and 1 % P/S under standard growth conditions of 37 ºC, 5 % CO2 and 95 % relative 
humidity for 7 days. The media was changed and collected every 24 hours to monitor the 
dissolution rate under in vitro conditions. The collected media was diluted in 0.03 M Tris buffer 
solution and analyzed using inductively coupled plasma optical emission spectroscopy (ICP-
OES, iCAP duo 6500 Thermo Fisher). Magnesium ion concentrations in solution were compared 
to media and uncoated substrate controls. Samples were prepared in triplicate for each condition. 
Statistically significance differences were assessed daily through ANOVA with Dunnett’s 1-
tailed t-test post-hoc testing, assuming AZ31 control values to be higher than coated substrates. 
Significance was set at the p<0.05 level.  IBM-SPSS statistical analysis software was used for 
calculations.   
C.2.5 Hydrogen Evolution 
The evolution of hydrogen was tested by placing the substrates in Hank’s solution (Sigma 
Aldrich) at 37 °C and measuring the evolved hydrogen over a two week time span. Sample 
dimensions were recorded prior to sterilizing under UV radiation, 1 hour each side.  Samples 
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were placed in individual mesh bags and suspended within 1 liter beakers of Hank’s solution, 
underneath an inverted funnel.  A burette was placed over-top of the funnel above the samples to 
capture hydrogen released. Three samples were suspended for each condition to account for the 
low hydrogen evolution anticipated from the coated samples. To the greatest extent possible, 
difficulties and concerns associated with measurement of hydrogen evolution have been 
addressed [275]. All beakers, funnels and burettes are glass so as to prevent hydrogen 
permeation.  The samples were suspended to ensure full surface exposure and the inverted 
funnels were elevated to prevent ion accumulation within the funnel volume.   Solution level in 
each burette was measured intermittently for two weeks. The coatings were characterized post-
corrosion using a scanning electron microscopy.  
C.2.6 Cell culture 
Murine MC3T3 –E1 pre-osteoblast cells and Human Mesenchymal Stem Cells (hMSC, Lonza 
USA) were utilized for cell culture studies. Cells were cultured in minimum essential medium 
alpha (α-MEM, Gibco, Grand Island, NY) containing 1 % penicillin/streptomycin antibiotics 
(P/S, Gibco, Grand Island, NY) and either 10 % fetal bovine serum, for MC3T3, or 20 % fetal 
bovine serum, for hMSC (FBS, Atlanta Biologicals, Lawerenceville, GA) at 37 oC, 5 % CO2 and 
95 % relative humidity. Substrates were placed in 12-well plates and sterilized using UV 
radiation for 40 minutes on each side. The substrates were then seeded with cells with a total 
media volume of 2 ml/well. Media was changed every other day throughout the testing period. 
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C.2.7 Cytocompatibility 
Cell viability was assessed using Live/Dead staining, as previously described. Cellular adhesion 
and morphology was observed using actin and nucleus staining.  MC3T3 and hMSC cells were 
seeded on sterilized substrates at a concentration of 20,000 cells/ml and cultured in appropriate 
media for 24 hours. Cells were then rinsed with PBS, fixed using a 4 % paraformaldehyde 
solution then permeabilized with a 0.2 % Tween20 solution (Bio-Rad, USA). Following this 
cellular actin was stained using phalloidin (Sigma Aldrich) and nuclei were stained using dapi 
(Applichem) according to manufacturer’s instructions. Cells were imaged using fluorescence 
microscopy.  Following fluorescence imaging, fixed samples were then subjected to alcohol 
dehydration and mounted for SEM imaging.  
Quantification of cellular DNA levels as a measure of proliferation was assessed with 
MC3T3 cells. Cells were seeded at a density of 80,000 cells/ml and cultured for 1, 3 and 7 days. 
Substrates were rinsed with PBS then cells were lysed (CellLytic, Sigma Aldrich). The Quan-It 
PicoGreen dsDNA Reagent and Kit (Invitrogen) was used to measure cellular DNA according to 
manufacturer’s instruction. Lamda dsDNA was used for the standard curve and the fluorescence 
level was measured using Synerge2 Multi-Mode Microplate Reader (Biotek, USA).  Statistically 
significant differences were assessed through ANOVA with Dunnett’s 1-tailed t-test post-hoc 
testing, assuming AZ31 control values to be lower than coated substrates. Significance was set at 
the p<0.05 level. IBM-SPSS statistical analysis software was used for calculations.   
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C.3 RESULTS 
C.3.1 Coating Characterization 
Glancing angle x-ray diffraction (GA-XRD) was used to confirm the formation of the Mg(OH)2 
layer on the surface of the AZ31 substrates. Following sodium hydroxide treatment and rinsing 
in DI water, the substrate was dried and kept in a desiccator until the diffraction measurement 
was completed.  Figure C-1 shows the collected GA-XRD spectra along with simulated spectra 
for pure magnesium and magnesium hydroxide. The collected spectra shows minor peaks 
associated with major peaks of Mg(OH)2 spectra, particularly at  approximately 18.5º and 38º 2θ 
angles.  
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Figure C-1 Simulated x-ray diffraction patterns of pure magnesium [JCPDS 35-0821] (a)  and Mg(OH)2 
[JCPDS 7-239] (b) with glancing angle x-ray diffraction of (c) NaOH-treated AZ31 substrate showing growth 
of Mg(OH)2 layer, indicated by the asterisk *. 
FT-IR was used to follow the development of the layer-by-layer coatings on the AZ31 
substrates. Figure C-2 shows the FT-IR spectrum of the PCL (i), PLGA50:50(ii) and PLGA75:25 
(iii) coated samples after all 5 cationic/anionic layer pairs were applied, respectively. Further FT-
IR testing of individual layer assembly shows small peaks of cationic polymers when these 
polymers are the top coat (Results not shown.) For each coating type, the coated substrate is 
compared to FTIR spectra of Mg(OH)2-treated substrate and pure spectra of each utilized 
polymer component.  The characteristic bonds at numerous wave numbers, especially the C=O 
stretching at 1750 cm-1 and the numerous C–O–C and C-H bending peaks between near 1080 
cm-1  and 1500 cm -1, are indicative of the presence of the PCL and PLGA polymers. 
247 
Additionally, there are minor peaks around 1625 cm -1 visible which match the pattern for PAH 
and are likely associated with C=C bonds of unreacted ends of the PAH chains.  No carbon or 
nitrogen-based peaks are seen on the bare metal substrates devoid of the polymer, though the 
peak at around 3600 cm -1 is associated with free –OH bonds. The coated substrate spectra shown 
are after completing the coating process and the presence of the thicker, top-coating anionic 
polymers (PCL, PLGA50:50 and PLGA75:25) mask most bond peaks characteristic of the 
cationic PEI and PAH polymers.  
Figure C-2 FTIR spectra of coated substrates and individual components.  In each set of spectra, (a) is 
AZ31 with NaOH treatment, (b) is pure PEI and (c) is pure PAH while (d) is the utilized anionic polymer and 
(e) is the fully coated substrate. Spectra set (i) presents the PCL coatings, (ii) presents the PLGA50:50 series 
and (iii) presents the PLGA75:25 series, each showing clear presence of the anionic polymers on coated 
substrates. The presence of the cationic polymers is obscured by thick top coating. 
Scanning electron microscopy was used to observe the morphology of the substrates after 
the coating process. Figure C-3 shows images of the substrates as-polished (a) and after layer-by-
layer coatings (b-d).  The as-prepared AZ31 substrate shows a flat but imperfect surface with 
grooves remaining from the final 5 µm polishing paper. The sodium hydroxide-treated surface, 
not shown, displays slightly altered morphology of the substrate, reducing the visibility of 
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residual grooves from polishing.  The PCL (b), PGLA50:50 (c) and PLGA75:25 (d) layer-by-
layer coated substrates show smoother, muted surfaces with only slight remnants of the polishing 
artifacts remaining. The coatings are non-porous and do not show any signs of delamination 
from the alloy surface. Qualitatively, this reinforces the confirmation of the successful Mg(OH)2 
treatment and anionic-cationic layer-by-layer assembly to the surface of AZ31 substrates. 
Figure C-3 SEM images of uncoated AZ31(a),  PCL (b), PLGA 50:50 (c) and PLGA 75:25 (d).  Scale bar 
is 50 μm. 
C.3.2 Corrosion Characterization 
Polarization curves (a) and impedance spectra (b) for the uncoated and coated substrates can be 
seen in Figure C-4. Table C-1 gives a summary of the corrosion potential and corrosion current 
densities as calculated from extrapolation of the Tafel plots.  All three coatings, PCL (ab), 
PLGA50:50 (ac) and PLGA75:25 (ad) as well as solely the Mg(OH)2 conversion coating (ae) on 
the substrates resulted in icorr values lower than  the uncoated AZ31 alloy substrate (aa) as well as 
Ecorr  values that are more anodic  than the uncoated AZ31 alloy. PCL offered the greatest 
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reduction in corrosion current over the uncoated alloy, which was measured at 2.75E-05, with an 
icorr value of 3.35E-07, followed by PLGA50:50 and PLGA75:25, which were similar at icorr 
values of 1.12 E-06 and 1.56 E-06 respectively which was also quite similar to the Mg(OH)2 
coating, which measured at 1.02E-06. Both PGLA50:50 and PLGA75:25 show a breakdown in 
the anodic corrosion current at lower potential values.  EIS results correspond with polarization 
measurements, indicating that PCL coating is the most protective and that all coatings provide 
increased corrosion impedance over the uncoated alloy. 
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Figure C-4 Polarization curves (a) of  uncoated AZ31 (aa), PCL (ab), PLGA50:50 (ac), PLGA75:25 (ad) 
and Mg(OH)2 (ae) showing less negative corrosion potential and reduced corrosion current for all coated 
substrates over the uncoated alloy. Electrochemical Impedance Spectroscopy (EIS) measurements of the 
coated and uncoated substrates are shown in (b).   Measurements were taken in the frequency range of 1000-
0.01 Hz with an amplitude of 0.005 V.  
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Table C-1 Corrosion potential (Ecorr) and current density (icorr) values for coated and uncoated 
substrates. 
 Ecorr (V) icorr (A/cm
2) 
Uncoated AZ31 -1.54 2.75E-05 
PCL -1.50 3.35E-07 
PLGA5050 -1.52 1.12E-06 
PLGA7525 -1.44 1.56E-06 
Mg(OH)2 -1.45 1.02E-06 
Daily released magnesium ion concentration in media for coated and uncoated substrates 
can be seen Figure C-5. This data shows the dissolution profile as a function of soluble 
magnesium ion release over a one week period under in vitro culture conditions. Although 
connected more directly with passivation coating dissolution, or here Mg(OH)2 dissolution, than 
magnesium corrosion, the localized ion concentrations are an important consideration for 
biocompatibility of the substrate.  At each time point the magnesium level in media for coated 
samples is significantly lower (p<0.05) than the uncoated AZ31 substrates. Though not 
calculated, it appears that magnesium ion levels of coated substrates remaining higher than basal 
media levels for all time points. This indicates that the coatings provide some corrosion 
protection but do not fully passivate the substrate from corrosion.  
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Figure C-5  ICP measurements of daily released magnesium ion concentration in extracted incubation 
media for AZ31 coated and uncoated samples. For every time point, all coated samples show 
statistically lower ion concentrations (p<0.05) than the uncoated AZ31, indicated by the *asterisk. 
Cumulative hydrogen gas evolution plots for the uncoated and coated substrates can be 
seen in Figure C-6.  Measurements indicate that cumulative hydrogen released from uncoated 
AZ31 is much higher than that of coated substrates. Uncoated AZ31 shows a characteristically 
high corrosion rate initially, through about the first 12 hours, followed by slower, relatively 
constant corrosion rate through the remaining period of the study. All coated substrates showed a 
slow rate of hydrogen release initially, through the first 48 hours of testing.  The corrosion then 
plateaued, showing no additional measurable release after this 48 hour period. Figure C-7 shows 
the SEM images of samples post corrosion in Hanks solution. Electron microscopy of these 
samples at the end of the corrosion period shows the presence of surface cracks on the uncoated 
AZ31 (a), characteristic of magnesium corrosion morphology. The polymer-coated substrates 
show various levels of corrosion progression. PLGA50:50 (c) shows the most aggressive 
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progression of corrosion, with cracking morphology similar to the uncoated substrate and nearly 
no visible polymer remaining. PLGA75:25 (d) shows some underlying cracking beginning to 
form, with the bulk of the sample still coated in polymer. PCL (b) shows the least amount of 
corrosion, displaying some defects in the polymer coating but no visible cracking morphology.  
Figure C-6 Cumulative hydrogen evolution in Hanks solution over a two-week period, showing a 
marked reduction in hydrogen release with coated samples in comparison to uncoated AZ31. 
Figure C-7 SEM images of substrates Uncoated AZ31(a), PCL(b), PLGA 50:50 (c) and PLGA 75:25 (d) 
following two week incubation for hydrogen-evolution testing. Scale bar is 50 µm. 
254 
C.3.3 Cytocompatibility 
Live/Dead staining of osteoblasts and hMSCs 3 days post seeding can be seen in Figure C-8, 
respectively. For both MC3T3 and hMSC cell cultures, live/dead staining indicates improved cell 
viability and proliferation on coated substrates over the uncoated AZ31 alloy. No discernible 
difference can be seen between the three types of polymer coatings. Actin staining of osteoblasts 
and hMSCs 24 hours post seeding can be seen in Figure C-9. For MC3T3 cells (a-d), cellular 
morphology is circular and poorly defined on the uncoated AZ31 (a), without strong actin fiber 
staining, indicating that the cells are likely poorly adhered to the substrate. On the PCL-coated 
substrate (b) cells appear elongated while on the PLGA50:50 (c) and PLGA75:25 (d) coated 
substrates cells appear well spread out, showing strong actin filaments extended in numerous 
directions. For hSMCs (e-h), cells cultured on uncoated AZ31 (e) appear extremely elongated, 
though better adhered than the MC3T3s under the same conditions. On the PCL (f) coated 
substrates hMSCs appear somewhat elongated, but less than the MC3T3s did under the same 
condition. The hMSCs grown on the PLGA50:50 (g) and PLGA75:25 (h) coated substrates 
appear very healthy and well adhered with strong actin fibers extending in various directions on 
the substrates.  
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Figure C-8 Live/Dead staining of MC3T3 osteoblasts (a-d) and hMSCs (e-h)  on day 3 of culture post 
seeding on uncoated AZ31 (a & e),  PCL (b & f),  PLGA 50:50 (c & g) and PLGA 75:25 (d & h) indicating 
improved biocompatibility of coated substrates over uncoated substrates. Scale bar is 200 μm. 
Figure C-9 Cell morphology of MC3T3 osteoblasts (a-d) and hMSCs (e-h) observed at 24 hours post 
seeding through actin-nucleus co-staining on uncoated AZ31 (a & e),  PCL (b & f),  PLGA 50:50 (c & g) and 
PLGA 75:25 (d & h). Scale Bar is 100 μm. 
In Figure C-10 can be seen the same substrates from the cell morphology study, 
dehydrated and mounted for electron microscopy examination, which allows simultaneous 
observation of the coatings, the cells and the interaction between the two. Fixed MC3T3 cells are 
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barely visible on the corroded AZ31 substrate (a). Morphologies of MC3T3s on the polymeric 
coatings (b-d) are similar to those observed through actin staining: the cells grown on the PCL 
(b) coated substrate appear more elongated while the cells grown on the PGLA50:50(c) and 
PLGA75:25 (d) substrates appear more spread out. The cells on PCL substrates do not appear to 
be as fully adhered as those on the PLGA substrates, with some portions of the cytoskeleton 
rising up above the surface of the polymer. SEM images of hMSCs fixed on the coated and 
uncoated substrates show similar trends. Cells on the uncoated AZ31 (e) are thin and very 
elongated, cells on the PCL (f) are also elongated but to a lesser extent while cells on 
PLGA50:50 (g) and PLGA75:25 (h) are spread out and well adhered to the substrates.  
Figure C-10 SEM morphology of fixed MC3T3 osteoblasts (a-d) and hMSCs (e-h) at 24hrs post-seeding 
on Uncoated AZ31 (a & e), PCL (b & f),  PLGA 50:50 (c & g) and PLGA 75:25 (d & h). Scale Bar is 100 μm. 
The quantification of total DNA content from MC3T3 cells can be seen in Figure C-11.  
Grown over the period of 1, 3 and 7 days, DNA quantification studies support what was seen 
qualitatively in the live/dead staining, that the cell viability and proliferation is higher on the 
coated substrates in comparison to the uncoated substrate. Although there was no statistical 
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difference after day 1, days 3 and 7 samples coated with PCL, PLGA50:50 and PLGA75:25 
show significantly higher DNA levels than the uncoated substrates, indicated by the asterisks in 
the figure. High DNA levels are correlated with higher numbers of cells on the substrates. 
Figure C-11 Quantification of total DNA content, using MC3T3 osteoblasts, on substrates at various 
time points. On day 3 and day 7 all coated substrates showed statistically higher (p<0.05) levels of DNA 
than the uncoated substrate, indicated by the *asterisk. 
C.4 DISCUSSION 
The application of coatings to the surface of implants is an accepted technique to improve the 
initial corrosion resistance and biocompatibility of magnesium-based alloys. Degradable 
polymeric coatings can be used to provide localized drug and gene delivery to the implant site 
accelerating the regeneration process. With the intent of both slowing corrosion and facilitating 
the delivery of biological agents, the coatings explored in this study combine a passivating 
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conversion coating with a layer-by-layer deposition coating of polymers. The choice of polymers 
is designed to utilize those polymers known for their drug and gene delivery functionality as well 
as their biocompatibility. The conversion coating consists of a Mg(OH)2 passivation layer, which 
reduces the initial magnesium surface reactivity as a stand-alone coating. The spontaneous 
formation of a magnesium oxide/magnesium hydroxide layer on magnesium exposed to 
humidity, as well as the increased thickness of the hydroxide layer when immersed in water, has 
been previously studied [293].   Studies have shown that this passivation coating, while it 
provides initial protection, is not stable in ionic solutions, where chlorine in culture media aids in 
breaking down the hydroxide layer.  More importantly, a recent study showed that while the 
hydroxide layer improves corrosion resistance, the coating was able to delay  cell death but 
resulted in reduced cell densities and abnormal cellular morphology, thus making it a poor 
choice as a stand-alone protective layer against corrosion  [316].   
The deposition coating is formed through the layer-by-layer assembly of anionic and 
cationic polymers. The anionic polymers explored in this study were polycaprolactone and two 
different poly(lactide-go-glycolide) formulations. These polymers are biodegradable and are 
frequently studied for drug delivery [283, 284, 317].  The three anionic polymers used in this 
study were chosen based on the variety of anticipated degradation rates, from PLGA50:50 
degrading the most rapidly to PCL degrading the most slowly [318, 319]. The cationic polymers 
explored were polyethylenimine and polyallylamine hydrochloride. These polymers have been 
studied for applications such as gene delivery, antibacterial uses and cell encapsulation [310, 
313-315]. Cationic polymers function in such capacities due to the cell-membrane-disrupting 
potential charge. For the same reason, these polymers can be toxic in bulk quantities [320]. 
Recently, PEI was studied as a protective coating on magnesium. It was shown that the imide 
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rings of PEI interact with the magnesium hydroxide corrosion product and that the PEI coating 
shows general improvement to the corrosion resistance of the alloy [321, 322].  Importantly, it 
has been seen that the coupling of cationic and anionic polymers significantly reduces the 
cytotoxicity of the cationic polymers [315].   Cationic polymers such as these are largely not 
degradable in vivo thus lower molecular weight options are favorable, as these are both more 
water soluble and typically shower lower toxicity [323]. Some evidence indicates that these non-
degradable polymers can accumulate in critical organs [314].  Although the specific PEI and 
PAH polymers in this study are not biodegradable, much research has focused on  tailoring such 
polymers to facilitate degradation in vivo [324, 325]. 
XRD and FTIR techniques used to characterize the passivation and layer-by-layer 
coatings in Figures C-1 and C-2 have confirmed that coating synthesis was completed as 
intended.  Electron microscopy in Figure C-3 additionally confirmed that the coatings are 
homogenous over the surface of the substrate.  
The corrosion studies carried out in this work are sufficiently complimentary in their 
depiction of the protective nature of these coatings on the magnesium substrate.  The protective 
nature of the coatings shown in the electrochemical corrosion studies is supported by the lower 
hydrogen evolution and magnesium ion release of these samples at initial incubation in solution. 
Overall the level of protection from the three different coatings is somewhat varied when 
comparing them in both the polarization testing in Figure C-4 and magnesium ion release in 
Figure C-5. Polarization studies showed PCL to be most protective, while ion release studies 
indicate that PLGA75:25 is most protective upon initial incubation in media, while PCL is 
intermediate and PLGA50:50 is the least protective. It should be noted however that polarization 
curves are of only one representative sample and the statistical significance between coated 
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samples in the ion concentration study is not computed due to low sampling power. In these 
studies the intent was to show the protective nature of the composite Mg(OH)2-layer-by-layer 
coatings over uncoated substrates and only the qualitative differences between the types of 
coatings can be discussed. Magnesium ion concentrations, Figure C-5, of coated samples for the 
first 48 hours of testing appear to be similar to hydrogen evolution results, Figure C-6, however, 
the ion concentration curves predict some corrosion that is not seen as additional hydrogen 
release beyond this time period.  This is likely due to the difference between corrosion, and thus 
hydrogen production, and corrosion product dissolution. Because the coated substrates begin 
with an exaggerated ‘passivation’ layer, initial corrosion is minimal and likely due to defects in 
the samples. The magnesium ion release is due to the slow dissolution of the Mg(OH)2 layer.  
The initial spike in ion concentration and hydrogen evolution for uncoated AZ31 is due to the 
total sample surface area being exposed. Once a passivation layer is formed, the corrosion rate is 
reduced.  However it is not halted all together due to the instability of the passivation layer and 
the solubility of this layer in chloride-containing solutions. The application of the initial 
conversion layer (Mg(OH)2) coating prevents this immediate spike in corrosion for the coated as 
well as stabilizing the substrate surface for subsequent layer-by-layer coating. The application of 
polymeric coatings additionally prevents the fragmentation of the conversion layer, which is 
quite similar to a natural passivation layer in nature and thus not fully stable. Visibly, the 
corrosion progression seen through SEM in Figure C-7 appears to confirm the anticipated rates 
of polymer degradation, with PLGA50:50 showing the least remaining polymer, PLGA75:25 
showing some remaining polymer and PCL showing the most intact polymer remaining. All 
three anionic polymers undergo bulk hydrolytic degradation, allowing aqueous penetration as the 
degradation progresses. The access of water to the Mg(OH)2 layer, and subsequent partial 
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dissolution of this layer, explains the discrepancy between elevated magnesium ion levels and 
lack of hydrogen evolution at later time points.   Once the polymer layer completely degrades 
away, the passivation layer can begin to break down or dissolve. Thus at short time points, the 
magnesium ion levels are dependent upon the polymer hydrolytic degradation rate and ion 
diffusion through the polymer and subsequent low level dissolution of the magnesium hydroxide.   
During this, the bulk breakdown of the base Mg(OH)2 layer and subsequent magnesium alloy 
corrosion is halted until full degradation of the polymer occurs.  When the polymer has 
completed dissolved, it is expected that the underlying alloy would corrode similar to a 
magnesium implant once it has reached a steady corrosion rate. Initially, upon implantation, 
magnesium alloys show a short-term burst of very active corrosion, as the native material builds 
a passivation layer. After this burst, the rate of corrosion decreases significantly, to a level which 
the hydrogen evolution is tolerable in vivo [281, 299, 326]. Following dissolution of the 
polymeric coating, it is expected that the hydroxide coating would behave as the passivation 
layer formed on native alloys, maintaining the corrosion rate at that of the passivated native 
alloy. This formed hydroxide layer would slowly break away, allowing fresh corrosion to occur 
before a new passivation layer forms in the way that typical magnesium corrosion occurs in vivo.   
Ideally, throughout the degradation of the polymers, cellular integration with the implant is 
achieved, which would help ensure that the implant maintains this comparatively slow and 
steady rate of hydrogen gas and magnesium release.  
The corrosion results shown are in stark contrast to what has previously been seen in the 
application of PCL and PLGA-type polymers to magnesium alloys. Previously, it has been 
shown in our laboratory as well as by others that the application of such polymers results in 
bubbling of the water-penetrable polymer and poor corrosion protection beyond 24 hours of 
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incubation. In fact, many researchers have seen that these coatings have an antagonistic effect on 
corrosion, increasing corrosion rates of the coated samples over uncoated alloys   [280, 289, 
327]. It has been postulated that this effect is due to the bulk degradation exhibited by the 
polymers, allowing water to contact the alloy surface, and acidic polymer degradation products 
increasing the solubility of the passivation layer that would otherwise form on areas of the metal 
exposed to water. Additionally, the bubbling effect may create localized galvanic corrosion 
effects.  Our results indicate that while the degradation of the polymers may prevent the 
formation of a Mg(OH)2 passivation, it does not weaken or dissolve the pre-formed passivation 
layer, which would result in similar antagonistic corrosion as seen previously [280, 289, 328].     
The combination of the water-soluble, but not degradable, PAH and PEI polymers layered in 
between the degradable PLGA or PCL polymers likely slows the penetration of water through 
the coating, thus further slowing the degradation of the coating in comparison to pure PLGA or 
PCL coatings.  
Cytocompatibility studies show that the layer-by-layer coatings indeed improve the 
viability of osteoblast and hMSC cultures on magnesium substrates. Live/Dead staining C-3 days 
post seeding, Figure C-8, as well as total DNA quantification at 3 and 7 days, Figure C-11, show 
that  cell numbers are markedly increased on coated samples in comparison to uncoated samples 
indicating cells are growing faster. Additionally, actin staining and SEM imaging at 24 hours 
post seeding, Figures C-9 and C-10, indicate that the adhesion of both osteoblasts and hMSCs is 
more favorable on the coated substrates than the native AZ31 surface in culture. Especially on 
the PLGA50:50 and PLGA75:25 surfaces, cells appear to favor the surface, extending in 
numerous directions and integrating well with the polymer.  In comparison, the few cells on the 
native AZ31 surface appear elongated or rounded and not integrate well with the surface, 
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indicating that the cells are poorly attached to this surface. For magnesium alloys it is often 
difficult to separate the poor viability due to high magnesium levels with the poor viability due to 
the ever changing and corroding surface of the alloys, but the overall result is generally that the 
alloys need some way to improve the biocompatibility of the surface that facilitates cell 
adhesion, proliferation and ultimately differentiation on the surface of the metal. The intention of 
the Mg(OH)2 and layer-by-layer coating presented here is to facilitate this, improving initial 
cellular adhesion, proliferation and integration with the implant. Morphology observations and 
viability and proliferation results have confirmed improved adhesion and proliferation over the 
native alloy. These results indicate that the intention lain out above, where-in the combination of 
layer-by-layer and conversion coating techniques allows for impeded degradation and improved 
cytocompatibility and cellular integration, can be achieved. The next step in coating design is to 
study long term cellular integration and differentiation as the polymer and underlying alloy 
degrade. Ultimately, the layer-by-layer coating will be further tailored to facilitate the delivery of 
drugs, growth factors or gene transfer particles to yield a coating specifically designed to provide 
the most beneficial aspects of biomedical engineering to the patient. 
C.5 CONCLUSION 
Electrostatically assembled layers of anionic biodegradable polymers PLGA or PCL and cationic 
polymers PEI and PAH combined with Mg(OH)2 surface treatment serve to provide a protective 
coating on AZ31 magnesium alloy substrates.  This ceramic conversion coating and layer-by-
layer polymeric coatings combination were shown to reduce immediate and long term corrosion 
of the substrate. The coatings also provided improved biocompatibility, cellular adhesion and 
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proliferation in comparison to the uncoated alloy surface. The implementation of such coatings 
on magnesium alloy implants could serve to improve the corrosion resistance and perhaps 
contribute to cellular integration of these implants with the native tissue while also serving to 
deliver vital drugs or biological elements to the site of implantation.  
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